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The axon initial segment (AIS) is a specialized compartment crucial for generating action 
potentials and maintaining neuronal polarity. An integrated structure composed of a high 
concentration of voltage gated ion channels, a specific cytoskeleton architecture, as well as, 
scaffold proteins like ankyrinG and βIV-spectrin, contributes to these functions. Recent studies 
have revealed that AIS is dynamically regulated in molecular composition, length and location 
in response to neuronal activity alterations both in physiological and pathological conditions. 
Some mechanisms acting on AIS plasticity have been uncovered lately, which include calcium 
dependent calpain or calcineurin modulation, as well as, modifications of cytoskeleton proteins. 
However, it is not clear how AIS is regulated in its structure and functions, and which proteins 
may regulate AIS cytoskeleton. In this study, using pharmacological methods we found that 
formins modulate AIS maintenance in vitro and in vivo. Formins are a group of proteins 
involved in cytoskeleton regulation. Currently, 15 formin members are identified in mammals. 
In neurons, different formins show differential distribution and regulation mechanisms. Only a 
few studies have revealed that formin members play different roles in neurons, such as axonal 
and dendritic development, spine morphogenesis and synapse modulation. Regarding brain 
diseases, some mutations in formin proteins were found in patients suffering mental retardation, 
Alzheimer’s disease, seizures and schizophrenia, suggesting that formins may play some 
important roles on neuronal activity. Our study demonstrates that formins inhibition modifies 
AIS cytoskeleton properties and their associated structural proteins and function. Interestingly, 
we found that mDia1 is at least one major formin family member that functions both in the AIS 
assembly and maintenance. mDia1 inhibition or suppression affects AIS length and structural 
and functional AIS proteins. Consistently, after blocking mDia1 activity, the action potential is 
affected, as well as, axonal polarity maintenance. These effects are due to the deficiency of AIS 
structural stability and alterations in axonal protein traffic, which can be compensated through 
expression or modulation of microtubules and microfilaments regulators. Taken together, our 
results indicate a new AIS regulator involved in AIS formation, maintenance and plasticity, 
which provides new insights on AIS regulation mechanisms. Further experiments will be 
necessary to completely understand mDia1 regulation at the AIS, and its implications in brain 
































           
Presentación 




        El segmento inicial del axón (AIS) es un compartimento especializado crucial para generar 
potenciales de acción y mantener la polaridad neuronal. Una estructura integrada compuesta por 
una alta concentración de canales iónicos activados por voltaje, una arquitectura específica del 
citoesqueleto, así como proteínas de andamio como ankyrinG y βIV-spectrin, contribuyen a 
estas funciones. Estudios recientes han revelado que el AIS está regulado dinámicamente en la 
composición molecular, la longitud y la ubicación en respuesta a las alteraciones de la actividad 
neuronal tanto en condiciones fisiológicas como patológicas. Recientemente se han descubierto 
algunos mecanismos que actúan sobre la plasticidad AIS, que incluyen la modulación de la 
calpaína o la calcineurina dependientes de calcio, así como las modificaciones de las proteínas 
del citoesqueleto. Sin embargo, no está claro cómo AIS está regulado en su estructura y 
funciones, y qué proteínas pueden regular el citoesqueleto AIS. Este citoesqueleto, esencial para 
mantener la integridad del AIS, está compuesto por microtúbulos, que incluyen modificaciones 
postraduccionales de tubulina, y micofilamentos con diferentes tipos de estructuras. En este 
estudio, utilizando métodos farmacológicos, encontramos que las forminas modulan el 
mantenimiento de AIS in vitro e in vivo. Las forminas son un grupo de proteínas involucradas 
en la regulación del citoesqueleto, tanto de microtúbulos como de actina, y por tanto, candidatos 
potenciales para la regulación del AIS. Actualmente, se han identificado 15 miembros de 
formina en mamíferos. En las neuronas, las diferentes forminas muestran mecanismos 
diferenciales de distribución y regulación. Solo unos pocos estudios han revelado que los 
miembros de formina juegan diferentes roles en las neuronas, como el desarrollo axonal y 
dendrítico, la morfogénesis de las espinas dendríticas y la modulación de las sinapsis. Con 
respecto a las enfermedades cerebrales, se han encontrado algunas mutaciones en las forminas 
en pacientes que sufren retraso mental, enfermedad de Alzheimer, convulsiones y esquizofrenia, 
lo que sugiere que las forminas pueden desempeñar algunas funciones importantes en la 
actividad neuronal. Nuestro estudio demuestra que la inhibición de las forminas modifica las 
propiedades del citoesqueleto AIS y sus funciones y proteínas estructurales asociadas. 
Curiosamente, descubrimos que mDia1 es al menos un miembro importante de la familia que 
funciona tanto en el ensamblaje como en el mantenimiento del AIS. La inhibición o supresión 
de mDia1 afecta la longitud del AIS y las proteínas AIS estructurales y funcionales. 
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Consistentemente, después de bloquear la actividad de mDia1, el potencial de acción se ve 
afectado, así como el mantenimiento de la polaridad axonal. Estos efectos se deben a la 
deficiencia de la estabilidad estructural AIS y las alteraciones en el tráfico de proteínas axonales, 
que se pueden compensar mediante la expresión o la modulación de microtúbulos y reguladores 
de microfilamentos. Tomados en conjunto, nuestros resultados indican un nuevo regulador del 
AIS involucrado en la formación, mantenimiento y plasticidad del AIS, lo que proporciona 
nuevas ideas sobre los mecanismos de regulación del AIS. Se necesitarán más experimentos 
para comprender completamente la regulación mDia1 en el AIS y sus implicaciones en las 
























ADAM22: a disintegrin and metalloproteinase domain-containing protein 22 
AIS: axon initial segment 
ALS: amyotrophic lateral sclerosis 
APC: adenomatous polyposis coli 
AraC: 1-β-D-arabinofuranosylcytosine 
Arp2/3: actin related protein 2/ 3 complex 
ATP: adenosine triphosphate 
CA: constitutively active 
CAMs: cell adhesion molecules 
Caspr2: contactin-associated protein-like 2 
CK2casein kinase 2 
CLASPs: CLIP-associated proteins 
CLIPs: cytoplasmic linker proteins 
CMF: correct mean fluorescence 
CO: cisternal organelle 
C-terminal: carboxy terminal 
CTF: correct total fluorescence 
DAAM: dishevelled associated activator of morphogenesis 
DAD: diaphanous autoregulatory domain 
Dia/ DIAPH: diaphanous related formins 
DID: diaphanous inhibitory domain 
DN: dominant negative 
DRFs: 4 subclasses of formins, including Dia, DAAM, FMNL, FHOD 
EB: microtubule plus-end binding protein 
ECM: extracellular matrix molecules 
EDTA: ethylenediaminetetraacetic acid 
EGTA: ethylene glycol-bis(-aminoethyl ether)-N, N, N ,́ N -́tetraacetic acid 
F-actin: filamentous actin 
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FH1: formin homology 1 domain 
FH2: formin homology 2 domain 
INF1: inverted formin 1 
FHOD: formin homology 2 domain containing 
FMN: formin 
FMNL: formin-like subtypes 
Formins: formin homology proteins 
FRAP: fluorescence recovery after photobleaching 
FSI: formin-spire interaction domain 
GBD: GTPase-binding domain 
GRID2IP: grid2 interacting protein 





 free Hank’s buffered salt solution 
HDAC6: histone deacetylase 6 
IC: immunocytochemistry 
IH: immunohistochemistry 





 cotransporter 2 
L1CAM: L1 cell adhesion molecule protein 
LGI1: leucine-rich glioma inactivated protein 1 
Lis1: lissencephaly-1 homolog 
LTD: long-term depression 
MAP: microtubule-associated protein 
MAP2: microtubule-associated protein 2 
MEM: minimum essential medium 
N/A: not applicable 
NDEL1: nuclear distribution protein nudE-like 1 
NF186: neurofascin 186 
NrCAM: neuron-glia-related cell-adhesion molecule 
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N-terminal: amino terminal 
OCD: obsessive-compulsive disorder 
PanNaCh: pan voltage gated sodium channels 
PB: phosphate buffer 
PBS: phosphate buffered saline 
PDZ: PSD95-Dlg1-Zo-1 domain 
PFA: paraformaldehyde 
pMLC: phosphorylated myosin light chain 
PSD: postsynaptic density protein 
PTSD: post-traumatic stress disorder 
ROCK: Rho-associated kinase 
RT: room temperature 
shRNA: short hairpin RNA 
SNPs: single nucleotide polymorphisms 
STORM: stochastic optical reconstruction microscopy 
Tag-1: transient axonal glycoprotein-1 
+TIPs: microtubule plus-end-tracking proteins 
TRIM46: tripartite motif-containing protein 46 
WH2: Wiskott-Aldrich homology 2 
WHIF1: WH2 domain-containing formin 1 



























































Neuronal development has been thoroughly studied in hippocampal cultured neurons 
(Barnes and Polleux, 2009; Kaech and Banker, 2006), which in somehow reflects the neuronal 
development observed “in vivo”. During hippocampal neuronal development in vitro, five 
different stages have been described (Fig. I1). After plating, neurons extend an actin lamella all 
around the cell body (Stage 1). Then, minor neurites begin to extend in the cell periphery (Stage 
2). In this stage, cell retains its symmetric appearance and lasts for 12-36 h. Next, one neurite 
grows for an extended period without retraction and acquires axonal characteristics (Stage 3). 
After 3-4 days in culture, the remaining minor neurites slowly elongate to become dendrites. At 
roughly the same time, AIS forms in the axon in a tiny domain proximal to the soma, being first 
detected by early AIS protein ankyrinG and voltage gated ion channels (Alpizar et al., 2019; 
Nakada et al., 2003). The AIS turns to be mature rapidly in two weeks (Stage 4) with the 
addition of more components, such as potassium channels (Sanchez-Ponce et al., 2012b), and 
the maturation of the diffusion barrier (Brachet et al., 2010). 
Figure I1. Developmental stages of cultured hippocampal neurons. Adapted from (Barnes and Polleux, 2009). 
1. The Axon Initial Segment (AIS) 
The axon initial segment (AIS) is a highly specialized neuronal compartment located in 
between axonal and somatodendritic domains (Fig. I2). It contains a high concentration of 
different sodium, potassium and calcium voltage gated ion channels, which allows its function 
as the site of action potential generation. The AIS is also characterized by a high density of cell 
adhesion molecules (CAMs), such as neurofascin. Both, voltage gated ion channels and CAMs 
are anchored to the AIS cytoskeleton by the scaffold proteins ankyrinG, βIV-spectrin and 
PSD93. Among them, ankyrinG is the main scaffold protein and it is extremely important for 
the maintenance of the whole structure, keeping AIS integrity and function. AnkyrinG and βIV-
scpectrin also serve as the linker with the AIS cytoskeleton, which is composed by different 
actin structures and bundled microtubules with specific characteristics. This cytoskeleton, 
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together with membrane proteins maintains axonal polarization to exclude somatodendritic 
proteins entrance into the axon. 
 
 
Figure I2. Axon Initial Segment (AIS) structure 
and compositions. AIS is the place of action 
potential initiation. It contains a high density of 
sodium (Nav) and potassium channels (Kv and 
KCNQ2/3), which are anchored by ankyrinG (AnkG) 
and βIV-αII-spectrins to the actin and microtubules 
cytoskeleton. Its membrane also contains a high 
density of adhesion molecules (NF186, ADAM22, 
Caspr2 or NrCAM). These molecules are associated 
with extracellular glicoproteins, such as Brevican or 
Versican. This whole complex structure maintains 
somatodendritic-axonal polarization, and is the site of 
action potential generation, which is maintained and 





1.1. The AIS structure 
1.1.1. AnkyrinG: the key AIS organizer 
AnkyrinG is a submembranous scaffold protein in the AIS. In mammals, three ankyrin 
genes were discovered (Bennett and Baines, 2001) and ankyrinG is the third member of the 
ankyrin family (ANK3), which is expressed in the brain, heart, muscle and epithelial cells. In 
neurons, there are three splice variants of ankyrinG. The largest isoform of ankyrinG is a 480 
kDa protein (giant ankyrinG), which contains several major domains (Bennett and Lorenzo, 
2013): a membrane-binding domain for cell adhesion molecules and ion channels interaction, a 
spectrin-binding domain for β-spectrin interaction, an unstructured serine-rich domain for 
microtubules interaction (Freal et al., 2016), a tail domain and a C-terminal containing a death 
domain. The medium isoform of ankyrinG is a 270 kDa protein, which lacks of the tail domain. 
And the smallest isoform of ankyrinG is a 190 kDa protein, which only has N-terminal amino 
acids and lacks the serine-rich domain and the tail domain. However, only the largest and the 
medium isoform of ankyrinG are specifically localized in the AIS and nodes of Ranvier in 
neurons (Jenkins et al., 2015; Kordeli et al., 1995). As a scaffold, βIV-spectrin contributes to 
anchoring ankyrinG to the cytoskeleton (Komada and Soriano, 2002), but also maintaining 
plasma membrane adhesion and membrane polarization through binding to phosphoinositides 
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(Lemmon et al., 2002). Consistently, mutant mice lacking βIV-spectrin causes axonal molecules 
L1CAM and ankyrinG to mislocalize to the somatodendrites both in vitro and in vivo (Komada 
and Soriano, 2002; Nishimura et al., 2007). 
Shortly after axon and dendrites specification, ankyrinG starts to cluster at the proximal 
axon and then recruits other AIS components (Hedstrom et al., 2007; Yang et al., 2019). An 
amino acids motif (AIS motif) in voltage gated sodium (Nav) and potassium (Kv7) channels has 
been described that target these channels to the AIS through interaction with ankyrinG (Garrido 
et al., 2003; Pan et al., 2006). As a master regulator, ankyrinG controls both ion channels 
clustering and the maintenance of neuronal polarity. Previous studies in knockout mice and 
cultured neurons have shown that the loss of ankyrinG is associated with loss of voltage gated 
ion channels, cell adhesion molecules and the loss of AIS integrity (Hedstrom et al., 2007; 
Jenkins and Bennett, 2001; Zhou et al., 1998). Moreover, ankyrinG concentration at the AIS is 
necessary to maintain axonal polarity and impairs somatodendritic proteins to enter the axon. In 
fact, absence of ankyrinG in cultured hippocampal neurons dismantles the AIS structure and 
causes somatodendritic proteins (MAP2, KCC2, PSD95) to redistribute and enter the axon, 
where spine-like structures and postsynaptic densities can even develop (Hedstrom et al., 2008). 
This is corroborated by in vivo experiments in ankyrinG knockout of Purkinje neurons, which 
develop dendritic spines enriched with postsynaptic proteins in the axons (Sobotzik et al., 2009). 
1.1.2. Other AIS enriched proteins 
1.1.2.1. Voltage-gated ion channels 
Vol tage-gated ion channels are one of major constituents concentrated in the AIS. AIS is 
enriched with multiple types of voltage gated sodium channels, potassium channels and calcium 
channels. These channels play varied roles in action potential initiation and shaping the spike 
waveforms (Bender and Trussell, 2012; Kole and Stuart, 2012). Sodium channels α subunit, the 
pore-forming subunit, directly interacts with ankyrinG through the AIS motif in cytoplasmic II-
III loop and is recruited to the AIS domain (Garrido et al., 2003; Lemaillet et al., 2003; Zhou et 
al., 1998).  The phosphorylation of several serine residues (S1112, S1124, and S1126) at AIS 
motif tightens the interaction between ankyrinG and Nav1.2, which further contributes to the 
sodium channels clustering in the AIS (Brechet et al., 2008). 
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In neurons of central nervous system, there are three major subtypes of sodium channels at 
the AIS: Nav1.1, Nav1.2 and Nav1.6 (Boiko et al., 2003; Duflocq et al., 2008). Each type of 
neurons contains a different combination of voltage gated ion channels (Debanne et al., 2011). 
Nav1.6 is the dominant isoform of sodium channels in the AIS for mature neurons both in 
rodent (Kress et al., 2010; Lorincz and Nusser, 2008; Van Wart et al., 2007) and human (Inda et 
al., 2006; Tian et al., 2014). In immature neurons, Nav1.2 is more abundantly expressed in the 
AIS (Boiko et al., 2003). Nav1.1 channels have also been detected in motoneurons (Duflocq et 
al., 2008), cortical interneurons (Ogiwara et al., 2007; Van Wart et al., 2007) and cerebellar 
Purkinje cells (Xiao et al., 2013). Those different subunits of sodium channels can play different 
roles for the generation of action potentials (Hu et al., 2009). Potassium channels are also richly 
expressed in the AIS (Lorincz and Nusser, 2008; Pan et al., 2006). In addition to Kv7.2/7.3 
channels clustered by ankyrinG, Kv1.1 channels are clustered at the AIS through binding to the 
scaffold protein PSD93 (Ogawa et al., 2008). Kv7.2/7.3 is not clustered at the AIS in ankyrinG 
knock-out mice of cerebellum (Pan et al., 2006; Rasmussen et al., 2007). Previous studies have 
established that potassium channels affect resting membrane potential as well as repolarization 
by shaping the width and repetitive spiking of action potentials (Clark et al., 2009; Kole et al., 
2007; Shah et al., 2008).  
Vol tage-gated calcium channels Cav2.1 (P/Q-type current) and Cav2.2 (N-type) also 
concentrate along the AIS of ferret prefrontal cortical neurons (Yu et al., 2010). Cav3.1/3.2 (T-
type) channels at the AIS are identified in pyramidal cells of primary somatosensory cortex 
layer 5b and cerebellar Purkinje cells in mice through electrophysiology techniques (Bender and 
Trussell, 2009). Ca2+ influx in the AIS is mediated by low voltage-activated (LVA) Ca2+ 
channels, including T- and R-type isoforms. However, the knowledge of these calcium channels 
at the AIS is limited. 
1.1.2.2. Cell adhesion molecules 
Several cell adhesion molecules (CAMs) are richly expressed in the AIS. NrCAM, 
neurofascin (NF186) and L1CAMs are recruited in the AIS by ankyrinG through their 
cytoplasmic FIGQY motif (Davis and Bennett, 1994). Phosphorylation of the tyrosine (Y) in the 
FIGQY motif decreases L1CAMs-ankyrin interactions (Jenkins et al., 2001; Tuvia et al., 1997). 
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Indeed, knocking down either of those CAMs has no effects on other AIS components 
clustering in the AIS (Hedstrom et al., 2007). Consistently, ablating NF186 can not modify 
overall enrichment of sodium channels and its distribution (Alpizar et al., 2019). However, the 
loss of NF186 perturbs ankyrinG accumulation, which indicates that NF186 may play vital roles 
for AIS components recruitment. Besides, NF186 is responsible for the collection of 
extracellular matrix molecules (ECM) to the AIS, such as brevican, versican and aggrecan, and 
thereby links the intracellular cytoskeleton to the ECM (Bruckner et al., 2006; Hedstrom et al., 
2007; John et al., 2006). In the cerebellum, NF186 contributes to the innervations by basketball 
interneurons in Purkinje neurons AIS (Ango et al., 2004). Some CAMs are specifically clustered 
at the distal AIS region, including Caspr2 (contactin-associated protein-like 2), Tag-1 (transient 
axonal glycoprotein-1) and a disintegrin and metalloproteinase domain-containing protein 22 
(ADAM22). Those proteins are recruited directly or indirectly by PSD93 (Ogawa et al., 2008). 
PSD93 as well as NF186 and NrCAM can be modified by lipids (El-Husseini et al., 2000; 
Ogawa et al., 2008; Ren and Bennett, 1998). These lipid modifications facilitate protein 
interactions with lipid bilayers and regulate protein sorting, localization and function in 
specialized lipid microdomains (el-Husseini Ael and Bredt, 2002). Consistent with the finding 
of ADAM22 in the AIS (Ogawa et al., 2010), its ligand, the secreted leucine-rich glioma 
inactivated protein 1 (LGI1) is enriched at the AIS and colocalizes with Kv1 channels in 
cultured hippocampal neurons. LGI1 deficiency decreases Kv1 channels expression and leads to 
neuronal intrinsic excitability (Seagar et al., 2017). 
1.1.3. AIS cytoskeleton 
1.1.3.1. Actin cytoskeleton in the AIS 
F-Actin structures function as a barrier in the AIS both for membrane components and 
intracellular vesicles (Song et al., 2009; Winckler et al., 1999). Disruption of F-actin abolishes 
AIS barrier and leads to a redistribution of membrane proteins, which is accompanied by the 
entrance of macromolecules to the axon. 
F-actin orchestrates the AIS in several different ways. At least three types of actin 
structures have been idenditifed in the AIS: actin rings, actin patches and actin trails. Actin can 
bind to ankyrinG through βIV-spectrin. βIV-spectrin stabilizes ankyrinG by binding to its 
spectrin repeat, while the interaction with actin cytoskeleton is via an actin-binding domain at 
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the N-terminal. Recent studies using stochastic optical reconstruction microscopy (STORM) 
reveal that actin in the AIS forms a periodic structure with actin filament rings spaced 190 nm 
intervals (Leterrier et al., 2015; Xu et al., 2013). Actin rings are connected by βIV-spectrin in a 
mode of head-to-head. A current study revealed that contractile myosin II activator, pMLC, is 
associated with actin rings (Berger et al., 2018). The function of this actin rings structure is 
unknown, but it may be involved in the stabilization of AIS due to their strong resistance to 
actin destabilizing drugs (Abouelezz et al., 2019; Leterrier et al., 2015). Together with actin 
rings, other AIS components such as ankyrinG, sodium channels and NF186 in the AIS are also 
periodic (Xu et al., 2013). In addition to actin rings in the AIS, 2-3 µm actin patches are 
reported in the AIS (Watanabe et al., 2012). Those actin patches are present shortly after 
neuronal specification with a highly dynamic modulation (Balasanyan et al., 2017). Actin 
patches loss induced by inhibition of the actin nucleator Arp2/3 activity results in the 
mislocation of somatodendritic proteins to the axon. In the AIS, actin patches function to block 
dendritic protein vesicles entry in the axon. In fact, somatodendritic proteins are much more 
likely to stop and reverse their movement direction in regions occupied by the actin patches 
(Watanabe et al., 2012).  
Actin related proteins are expressed in the AIS and allow the identification in the AIS of 
another small sized and actin condensed structure, the cisternal organelle (CO) (Sanchez-Ponce 
et al., 2012a). The CO is identified as patches in the AIS of variable size and is thought to be a 
calcium store in neocortical and hippocampal neurons (Bas Orth et al., 2007; Benedeczky et al., 
1994; Sanchez-Ponce et al., 2011a). Besides, other calcium regulation related molecules, such as 
inositol 1,4,5-triphosphate receptor 1 (IP3R1), annexin 6 and SERCA-type Ca2+ pump 
(Benedeczky et al., 1994; Sanchez-Ponce et al., 2011a) have been identified at the AIS. Apart 
from those molecules, actin binding or associated proteins α-actinin and synaptopodin are also 
expressed in the CO (Sanchez-Ponce et al., 2012a). Synaptopodin knockout mice are 
characterized by the lack of CO in CA1 pyramidal cells, but without altering neuronal 
excitability (Bas Orth et al., 2007). Recent studies revealed a dynamic remodeling of CO along 
with AIS length modifications during visual cortex development (Hofflin et al., 2017; Schluter 
et al., 2017). Visual deprivation leads to an increase of CO patches size and AIS length in 
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pyramidal neurons of layers II/III in visual cortex (Schluter et al., 2017). This is also observed 
in retinal ganglion cells (Schluter et al., 2019). However, AIS shortening is observed in 
synaptopodin-deficient mice lacking the CO after visual deprivation. The relation of CO and 
AIS can also be supported by a study that CO integrity depends on the ankyrinG expression in 
the AIS (Sanchez-Ponce et al., 2011a). This suggests that the CO is an essential part of the AIS 
machinery required for AIS plasticity in response to changes in network activity. However, our 
knowledge of this structure is limited. 
Using platinum replica electron microscopy, short, stable filaments and slightly longer 
dynamic filaments are previously identified in the AIS (Jones et al., 2014). Stable actin 
filaments together with other known AIS proteins function as a diffusion barrier to prevent 
mixing of axonal and dendritic proteins, whereas dynamic actin may promote AIS coat 
remodeling and allows for selective passage of vesicles during establishment of neuron polarity. 
Another form of dynamic actin filaments known as actin trails is found along the axon including 
the AIS. Those actin trails originate from “actin hotspots” and spurt bidirectionally along axons. 
Formins are responsible for actin trails regulation and loss of formins activity attenuates these 
actin trails (Ganguly et al., 2015). 
1.1.3.2. Microtubules cytoskeleton in the AIS 
Microtubules are uniformly oriented with their plus ends pointing to the distal axon, both 
in the AIS and the axon, whereas in dendrites microtubule orientations are mixed (Baas et al., 
1988; Stepanova et al., 2003; Stone et al., 2008). Microtubules in the AIS are tightly packed into 
fascicles, a composition absent from other neuronal regions, even the similar excitable structure, 
the nodes of Ranvier (Palay et al., 1968). Recently, a microtubule associated protein (MAP), 
TRIM46, is identified and enriches in the AIS, which function is to maintain the uniform axonal 
microtubule orientation and microtubules fasciculation (Harterink et al., 2019; Palay et al., 1968; 
van Beuningen et al., 2015). Depletion of TRIM46 results in a mixed microtubule polarity and a 
decrease of axonal trafficking efficiency. TRIM46 partly overlaps with ankyrinG and maintains 
the uniform plus-end outward microtubule fascicles. And loss of ankyrinG greatly disrupts the 
distribution of TRIM46.  
AIS microtubules together with other AIS scaffold and membrane proteins form a 
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submembranous coat to maintain AIS stability (Jones et al., 2014). Indeed, microtubules are 
tightly related with AIS master protein ankyrinG. It is reported that fasciculated microtubules 
are absent in the proximal axon of ankyrinG knock-out mice in the cerebellum (Sobotzik et al., 
2009). In addition, ankyrinG binds to microtubules via the microtubule plus-end-binding 
proteins EB1 and EB3 (Leterrier et al., 2011). EB proteins are localized in the AIS and 
contribute to AIS assembly and maintenance through interaction with ankyrinG (Freal et al., 
2016; Leterrier et al., 2011). Although EB proteins can recruit other plus-end-tracking proteins 
(+TIPs) such as CLASPs and CLIPs (Akhmanova and Steinmetz, 2010), no signal is observed 
for CLIP170, CLASP1/2 and APC in the AIS of mature cultured rat hippocampal neurons 
(Leterrier et al., 2011). 
Microtubules properties can be regulated by post-translational modifications, such as 
tyrosination, detyrosination, polyglutamylation, polyglycylation. Detyrosinated and acetylated 
tubulin are more resistant to depolymerization agents and are considered as more stable 
microtubules (Baas and Black, 1990). Indeed, a stable pool of microtubules was identified in the 
AIS, which is characterized by higher level of acetylated and detyrosinated microtubules in 
cultured hippocampal neurons (Tapia et al., 2010). Several mechanisms and proteins have been 
identified to modify tubulin post-translational modifications at the AIS. HDAC6 is a tubulin 
deacetylase and it is involved in the AIS assembly through α-tubulin deacetylation in the distal 
axon, conferring AIS specific higher acetylation (Tapia et al., 2010). Casein kinase 2α (CK2α) 
clusters at the AIS and its inhibition blocks sodium channels and ankyrinG assembly and 
maintenance, which is accompanied by the increase of tubulin acetylation in the AIS (Sanchez-
Ponce et al., 2011b). In addition, an important regulator of microtubules, glycogen synthase 
kinase 3 (GSK3), was also identified in the AIS.  It is known that inhibition of GSK3β results in 
the increase of tubulin acetylation, detyrosination, and polyglutamylation (Hammond et al., 
2010), but also decreases the levels of ankyrinG and sodium channels at the AIS (Tapia et al., 
2013).  
This structural and regulatory complex cytoskeleton is necessary not only to anchor AIS 
proteins, but also to decide which motor proteins can go into the axon to transport axonal 
cargoes. Among them, kinesins and dyneins are the most studied. Kinesins are generally plus-
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end-directed microtubule motors driving long-distance movement in neurons. They are a large 
superfamily, organized in 14 families, being kinesin1 family the main one responsible for the 
anterograde transport into the axon and AIS (Konishi and Setou, 2009; Reed et al., 2006). 
Kinesin1 mediated axonal transportation is related with microtubule stability binding to 
acetylated and detyrosinated microtubules at the AIS and along the axon. Long-term increase of 
tubulin acetylation disrupts KIF5C redistribution between somatodendritic and axonal 
compartments and alters AIS components accumulation (Tapia et al., 2010). For the retrograde 
transport in the AIS and axon, dynein counteracts mislocalized somatodendritic cargoes and 
redirects them to the soma and dendrites along the minus-end microtubules. In addition, dynein 
regulator NDEL1 stably binds to ankyrinG at the AIS and cooperates with its effector Lis1 for 
efficient local cargo reversal (Klinman et al., 2017; Kuijpers et al., 2016; Waterman-Storer et al., 
1995). Depletion either of them leads to both cell-wide and local defects, including the non-
polarized trafficking of dendritic cargos through the AIS (Kuijpers et al., 2016). 
 1.2. AIS development and maturation 
Previous studies have provided a few clues for AIS early assembly. The specific 
accumulation in the AIS of ankyrinG, as the master and organizer protein for AIS assembly, 
determines the fate of AIS formation (Rasband, 2010). Several hypotheses have been proposed 
for AIS establishment. First, a distal axonal submembranous cytoskeleton composed of 
ankyrinB, αII-spectrin, and βII-spectrin, defines ankyrinG location in the proximal axon 
(Galiano et al., 2012). Second, local higher acetylation of microtubules in the AIS due to distal 
axon expression of the tubulin deacetylase HDAC6, allows AIS components clustering in the 
AIS (Tapia et al., 2010). Moreover, the cooperation of microtubule end-binding proteins (EBs) 
and giant ankyrinG is decisive for AIS assembly and neuronal polarity (Freal et al., 2016). In 
fact, disrupting the interaction between giant ankyrinG and βIV-spectrin impairs AIS 
composition targeting to the AIS (Yang et al., 2019).  A current study also found that an actin 
motor, myosin II, contributes to the assembly of AIS (Berger et al., 2018). Interestingly, myosin 
II activator pMLC (phosphorylated myosin light chain) is richly expressed in the AIS and 
controls ankyrinG accumulation.  
The AIS initially appears between stage 3 and stage 4 in cultured hippocampal neurons 
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(Barnes and Polleux, 2009; Kaech and Banker, 2006) after axon has started its elongation. Thus, 
AIS assembly and axon specification are two different events. Consistently, knocking down 
ankyrinG before axon specification does not impair a morphological neuronal differentiation 
into axons and dendrites (Sanchez-Ponce et al., 2011b). However, once AIS is formed, it starts 
to maintain neuronal polarity by preventing somatodendritic proteins from entering axonal 
domains (Rasband, 2010; Sobotzik et al., 2009). Along with AIS development, various 
transmembrane proteins, such as, voltage gated sodium channels, neurofascin, scaffold proteins 
continuously assemble in the AIS (Alpizar et al., 2019; Jones et al., 2014; Nakada et al., 2003). 
In addition, AIS actin and microtubules cytoskeleton turn to be more stable along with AIS 
development  (Jones et al., 2014). During this maturation period, AIS becomes a diffusion 
barrier, between 4 and 10 DIV, and a place of axonal traffic control that contributes to 
maintenance of neuronal polarity. Finally, between 14 and 21 DIV, all kinds of voltage gated ion 
channels are established at the AIS and action potential properties are fully mature.  
2. AIS plasticity and regulation 
Despite AIS has a highly stable and specialized cytoskeletal architecture, recent studies 
have highlighted that the AIS possesses a high plasticity characterized by dynamic alterations in 
its molecular compositions, changes of distance to the soma or changes in its length. These 
structural and compositional modifications happen in response to changes in neuronal activity 
input during development or from pathological alterations.  
2.1. AIS plasticity during neuronal development 
Different types of neurons may have distinct AIS ion channels, locations and lengths that 
tune the electrophysiological properties of each specific cell type (Hofflin et al., 2017; Lorincz 
and Nusser, 2008; Yoshimura and Rasband, 2014). To be functionally developed, the AIS 
undergoes changes in its structure and compositions during AIS maturation along with neuronal 
development. In retinal ganglion cells, Nav1.2 channels expression precedes that of Nav1.6 
channels and Nav1.6 turns to be the major Na+ channel subtype when the neuron is mature 
(Boiko et al., 2003). Similarly, in cerebellar granule cells, Nav1.2 accumulates rapidly in the 
AIS at early stages, while Nav1.6 clusters at AIS from P21 to P40 and later co-localizes with 
Nav1.2 (Osorio et al., 2010). Besides the sodium channels, notable changes in AIS length and 
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thickness throughout cell maturation have been described (Bolos et al., 2019). Also, in 
developing visual cortex, AIS length undergoes dynamic changes along postnatal development, 
increasing its length till postnatal day 15. Later and coinciding with the critical period with the 
highest sensitivity to input imbalance, the AIS becomes shorter around P28, but increases its 
length around P35 till adult stage (Gutzmann et al., 2014). Among the factors and receptors 
controlling initial development of the AIS, purinergic P2Y1 and cannabinoids CB1 receptors are 
essential to properly start AIS development (Tapia et al., 2017; Zhang et al., 2019). 
2.2. Activity dependent AIS plasticity 
AIS modeling during development could be due to the activity alterations (Gutzmann et al., 
2014; Kuba et al., 2014; Kuba et al., 2006). Several works have demonstrated that neuronal 
activity contributes to the AIS plasticity. Computer modeling analysis first showed that AIS 
length and location are optimized to reduce the threshold of spike generation (Kuba et al., 2006). 
This was indeed proved in a study in chicken audiotry cortical neurons, that were deprived of 
their inputs from cochlear neurons (Kuba et al., 2010). Deprivation of auditory inputs leads to 
nucleus magnocellularis neurons AIS elongation, which was accompanied by changes of 
ankyrinG and sodium channels distribution along the AIS. In addition, the input deprived cells 
become more excitable to compensate for the lost of input and to maintain a maximum of 
efficiency. Consistent with theses findings, chronic increase neuronal activity using high 
extracellular potassium or photostimulation results in a significant shift of AIS position along 
the axon away from the soma in cultured hippocampal neurons (Grubb and Burrone, 2010). 
Those neurons with distal shift of AIS are characterized by higher current thresholds to respond 
and compensate this higher neuronal ongoing excitability. 
Abnormal neuronal firing often happens in neuropathological conditions. AIS plasticity in 
response to neuronal excitability is also applicable to this situation. With aging, neurons from 
visual cortex of aged individuals show an increased excitation (Ding et al., 2017; Hua et al., 
2006; Leventhal et al., 2003). A recent research showed that the primary visual cortex neurons 
in layer II/III of aged rats have shorter AIS length and less Nav1.6 channels intensity, indicating 
that AIS plasticity is a mechanism to compensate for age-related enhancement of neuronal 
excitation in the visual cortex (Ding et al., 2018). Changes in AIS length have been described in 
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Alzheimer’s disease models (Marin et al., 2016) and a mouse model of Angelman syndrome 
shows an increased ankyrinG and sodium channels expression at the AIS (Kaphzan et al., 2011). 
2.3. Potential mechanisms for AIS plasticity 
Neurons can sculpture AIS in order to meet their specific functional requirements. 
However, the mechanisms involved in the control of AIS structure and composition changes 
during AIS rearrangements in physiological and pathological conditions remain mostly 
unknown. There are several proposed mechanisms for AIS plasticity with calcium signaling as a 
common mediator. Given the presence of cisternal organelles (Benedeczky et al., 1994) and 
calcium channels (Bender and Trussell, 2009) at the AIS, calcium-dependent pathways may 
have profound impacts on AIS plasticity. AIS location distal shifting after induction of long-
term depolarization can be blocked in pyramidal hippocampal neurons by T- and/or L-type 
voltage-gated calcium channels antagonists (Grubb and Burrone, 2010). However, this elevated 
neuronal activity shortens the AIS length in dentate granule cells mediated through L-type Cav1 
calcium channels (Evans et al., 2015). In the other hand, even higher extracellular potassium 
concentration reduces AIS components expression within minutes in hippocampal neurons. This 
quick effect can be blocked by extracellular calcium chelation with EGTA (Berger et al., 2018). 
This reduction in AIS proteins has also been described after activation of P2X7 purinergic 
receptor by  ATP, which triggers calcium influx. Consistently, the reduction of ankyrinG and 
sodium channels mediated by ATP-P2X7 activation can be inhibited through chelating 
extracellular calcium ions by EGTA (Del Puerto et al., 2015). Some calcium related proteins, 
including calcium-modulated protein calmodulin (Liu and Devaux, 2014), calcium-activated 
phosphatase calcineurin (Evans et al., 2013) and calcium-dependent cysteine protease calpain 
(Del Puerto et al., 2015; Schafer et al., 2009) have been described as mediators of AIS plasticity.  
While calmodulin enhances the heteromeric association of Kv7 heteromers and their clustering 
at the AIS (Liu and Devaux, 2014), slow activity-dependent AIS relocation and rapid activity-
dependent AIS shortening both rely on calcineurin activity (Evans et al., 2013). Instead, calpain 
is involved in AIS components degradation after neuronal injury or abnormal enhanced 
neuronal excitability, and its inhibition is sufficient to preserve the molecular organization of the 
AIS (Del Puerto et al., 2015). 
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 In addition, a recent research showed that actin destabilization could be a late-stage event 
that underlies activity-dependent AIS disassembly (Berger et al., 2018). Consistent with this 
finding, actin stabilization recoveries the decrease of AIS components caused by loss of P2Y1 
purinergic receptors (Zhang et al., 2019). Besides, myosin II and its activator pMLC have major 
roles in neuronal activity dependent AIS plasticity (Berger et al., 2018; Evans et al., 2017). 
Inhibition of myosin II ATPase activity blocks AIS long-term relocation and more rapid 
shortening in dentate granule cells. 
AIS plasticity is a complex process. It can occur over the course of hours or days. Besides, 
numerous stimuli can alter AIS both in nervous system development and pathologies. As a 
stable compartment in neurons, the AIS changes may need several coordinators. However, based 
on the current knowledge, our understanding of AIS plasticity processes is very limited. 
Therefore, it is necessary to identify new AIS plasticity regulators in order to get a better 
understanding of AIS homeostatic plasticity in physiology and pathology. 
3. The AIS in neurological disorders  
Given the vital roles of AIS on action potential generation and polarity maintenance, 
mutations or single nucleotide polymorphisms (SNPs) in genes responsible for the expression of 
AIS components could be a risk factor leading to some neurological disorders related to 
neuronal function. Some AIS proteins mutations cause neurological disorders. AnkyrinG 
abnormal expression or incorrect splicing of ANK3 are related with lots of neuronal pathologies. 
Multiple genome-wide association studies revealed that ANK3 is among the most frequently 
reported risk genes in bipolar disorder (Leussis et al., 2013; Leussis et al., 2012; Psychiatric, 
2011), with further evidence for association with other psychiatric disorders including 
schizophrenia (Schizophrenia Psychiatric Genome-Wide Association Study, 2011) and autism 
spectrum disorder (Codina-Sola et al., 2015). βIV-spectrin is another an important scaffolding 
protein in the AIS. Functional loss of βIV-spectrin gene (Spnb4) in mutant mice have 
phenotypes of ataxia and central auditory deafness (Parkinson et al., 2001). In patients, Spnb4 
mutants have myopathies and central auditory deficiency disorders (Knierim et al., 2017). 
Moreover, different autoantibodies against AIS proteins have been detected in different 
autoimmune diseases, such as, encephalopaties (LGI1), multiple sclerosis (NF186), Morvan 
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syndrome (Kv channels) or neuropathic pain (Nav channels) (Buffington and Rasband, 2011; 
Seagar et al., 2017).  
In addition, AIS alterations could occur in response to the abnormality of neuronal activity 
or microenvironments. Inflammatory or genetic diseases generate changes in AIS integrity and 
plasticity. For example, AIS components in ischemic brains are completely lost due to 
proteolysis of ankyrinG and βIV-spectrin by the Ca2+ dependent protease calpain in stroke 
brains (Del Puerto et al., 2015; Schafer et al., 2009). Within the peri-infarct cortex, AIS length 
decreases from the distal end (Hinman et al., 2013). In a blast wave induced mild traumatic 
brain injury model, the AIS shortens in both the cortex and hippocampus, although there is no 
change of AIS components (Baalman et al., 2013). Angelman syndrome is associated with a 
series of symptoms consisting of epilepsy, autism, intellectual disability and motor 
abnormalities. A mouse model for Angelman syndrome generated by knockout of ubiquitin 
ligase UBE3A gene exhibits upregulated ankyrinG and Nav1.6 channels together with longer 
AIS. Besides, severe AIS disruption and even loss of the AIS were observed in the neocortex of 
experimental autoimmune encephalomyelitis mice model, which can be impaired through 
inhibiting microglia activity (Clark et al., 2016). In line with the finding that microglia activity 
affects AIS integrity, higher densities of microglia surrounding Aβ plaques may also damage the 
AIS (Marin et al., 2016). Given type-2 diabetes associated with cognitive and mood 
impairments, a more current study showed that AIS shortening occurs in the absence of altered 
AIS protein levels in diabetic mice (Yermakov et al., 2018). All together, AIS alterations could 
be a relatively common feature in nervous diseases and injuries, suggesting that AIS could be 
regarded as a possible target for therapeutic intervention in some brain diseases and disorders. 
4. Formin homology proteins (Formins) 
Actin and microtubules are key players in the AIS maintenance and their regulation and 
modifications are necessary for AIS plasticity and maintenance of neuronal polarity. Many 
regulatory proteins play an important role in actin or/and microtubules dynamics in different 
neuronal domains. However, the knowledge of how AIS actin and microtubules cytoskeleton is 
regulated remains elusive. Formins family members are potential candidates for AIS 
cytoskeleton regulation due to their ability to modulate actin and microtubules structures 
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(Bartolini and Gundersen, 2010; Courtemanche, 2018), their roles in maintaining apico-basal 
polarity in neuroepithelial and epithelial cells (Acharya et al., 2017; Herzog et al., 2011; 
Thumkeo et al., 2011), and their function in maintaining axonal actin structures (Ganguly et al., 
2015). 
4.1. Mammalian formin family members and protein domains 
Formins are defined by their most conserved formin homology 2 (FH2) domain (Higgs and 
Peterson, 2005). They are evolutionarily conserved in eukaryotes throughout a wide range of 
species, including slime molds, yeast, plants, mollusca, annelida, platyhelminthes, arthropoda, 
nematode, echinodermata and chordate (Higgs and Peterson, 2005; Pruyne, 2016). However, a 
different number of formin subtypes exist in different species, being 15 in mammals. These 15 
mammalian formins are further subdivided into eight different subfamilies based on their 
sequences and domain architectures (Schonichen and Geyer, 2010). Specifically, there are 3 
Diaphanous related formin subtypes (Dia1, Dia2, Dia3), 2 Dishevelled associated activator of 
morphogenesis subtypes (DAAM1, DAAM2), 3 formin-like subtypes (FMNL1, FMNL2, 
FMNL3), 2 formin homology 2 domain containing subtypes (FHOD1, FHOD3), 2 formin 
subtypes (FMN1, FMN2), as well as,  WH2 domain-containing formin 1 (WHIF1),  inverted 
formin 1 (INF1) and Grid2 interacting protein (GRID2IP). 
Figure I3. Domain organization of 
formin subfamilies and the regulation 
and function of DRFs. A. Formin 
subfamilies classification based on the 
sequence similarity of the FH2 domain. 
GBD: GTPase-binding domain. DID: 
diaphanous inhibitory domain. FH1: 
formin homology 1 domain. FH2: formin 
homology 2 domain. DAD: diaphanous 
autoregulatory domain. WH2: Wiskott-
Aldrich homology 2. FSI: formin-spire 
interaction domain. PDZ: PSD95-Dlg1-
Zo-1 domain. B. General mechanism of 
DRFs autoinhibition via DID-DAD 
intramolecular binding and release by 
RhoGTPase-binding to the GBD domain. 
C. When elongating actin, dimerized FH2 
domains form a ring-like structure near 
the barbed end of the actin filament, with 
the more flexible FH1 domains 
continuously adding actin monomers. 
Adapted from (Kawabata Galbraith and 
Kengaku, 2019). 
 
Formins are large and multi-domain proteins with more than 1000 amino acids (Fig. I3). 
The most conserved domain, FH2 domain, is a sequence of around 400 amino acids and 
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typically localizes in the C-terminal. FH2 domain is often immediately preceded by a proline-
rich formin homology 1 (FH1) domain. In C-terminal tail regions, many formins also encode 
additional actin-binding sites, including Wiskott-Aldrich syndrome protein homology-2 (WH2)-
like motifs in WHIF1 and FMNL3 (Chhabra and Higgs, 2006; Heimsath and Higgs, 2012) and 
formin-spire interaction domain in FMN1 and FMN2 (Pechlivanis et al., 2009). Most formins 
share an N-terminal diaphanous inhibitory domain (DID) and C-terminal diaphanous 
autoregulatory domain (DAD). A dimerization domain (DD) is adjacent to the DID and 
followed by coiled-coil domain. Four formin subtypes Dia, DAAM, FMNL and FHOD share a 
similar domain organization and belong to the DRFs. The other formins family members are 
non-DRFs that diverge from this pattern of domain organization. Among them, one or more 
conserved N-terminal domains are absent, instead replaced by other folds, such as PSD95-Dlg1-
Zo-1 domain (PDZ) of GRID2IP and microtubule-binding domains of FMN1 and FMN2 
(Kawabata Galbraith and Kengaku, 2019). 
FH2 domain is the core element for formins’ physiological functions through actin and 
microtubules regulation (Bartolini and Gundersen, 2010). However, the flanking regions of the 
FH2 domain vary considerably between individual formins, likely resulting in different cellular 
functions and regulation mechanisms. FH1 can bind to profilin-actin complexes and enhance the 
delivery of new actin monomers onto the growing filaments (Paul and Pollard, 2008; Romero et 
al., 2004). FH1, FH2 and C-terminal domains also contribute to the dynamics of microtubule 
regulation in some formins, such as Dia, DAAM, INF1 and WHIF1 (Bartolini and Gundersen, 
2010). Formins in resting state are autoinhibited through the binding of DID and DAD, which is 
disrupted by binding of RhoGTPase in the formins GTPase-binding domain (GBD) (Kuhn and 
Geyer, 2014). Disruption of this DID-DAD interaction results in releasing intramolecular 
autoinhibition and partially activating the actin polymerization abilities. 
4.2. Physiological functions of formins 
4.2.1. Actin filament nucleation and elongation 
Formins play various cellular roles and the most common one is on actin filament 
nucleation and elongation. A ring-like head-to-tail FH2 dimer binds directly to G- and F-actin 
and nucleates actin molecules, which is followed by actin filaments elongation (Goode and Eck, 
2007). During this process, FH1 domain recruits G-actin molecules through interaction with 
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profilin and affects the actin polymerization rate (Kovar et al., 2006; Romero et al., 2004). 
Dimerized FH2 domains robustly stimulate actin nucleation rates in bulk kinetic assays 
(Courtemanche, 2018). In some formins, specific factors can contribute to the nucleation 
activity. For example, the C-terminal WH2 motif of FMNL3 enhances nucleation through 
binding actin monomers, which is independent of the actin subunits recruited by FH2 dimers 
(Thompson et al., 2013). The C-terminal DAD motif is another domain binding actin monomers 
and increases rates of nucleation, which is found in mammalian formins mDia1 and DAAM1 
(Gould et al., 2011). Besides, other ligands of formin C-terminal tail regions can also enhance or 
inhibit formin nucleation activities, such as the enhancement of Disheveled on DAAM1, APC 
on mDia1, Spire on FMN formins and the inhibition of Ena/Vasp on Dia formins 
(Courtemanche, 2018). 
Apart form actin nucleation, formins also function on actin elongation (Higashida et al., 
2004). A “gating” model was proposed to explain the formin-mediated actin elongation. In this 
model, FH2 domains are in rapid equilibrium among “open” and “closed” conformations that 
allow or block actin addition. Thus, the elongation rate is dictated by the probability that 
incoming actin monomers find the FH2-barbed end complex in an open conformation 
(Vavylonis et al., 2006). Indeed, the inhibition ability of elongation varies widely among 
formins from 99% in mammalian GRID2IP (Dutta et al., 2017; Silkworth et al., 2018) to about 
5-10% in mouse mDia1 (Kovar et al., 2006). Additionally, the elongation rate mediated by 
formins could be affected by the application of force, but in isoform-specific ways. For example, 
the application of force speeds up the elongation by mDia1 (Yu et al., 2017), but not by mDia2 
(Zimmermann et al., 2017). Indeed, mDia1 is mechanosensitive and can efficiently elongate 
actin filaments in response to mechanical tensions, suggesting a mechanical protection role of 
mDia1 for cellular morphology (Jegou et al., 2013). 
In addition to actin nucleation and elongation, some formins have access to bind along the 
length of actin filaments. This can leads to actin filament bundling through binding actin 
filament sides. FH2 domain alone is sufficient for the bundling mediated by mammalian formin 
FMNL1 or mDia2. However, there is no polarity of bundled actin filaments mediated by those 
formins (Harris et al., 2006). Interstingly, WHIF1 is identified with the ability to accelerate both 
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actin polymerization and depolymerization and the latter effect is due to filament severing 
ability (Chhabra and Higgs, 2006; Gurel et al., 2014). 
4.2.2. Microtubule binding and stabilization 
So far, 6 mammalian formins have been shown to bind microtubules directly, such as 
mDia1, mDia2, INF1, WHIF1, FMN1 and FMN2. Except for INF1 and FMN1, the rest formins 
mDia1, mDia2, WHIF1 and FMN2 require the FH2 domain for microtubule binding. Constructs 
containing FH1, FH2, and C-terminal domains of mDia1, mDia2 and WHIF1 bind microtubules 
with high similar affinities (Gaillard et al., 2011). mDia2 FH1 and FH2 domains binds directly 
to microtubules and decreases tubulin dissociation rates in vitro (Bartolini et al., 2008). FMN2 
directly interacts with polymerized microtubules in vitro via FH2 domain (Kwon et al., 2011). 
INF1 encompassing the conserved FH1 and FH2 domains in its N-terminal, associates 
discretely with microtubules through its novel C-terminal microtubule-binding domain (Young 
et al., 2008). In contrast, a novel microtubule-binding peptide was identified in the N-terminal 
of FMN1, which is sufficient for microtubule binding, while loss of FH1-FH2 domains in 
FMN1 has no effects on microtubule binding capability (Zhou et al., 2006). 
In addition to direct binding of microtubule lattice, mDia1 also associates with 
microtubules indirectly via microtubule plus end binding proteins. Among them, microtubule 
end binding protein EB1 and cytoplasmic linker protein CLIP170 are two important interacting 
partners of mDia1 (Lewkowicz et al., 2008; Wen et al., 2004). CLIP170-mDia1 complexes can 
be recruited to the growing microtubule ends by EB1 with the advanced actin filament 
elongation. This enhancement is also applicable to other formins such as mDia2, DAAM1, INF1, 
and WHIF1 (Henty-Ridilla et al., 2016). 
Formins can also modulate microtubule properties through post-translational modifications. 
It is reported that it is a general formins’ feature to induce microtubule acetylation in NIH 3T3 
fibroblasts (Thurston et al., 2012). Besides, some formins are also reported to affect microtubule 
detyrosination. mDia1 or WHIF1 knockdown decreases detyrosinated microtubules in NIH3T3 
fibroblasts (Bartolini et al., 2016). Overexpression of mDia2 induces stable detyrosinated 
microtubules in serum-starved NIH3T3 fibroblasts (Bartolini et al., 2008). Interestingly, mDia1 
is also necessary to maintain the level of detyrosinated microtubules in hippocampal neurons 
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(Qu et al., 2017). Besides, the microtubule regulation mediated by mDia1 in turn affect actin 
filament polymerization and alignment (Gaillard et al., 2011). 
4.2.3. Formins regulation 
As above described, DRFs formins contains a GTPase binding domain in their N-terminal. 
DRFs formins are activated by RhoGTPase binding through releasing intramolecular 
autoinhibition. Rho, Rac and Cdc42 are three well studied GTPase in formins (Kuhn and Geyer, 
2014). mDia1 and mDia2 can also be regulated by another small RhoGTPase Rif during 
filopodium formation (Goh et al., 2011). In addition, RhoGTPase signaling is also involved in 
the regulation of formins’ membrane localization. FMNL2 and FMNL3 can undergo protein N-
myristoylation, which affects their localization and activity (Moriya et al., 2012). Interestingly, 
phospholipids can regulate mDia1 localization and activity (Ramalingam et al., 2010). 
Moreover, phosphorylation through serine/threonine kinases affects mDia3 and FMNL2 
activation (Cheng et al., 2011; Wang et al., 2015). 
4.2.4. Formins in neurons and neurological disorders 
Given the vital roles of formins on actin and microtubule dynamics, formins are involved 
in general cell functions such as cell division, migration, vesicle and organelle trafficking, 
membrane receptor trafficking, and polarization (Breitsprecher and Goode, 2013). Although 
formins have not been extensively studied in nervous system cells, some works point to an 
important role of formins in neuronal development and function. In neurons, several specific 
formins have been identified with a function in different compartments. Knocking down mDia1 
increases hippocampal dendritic spines number (Qu et al., 2017). However, loss of FMN2 leads 
to the decrease of spine density in hippocampal dentate granule neurons. Functional mutation of 
FMN2 also leads to synaptic density decrease (Law et al., 2014). Similarly, mDia2 knockdown 
results in a decrease of dendritic protrusion density with slight effects on spine morphology 
distribution (Hotulainen et al., 2009). Consistently, the aberrant lengthening of dendritic 
protrusions and gradual retraction of dendrites were observed after expression of constitutive 
active DAAM1 in Purkinje cells (Kawabata Galbraith and Kengaku, 2019). For dendrite 
development, mDia1 is involved in the regulation of dendrite architecture, which may be 
mediated through Golgi deployment (Hong et al., 2018). FMN1 overexpression induces an 
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increase of primary dendrites as well as glutamatergic synaptic inputs (Simon-Areces et al., 
2011). Several formins like mDia1, mDia3, FMN2 and DAAM have been linked to axon growth 
cone maintenance and pathfinding (Kawabata Galbraith and Kengaku, 2019). At the presynapse, 
DAAM1 loss of function impairs activity dependent F-actin assembly in hippocampal 
pyramidal cells. At the postsynapse, GRID2IP interacts with glutamate receptor δ2 (GluRδ2) 
and loss of GRID2IP reduces Ca2+ requirement for LTD induction. 
The importance of formins in nervous system has been further demonstrated in 
neurological disorders. Several formin genes have been identified as risk factors, such as FMN2 
in sporadic amyotrophic lateral sclerosis (ALS) (Schymick et al., 2007), DAAM2 in 
schizophrenia (Kuzman et al., 2009) and FMN1 in early-onset obsessive-compulsive disorder 
(OCD) (Cappi et al., 2014). Moreover, loss of function or mutation of certain formins results in 
neurological deficiency. Patients with loss of functional DIAPH1 (mDia1) have symptoms of 
microcephaly, severe vision impairment, early-onset epilepsy and intellectual disability (Al-
Maawali et al., 2016; Ercan-Sencicek et al., 2015). Formins deficiency of FMNL2 or FMNL3 
may also lead to mental retardation in patients (Kumar et al., 2015; Lybaek et al., 2009). 
Mutants of FMN2 can even have intellectual disability and severe hearing loss symptoms. 
Mutations in WHIF1 were identified in patients with Charcot-Marie-Tooth disease, a hereditary 

















































The axon initial segment (AIS) has an extremely important role for the maintenance of 
neuronal polarity and action potential initiation. Recent studies have highlighted the role of AIS 
alterations in mental disorders and neurodegenerative diseases. Due to the complexity of AIS 
structure and the limited knowledge of its regulation and protein composition, it is still elusive 
how AIS structure is regulated and which regulators are involved in the AIS assembly, 
maintenance and plasticity in physiological and pathological conditions. Given AIS 
cytoskeleton is the basement of AIS control of axonal traffic and polarity, it is important to 
understand which proteins and mechanisms modulate actin and microtubules within the AIS. A 
few studies have described some proteins at the AIS, related to actin or microtubules regulation, 
such as synaptopodin or TRIM46. Previous studies have also shown that alterations of actin 
dynamics or microtubules post-translational modifications affect AIS integrity. However, we are 
far away to understand AIS cytoskeleton regulation. In this context, we hypothesized that 
formin family proteins may function as AIS cytoskeleton regulators. Formins are a group of 
proteins capable of regulating actin microfilaments and microtubules. The sparse knowledge of 
this family of proteins in brain indicates that these proteins are related to mental and 
neurodegerative diseases. Furthermore, one of its members, mDia1, is involved in axonal 
growth, epithelial cells polarity maintenance and interacts with proteins previously described at 
the AIS, such as β-catenin. Moreover, mDia1, not only modulates F-actin polymerization, but 
also affects microtubule acetylation.Thus, we studied formins as potential candidates for AIS 
actin and microtubules regulation.  
The objectives of this study were: 
Objective 1: To explore how formins may affect AIS cytoskeleton, compositions, plasticity 
or function, using a general formins inhibitor, SMIFH2.  
        Objective 2: Analysis of formins expression at the AIS and their roles on AIS assembly and 
maintenance. This objective was tackled using immunofluorescence, interference shRNA or 
over-expression plasmids to decrease or increase formins expression, and analyze their effects 
on AIS compositions and plasticity. 
        Objective 3: To identify potential candidates for formins regulation at the AIS and 





































Animals were housed in the Experimental Animal Center of the Cajal Institute at controlled 
temperature and relative humidity with alternating 12 h light and dark cycles and free access to 
food and water. All animals were taken care in accordance with the appropriate national 
legislation (53/2013, BOE no. 1337) and guidelines of the Council of the European 




Pharmacological experiments were carried out in cultured hippocampal neurons or brain 
slices. Only SMIFH2 was used for acute treatments in brain slices. The reagents and their 
concentrations are listed in the following table:  
Chemicals Function Concentration Source Identifier 
SMIFH2 Formins inhibitor 
Cultured neurons: 15 µM; 
Brain slices: 15, 30 µM 
Sigma-Aldrich Cat# 4826 
SMIFH2 Formins inhibitor 
Cultured neurons: 15 µM; 
Brain slices: 15, 30 µM 








5, 10, 25 nM TOCRIS Cat# 2792 
Tubastatin A 
hydrochloride 
HDAC6 inhibitor 10 µM Sigma-Aldrich 
Cat# 
SML0044 
Ciliobrevin D Dynein inhibitor 20 µM Calbiochem Cat# 250401 
MDL 28170 Calpain inhibitor 50 nM, 1 µM TOCRIS Cat# 1146 
Y-27632 
dihydrochloride 
ROCK inhibitor 40 µM Sigma-Aldrich Cat# Y0503 
Y-27632 
dihydrochloride 
ROCK inhibitor 40 µM TOCRIS Cat# 1254 
CT04 Rho inhibitor 1.0 μg/ml Cytoskeleton Cat# T04 





Antibodies information and the dilution used for immunocyto- or immunohistochemistry is 
provided in the following table. The antibody dilution is for immunocytochemistry, unless 
explicitly stated. 
Antibodies Dilution Source Identifier 
Rabbit polyclonal anti-mDia1 1:70 Thermo Fisher Scientific Cat# PA5-27607 
Mouse monoclonal anti-AnkG (IgG2a) IC/IH: 1:150 NeuroMab clone N106/36 
Mouse monoclonal anti-AnkG (IgG2b) 1:500 NeuroMab clone N106/65 
Mouse monoclonal anti-PanNaCh (IgG1) 1:100 Sigma-Aldrich Cat# S8809 
Rabbit polyclonal anti-pMLC 1:200 Thermo Fisher Scientific Cat# PA5-17727 
Rabbit polyclonal anti-βIV-Spectrin 1:1000 
Dr. Matthew Rasband, 
Baylor College of Medicine 
N/A 
Chicken polyclonal anti-MAP2 1:5000 Abcam Cat# ab5392 
Rabbit polyclonal anti-GFP 1:1000 Thermo Fisher Scientific Cat# A-6455 
Mouse monoclonal anti-α-Acetylated 
tubulin (IgG2b) 
1:5000 Sigma-Aldrich Cat# T7451 
Mouse monoclonal anti-α-Tubulin (IgG1) 1:5000 Sigma-Aldrich Cat# T6199 
Rabbit polyclonal anti-Kinesin 5C 1:200 Abcam Cat# ab5630 
Mouse monoclonal anti-Tau1 (IgG2a) 1:1000 Millipore Cat# MAB3420 
Rabbit polyclonal anti-Synaptopodin 1:500 Sigma-Aldrich Cat# S9442 
Alexa Fluor 568 Phalloidin 1:100 Thermo Fisher Scientific Cat# A12380 
bisBenzimide H 33342 trihydrochloride IH: 5 μg/ml Sigma-Aldrich Cat# B2261 
Alexa Fluor 488, Alexa Fluor 568, Alexa 
Fluor 647 goat anti-mouse IgG2a 
IC: 1:1000 
IH: 1:500 
Thermo Fisher Scientific 
Cat# A21131; 
A21134; A21241 
Alexa Fluor 488, Alexa Fluor 568, Alexa 
Fluor 647 goat anti-mouse IgG2b 
1:1000 Thermo Fisher Scientific 
Cat# A21141; 
A21144; A21242 
Alexa Fluor 488, Alexa Fluor 568, Alexa 
Fluor 647 goat anti-mouse IgG1 
1:1000 Thermo Fisher Scientific 
Cat# A21121; 
A21124; A21240 
Alexa Fluor 488, Alexa Fluor 594, Alexa 
Fluor 647 donkey anti-rabbit IgG (H+L) 
1:1000 Thermo Fisher Scientific 
Cat# A21206; 
A21207; A31573 
Alexa Fluor 647 goat anti-chicken IgY 
(H+L) 
1:1000 Thermo Fisher Scientific Cat#  A21449 





2.3. Oligonucleotides and recombinant DNA 
The interference RNA plasmids of mouse for mDia1 were purchased from Origene with 
the RFP expression element. Two effective targets were identified: 5’-
TGCCACTGACGAGAAGGACAAGTTTGTTG-3’ (Cat# TF500527D, shmDia1-1) and 5’-
GAAGGAATCCTACTGCTGGTCAGAGCCAT-3’ (Cat# TF500527A, shmDia1-2). HDAC6 
interference RNA plasmid with GFP expression element is kept in the laboratory and has been 
previously described (Tapia et al., 2010). AnkyrinG-GFP (270 kD) plasmid was a kind gift from 
Dr. Van Bennett laboratory. pEGFP-N1, as a control plasmid of recombinant DNA expression 
was bought from Clontech (Cat# 6085-1). The GFP-CA-mDia1 vector expressing a 
constitutively active form of mDia1 was a gift from Klaus Hahn & Ronen Zaidel-Bar (Addgene 
plasmid # 45583). The pEFmEGFP-mDia2 vector expressing mDia2 was a gift from Arthur 
Alberts (Addgene plasmid # 25407). Three plasmids of EGFP-RhoA-WT (wild type, Addgene 
plasmid # 12965), EGFP-RhoA-T19N (dominant negative type, Addgene plasmid #12967) and 
EGFP-RhoA-Q63L (constitutively active type, Addgene plasmid # 12968) were all from Gary 
Bokoch. The recombinant vector of EB1-GFP was a gift from Tim Mitchison & Jennifer 
Tirnauer (Addgene plasmid # 39299). 
Plasmids were first transformed into competent DH5α bacteria. Transformed bacteria were 
selected on LB agar plates with appropriate antibiotics. Individual colonies were used for 
storing and replicating plasmids. HiSpeed Plasmid Maxi Kit (QIAGEN, Cat# 12663) was 
utilized for plasmids extraction and the plasmids quality was tested via agarose gel 
electrophoresis and spectrophotometer. Plasmids mainly presented as supercoiled DNA with a 
range of A260/280 ratio (1.8-2.0) read by NanoDrop-1000 were used for transfection. 
3. Hippocampal Cultures 
Mouse hippocampal neurons were prepared as previously described (Fig. M1)(Kaech and 
Banker, 2006). Briefly, neurons were cultured on polylysine-treated coverslips, which were 
suspended above an astrocyte feeder layer and maintained in serum-free medium. Astrocytes 
from cortex of embryonic day 17 (E17) CD-1 mouse were prepared 2 weeks in advance and 
used for co-culturing with neurons when they reach 60%-70% confluence. Neurons were 
obtained from E17 CD-1 mouse hippocampi, which were incubated in a 0.25% trypsin solution 
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in Ca2+/Mg2+ free  
Hank’s buffered salt solution (HBSS) 
and dissociated using fire-polished 
Pasteur pipettes. The cells were plated on 
polylysine coated coverslips (1 mg/ml) at 
a density of 6,000 cells/cm2 for 2 h in 
plating medium (minimum essential 
medium [MEM], 10% horse serum, 0.6% 
glucose and Glutamax-I). Then 
coverslips were inverted and transferred 
to culture dishes containing astrocytes. 
Astrocytes medium was replaced by 
neuronal culture medium 24 h before 
neuronal culture (Neurobasal medium, 
B27 supplement, Glutamax-I). To avoid 
contact between neurons and astrocytes, 
paraffin beads were placed on coverslips 
before neuronal plating. 
Figure M1. Three steps for preparing hippocampal neuronal  
cultures. Adapted from (Kaech and Banker, 2006). 
5  μM 1-β-D-arabinofuranosylcytosine (AraC) was added after 2 days in culture to curb glial 
cells proliferation. One third of neuronal medium was replaced every week. Pharmacological 
treatments were described in the results section. In the case of pharmacological treatments in the 
absence of glial cell layer, coverslips were transferred to plates containing glial cells 
conditioned medium. Conditioned medium was prepared from 24 h maintenance of 60%-70% 
glia using neuronal culture medium. For FRAP experiments, hippocampal neurons were plated 
directly on the glass bottom of µ-Dish 35 mm culture dishes treated with polylysine (Ibidi). 
Neurons were plated at a density of 20,000 cells/cm2  and glia cells were prepared on the 
coverslips with a diameter of 24 mm. Before plating glia cells, coverslips were treated with   




4. Neuronal transfection 
In this study, primary hippocampal neurons were transfected through two approaches: 
nucleofection and lipofection. 
Nucleofection was done using the P3 Primary Cell 4D-NucleofectorTM X Kit L for primary 
mammalian neural cells (Cat# V4XP-3012, Lonza) according to the manufacturer’s instructions. 
Namely, nucleofection for scrRFP, shmDia1-1, shmDia1-2, GFP, GFP-CA-mDia1, EGFP-
mDia2, EGFP-RhoA-WT, EGFP-RhoA-T19N, EGFP-RhoA-Q63L or shHDAC6 was performed 
using 3 μg of total DNA and 3 × 10 6 cells for each nucleofection. Given the similar molecular 
weight of plasmids between shmDia1-1 and shHDAC6, co-nucleofection was achieved using 
1.5 μg of DNA for each. After nucleofection, neurons were plated at a density of 15,000 
cells/cm2 and cultured as above described. 
Lipofection experiments were performed as follows, hippocampal neurons with a density 
of 20,000 cells/cm2 were transfected at 8-14 DIV with Lipofectamine 2000 (Cat#11668-030, 
Invitrogen) and maintained for another 24 or 48 h. Lipoplexes were prepared at a ratio of 1 μl of 
Lipofectamine per 1 μg of DNA. Total transfected DNA per 35 mm culture dish for GFP, GFP-
CA-mDia1, scrRFP, shmDia1-1, EGFP-RhoA-WT, EGFP-RhoA-T19N, EGFP-RhoA-Q63L or 
EB1-GFP was 2 μg and for ankyrinG-GFP it was 5 μg.  Specifically, coverslips coated with 
neurons were quickly inverted and transferred into a clean 35 mm culture dishes or 6-well plates 
in 2 ml mixed medium (1 ml conditioned medium and 1 ml Neurobasal medium). 
Lipofectamine and DNA were mixed with Neurobasal to a final volume of 50 μl per culture dish 
respectively and left for 3-5 min. Next, plasmid DNA solution was added to Lipofectamine 
solution and gently mixed and left for 20 min at room temperature (RT). Thereafter, 100 μl of 
the mix was dropwise added to each culture dish or well and left for 90 min in the incubator. 
Lipofectamine was then washed out 3 times with 2 ml Neurobasal medium pre-warmed to 37 °C. 
After washout, coverslips were transferred back to the original 35 mm culture dishes for 
continuous culture. For FRAP experiments, neuronal culture medium and coverslips coated with 
glia were removed before lipofection and kept in the incubator. After washout of Lipofectamine, 
neuronal culture medium and coverslips were transferred back to the original µ-Dish 35 mm 




Neurons were fixed in 4% paraformaldehyde (PFA) for 15 min and washed in phosphate 
buffered saline (PBS). After 3 washes, coverslips were treated with 50 mM NH4Cl and 
incubated in blocking buffer for 1 h (0.22% gelatin, 0.1% Triton X-100 in PBS) to avoid non-
specific binding. The cells were then incubated for 1 h with primary antibodies diluted in 
blocking buffer. Following 3 additional washes, coverslips were then incubated with appropriate 
secondary antibodies in blocking buffer for 45 min, followed by 2 washes in blocking buffer 
and 2 washes in PBS. F-actin was stained using Alexa-Fluor-568-conjugated Phalloidin. After 
staining, the coverslips were mounted with Fluoromount-G (Southern-Biotech). All above 
described procedures were performed at RT. Images were acquired on a Leica fluorescence 
inverted microscope DMI6000B (40x, oil immersion, 1.00 N.A.) or Leica SP5 confocal 
microscopes (40x, oil immersion, 1.25 N.A.). For quantitative analysis in different conditions, 
coverslips in each experiment were stained with freshly diluted antibodies at the same time and 
experienced the same procedures for labelling. Besides, samples from every experiment were 
photographed with the same settings of microscopes and all measurements taken under the same 
criteria. To validate the efficiency of mDia1 shRNAs, neurons were nucleofected with control 
scrRFP or mDia1 inteference shRNAs and fixed at 10 DIV. Hippocampal neurons were stained 
with mDia1 antibody as above described. The staining intensity was calculated by measuring 
the total mDia1 intensity in the soma and the background was subtracted. AIS measurements 
were separately described below. Figures were prepared for presentation using the Adobe CS4 
software. 
6. Detergent extraction of hippocampal neurons 
13, 14 or 20 DIV neurons were first rinsed in phosphate buffer (PB) and incubated in the 
extraction buffer (pH 7.0, 30 mM PIPES, 1 mM MgCl2, 5 mM EDTA, 0.5% Triton X-100) for 5 
minutes at 37 °C as previously described (Garrido et al., 2003). After extraction, neurons were 
rinsed in PB and fixed in 4% PFA for immunocytochemistry. For 4 °C extraction experiments, 
the same manipulations were performed except that neurons were incubated in the extraction 
buffer for 20 min on ice. Coverslips were photographed on an upright Leica SP5 confocal 
microscope using Leica DM6000B 40x 1.25 N.A. oil objective with 1024 x 1024 pixels. In the 
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case of deconvolution process, images with all stacks were processed by blind iterative 
deconvolution with 10 iterations according to standard procedures in Leica SP5 3D 
deconvolution software. Figures were prepared for presentation using the Adobe CS4 software. 
7. Fluorescence recovery after photobleaching (FRAP) 
Neurons were lipofected with AnkG-GFP at 8 DIV as above described and treated with 15 
µM SMIFH2 1 h prior to being applied to FRAP at 9 or 10 DIV. Live imaging was performed 
on a Leica SP5 inverted confocal microscope, equipped with Leica DMI6000B 63x 1.40 N.A. 
oil objective, live cell chamber and FRAP Wizard system. µ-Dish 35 mm culture dishes were 
mounted on an adaptor and maintained at 37 °C and 5% CO2 in the live cell chamber. Time-
lapse images were acquired using bidirectional scan at 1400 Hz with the format of 256 x 256 
pixels and the pinhole size was 2 airy units. AIS were distinguished through stronger GFP signal 
of AnkG-GFP. Besides, the morphological differences between axon and dendrites contribute to 
the AIS identification. A ROI with an area of 5 µm x 5 µm on the AIS was photobleached at 100% 
488-nm Laser Line Visible with 25% Argon Laser Power, reducing local fluorescence by 80-
95%. FRAP was performed with 10 frames of 0.1 s interval for Pre-bleach and 15 s for Bleach 
with 0.1 s interval, followed by Post-bleach with 240 frames of 0.5 s interval. For FRAP 
analysis, fluorescence signal was background subtracted using the formula ‘I(t) = I_indicated 
region(t) – I_background(t)’ frame by frame. The normalization of recovery R_norm(t) was 
calculated in the bleached ROI region according to the formula ‘R_norm(t) = (I_bleached 
region(t) - I_bleached region(0))/(I_bleached region(Δt) - I_bleached region(0))’, in which 
I_bleached region(0) indicates the region’s mean intensity directly after bleaching, and 
I_bleached region(Δt) indicates the intensity averaged over last five frames before bleaching. To 
account for the bleaching due to imaging itself, additional correction was performed using 
intensity of neighboring nonbleached regions in the AIS according to the equation ‘R(t) = 
R_norm(t) x (I_control(Δt)/I_control(t))’, where I_control corresponds to the mean fluorescence 
intensity subtracted background of the non-bleached region and I_control(Δt) denotes the 
average intensity from last five frames before bleaching. The recovery curve was generated by 
pooling together at least 15 neurons in each condition and averaging each frame the recovery 
rate. The maximum recovery percentage was obtained through averaging recovery data in 20 s 
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at the plateau from every neuron in Sigmaplot v12.5 (Systat Software Inc., San Jose, CA, USA). 
8. Immunohistochemistry 
Brains from mice P26-P30 days old were quickly removed and acute coronal slices (300 
µm) containing sensorimotor cortex were cut with a vibratome (4 °C) in a solution containing: 
234 mM sucrose, 11 mM glucose, 26 mM NaHCO3, 2.5 mM KCl, 1.25 mM NaH2PO4, 10 mM 
MgSO4, and 0.5 mM CaCl2 (equilibrated with 95% O2–5% CO2). SMIFH2 treatment was 
carried out at a concentration of 15 or 30 µM for 3 h and the same volume of vehicle DMSO 
was used as control. Treated brain slices were fixed for immunohistochemistry using 4% PFA 
for 30 min at RT and washed in PBS. To block antibody unspecific binding, slices were 
incubated for 2 h at RT with PBS containing 0.1% TritonX-100 and 10% goat serum. Thereafter, 
slices were immersed overnight at 4 °C with mouse monoclonal anti-AnkG (IgG2a, 1:150) in 
PBS containing 0.1% TritonX-100 and 1% goat serum on a small shaker, followed by 5 washes 
using antibody diluents with 1 h interval for each time. The secondary antibody goat anti-mouse 
IgG2a conjugated with Alexa Fluor 488 (1:500) was incubated for 2 h at RT. After 5 additional 
washes, sections were counterstained with bisBenzimide for nuclei staining before mounted in 
Fluoromount G. Images were acquired on an upright Leica SP5 confocal microscope using 
Leica DM6000B 40x 1.25 N.A. oil objective with 1024 x 1024 pixels. To capture ankyrinG 
signal entirely and increase the number of in-focus AIS, sections were imaged in z stacks of 70 
steps with a 0.5-μm step size. For qualitative analysis, a Z-projection (maximum intensity 
projection) was obtained in Fiji-ImageJ software and fluorescence signal was background 
subtracted. We measured cortical AIS in layers II/III, layer IV and layers V/VI. Cortical layers 
were distinguished according to nuclei patterns. In the case of CA1 staining quantification, 
every generated Z-projected image produces one datum. Correct total fluorescence (CTF) and 
correct mean fluorescence (CMF) were used to examine the ankyrinG changes according to the 
following formulas: ‘CTF = Integrated intensity - (Mean background x Area)’ and ‘CMF = 
Mean intensity - Mean background’, where Mean background denotes the intensity averaged 
over 6 mean background values along the whole selected AIS plexus. Figures were prepared for 
presentation using the Adobe CS4 software. 
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9. AIS length and fluorescence intensity measurements 
Hippocampal neurons were imaged using a Leica fluorescence inverted microscope 
DMI6000B (40x, oil immersion) or Leica SP5 confocal microscopes (40x, oil immersion). The 
settings were adjusted to prevent signal saturation and the images were taken in z stacks with a 
0.5-μm step size using confocal microscopes. Z stack images were projected into a single plane 
using maximum intensity projections, followed by AIS analysis in Fiji-ImageJ software. To 
compare fluorescence intensity, all the parameters were exactly the same to all conditions in one 
experiment. 8-bit images were used for AIS components and position measurement. For 
ankyrinG measurement, we drew a line starting at the limit of soma identified by MAP2 
staining, and extended it along the the axon, past the AIS. Data were smoothed every 1  µm 
using Sigma Plot 12.5 software, followed by the normalization according to the value of 
maximum mean fluorescence in control neurons to be 100%. AIS start and end positions were 
determined at the proximal and distal axonal positions respectively, where the normalized 
profile declined to 33% of maximum fluorescence intensity, as described previously (Grubb and 
Burrone, 2010). Then total ankyrinG fluorescence within AIS was obtained by adding intensity 
values from the start to the end position. To obtain the mean fluorescence per 1  µm, the 
normalized total ankyrinG intensity within AIS was then divided by the length. The sum of 
fluorescent intensity values added in the proximal axon of 30 μm length was used for total 
ankyrinG intensity comparations, unless explicitly stated. Likewise, PanNaCh, pMLC and βIV-
Spectrin were compared and presented as 100% in the control. For other AIS measurement, 
ankyrinG staining was employed to identify the AIS position. In the case of acetylated α-tubulin 
analysis, integrated acetylated α-tubulin was obtained from extracted hippocampal neurons. In 
the case of hippocampal neurons without extraction, the fluorescent intensity of acetylated α-
tubulin and total α-tubulin in the AIS and neighboring dendrites was collected from the same 
neuron respectively as above described. The ratio profile of acetylated α-tubulin / α-tubulin was 
first obtained every 0.12 µm, then was smoothed and normalized considering the starting value 
in control neurons to be 1. To study the ratio value of total acetylated α-tubulin / total α-tubulin, 
both signals were quantified respectively in the AIS or proximal dendrites within 30 µm length 
and then divided. The ratio value was normalized against control. In the case of F-actin analysis, 
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smoothed data were normalized taking the averaged F-actin intensity of the start position in 
control neurons to be 100%. Then total F-actin intensity was obtained by adding 30 µm 
intensity values along the AIS. In the case of cisternal organelle analysis, we labelled 
synaptopodin and ankyrinG to identify cisternal organelles and AIS respectively. Counting was 
performed on Leica SP5 confocal microscopes with 40x objectives. We randomly evaluated AIS 
positive neurons whether it is cisternal organelle positive or negative. Every 30-40 neurons 
generated one percentage datum and data were from 3 times independent experiments. In the 
case of KIF5C analysis, a line was drawn along the entire axon and started at the limit of soma. 
To compare somal KIF5C signal, integrated intensity of soma was measured and normalized 
against control. To compare axonal KIF5C, average intensity of the entire axon was calculated 
and normalized against control. To study the distribution of KIF5C in axons, we calculated total 
KIF5C intensity in the proximal and distal 50 µm length from the same axon respectively, 
followed by the division of proximal/distal axon. 
10. Axon and dendrites morphology analysis 
Nucleofected neurons were fixed at 3 DIV or 7 DIV for axon or dendrites analysis. Positive 
cells were randomly chosen and photographed with 40x Leica SP5 confocal microscopes in z 
stacks with a 1-μm step size. The settings were adjusted to prevent signal saturation and applied 
to all conditions in every experiment. Z-projected images were used for the following evaluation. 
Tau1 staining served to identify axons for 3 DIV nucleofected neurons. According to the number 
of axons for each neuron, three categories were performed: no axon, 1 axon and axons ≥ 2. 
Every 30 neurons from each coverslip generated one percentage datum for each category. 
MAP2 signaling served to identify dendrites for 7 DIV nucleofected neurons. To quantify 
axonal or dendritic length and ramifications, lines were semi-automatically traced along the 
entire extension of axons or dendrites and their branches using NeuronJ program in Fiji 
software. Data were from 3 times independent experiments. 
11. Electrophysiology  
Whole-cell patch clamp recordings were obtained from CA3 hippocampal neurons. The 
external solution contained (mM): 125 NaCl, 26 NaHCO3, 3 CaCl2, 2.5 KCl, 2 MgCl2, 0.8 
NaH2PO4, and 10 D-glucose, and was equilibrated with 95% O2-CO2. Patch pipettes (5-10 MΩ) 
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were filled with a solution containing (mM): 120 potassium gluconate, 20 KCl, 0.5 EGTA, 10 
HEPES, 2 Na2ATP, 0.3 NaGTP and 2 MgCl2, pH 7.4. Recordings were made at RT. The voltage 
and current signals were low-pass filtered (3 kHz) and acquisition of sequences (500-1,500 ms) 
was performed at a frequency of 0.1 Hz with P-clamp 8 or 10 (Axon Instruments). Sodium 
currents were evoked by a voltage step (50 ms) from -70 to 0 mV. The capacitive and leak 
components of the evoked current were subtracted with a conventional P/4 protocol. Intrinsic 
neuronal excitability was monitored with depolarizing current pulses (1 s) of increasing 
amplitude (from +10/+500 pA). 
12. Statistical analysis 
All statistical analyses were carried out in GraphPad Prism 5 and Sigmaplot v12.5. All data 
were collected and analyzed from at least 3 independent experiments. All statistical details 
including the number of experiments and statistical tests performed can be found in each figure 
and figure legends. Sample distributions were first assessed for normality using the D’Agostino 
and Pearson omnibus test or Shapiro-Wilk test. Statistical analysis was performed by two tailed 
t-test for two group comparisons: unpaired t test for normally distributed data and Mann-
Whitney test for non-normally distributed data. For multiple group comparisons, One-way 
analysis of variance with Tukey post test and Kruskal-Wallis with Dunn’s post test were 
performed for normally and non-normally distributed data respectively. Graphs were 
represented as the mean ± SEM. And the p value less than 0.05 was considered a significant 





























































1. Formins inhibition disrupts AIS integrity 
Actin and microtubules cytoskeleton plays an important role in the development, 
maintenance and function of the Axon Initial Segment (AIS). However, to our knowledge this 
cytoskeleton regulation on AIS is very limited. In this context, formins are known to control 
actin trails in the axon, and are able to regulate both actin and microtubules in different cellular 
compartments of different cell types (Ganguly et al., 2015; Palazzo et al., 2001; Qu et al., 2017; 
Soykan et al., 2017; Thurston et al., 2012). Thus, we hypothesized that formins may be involved 
in the regulation of the AIS.  
To determine the effects of formins activity on AIS structure and composition, we 
employed SMIFH2, an inhibitor of FH2 domain, a functional conserved region in formins 
(Bartolini and Gundersen, 2010; Courtemanche, 2018; Rizvi et al., 2009). First, we tested the 
optimal and non-toxic SMIFH2 concentration and time of treatment. The vehicle of DMSO was 
solvent and the same volume of DMSO was applied as the corresponding control. Our 
observations indicated that treatments with a SMIFH2 concentration higher than 15 µM for 
more than 3 h were deleterious for cultured hippocampal neurons. Morphologically, no 
difference was observed between control and SMIFH2 groups treated with a concentration of 15 
µM for 3 h (Fig. R1A). However, ankyrinG, the master protein of AIS, decreased after 3 h 
treatment of SMIFH2 during neuronal development (7, 14 and 21 DIV) (Fig. R1A, B). The 
reduction of ankyrinG intensity was pronounced at 7 DIV (68.47 ± 2.96% vs 100 ± 2.80% in 
control neurons, Mann Whitney test, p < 0.0001) and modest at 14 DIV (74.07 ± 1.90% vs 100 
± 2.10% in control neurons, Mann Whitney test, p < 0.0001), while more mature neurons at 21 
DIV showed 86.81 ± 2.68% total ankyrinG intensity after treatment compared to 100 ± 3.38% 
in the corresponding control neurons (Mann Whitney test, p = 0.0078). This suggests that 
increased maturity of the AIS along development makes AIS less susceptible to the loss of 
formins activity.  
Next, we shortened the treating duration of SMIFH2 ranging from 30 min to 3 h to 
examine how quickly this process takes place. 14 DIV neurons were treated for 30 min, 1 h, 2 h 
and 3 h (Fig. R1C). A significant decrease of total ankyrinG was detected as soon as 30 min 
after SMIFH2 treatment (85.56 ± 1.58% vs 100 ± 1.54% for 0 h, p < 0.001), that was maintained 
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for treatments of 1 h and 2 h (82.43 ± 1.44% and 84.63 ± 1.65%, respectively). The reduction of 
ankyrinG continuously increased after 3 h treatment (76.99 ± 1.53%), indicating a time-
dependent effect of lack of formins activity on ankyrinG intensity.  
Figure R1. Formins inhibition decreases AIS components in hippocampal neurons. (A) Neurons were cultured 
for 14 DIV and then treated for 3 h with vehicle DMSO or 15 µM SMIFH2. Neurons were fixed and stained with 
MAP2 (magenta) and ankyrinG antibodies (green). Magnification of AIS in each condition is shown in adjacent 
panels. Scale bar = 20 µm. (B) 7, 14 and 21 DIV hippocampal neurons were treated for 3 h with vehicle or 15 µM 
SMIFH2 respectively. Total ankyrinG fluorescence intensity was quantified and normalized to their respective vehicle 
treated neurons at each developmental stage. **p < 0.01, ***p < 0.0001, Mann Whitney test. (C) 14 DIV neurons 
were treated with DMSO or 15 µM SMIFH2 and fixed after 0, 0.5, 1, 2 and 3 h respectively. Total ankyrinG 
fluorescence intensity was normalized to the control (0 h). n.s., not significant, ***p < 0.001, Kruskal-Wallis, Dunn’s 
multiple comparison test. (D) Quantification of AIS total voltage gated sodium channels (PanNaCh), βIV-spectrin and 
phospho-myosin light chain (pMLC) fluorescence intensity in 14 DIV neurons treated with DMSO or 15 µM 
SMIFH2 for 3 h. ***p < 0.001, unpaired t test. All data were acquired from three independent experiments and 
represented as the mean ± SEM. 
In addition, we checked other richly accumulated AIS components, such as, βIV-spectrin, 
voltage-gated sodium channels (PanNaCh) and the newly AIS identified actin related phospho-
myosin light chain (pMLC). Neurons were treated for 3 h at 14 DIV and labeled with PanNaCh, 
βIV-spectrin or pMLC antibodies. In line with the decrease of total ankyrinG intensity at the 
AIS, the signal of PanNaCh, βIV-spectrin or pMLC was remarkably reduced after blocking 
formins activity (PanNaCh, 79.15 ± 2.24% vs 100 ± 2.02% in control neurons, p < 0.0001; βIV-
spectrin, 80.48 ± 2.63% vs 100 ± 1.65% in control neurons, p < 0.0001; pMLC, 92.3 ± 1.60% vs 
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100 ± 1.44% in control neurons, p = 0.0004; Fig. R1D). 
To corroborate the decrease of AIS components after inhibiting formins activity, we took 
advantage of the AIS property to be resistant to detergent extraction (Garrido et al., 2003; 
Winckler et al., 1999). Neurons at 13 DIV were treated with DMSO or SMIFH2, followed by 
the extraction of live neurons using 0.5% TritonX-100 at 37 ºC for 5 min. After fixation and 
immunoflurescence, the remaining AIS components were evaluated. Consistent with the results 
obtained previously from non-extracted neurons, formins inhibition decreased the intensity of 
ankyrinG (71.34 ± 3.51% vs 100 ± 10.61% in control neurons, Mann Whitney test, p = 0.0273) 
and βIV-spectrin (56.33 ± 3% vs 100 ± 11.45% in control neurons, Mann Whitney test, p = 
0.0001) (Fig. R2A, B). 
 
Figure R2. Formins inhibition reduces ankyrinG and 
βIV-spectrin intensity in hippocampal neurons detergent 
extracted at 37 ºC. (A) After 3 h treatment with DMSO or 
15 µM SMIFH2, 13 DIV neurons were extracted using 
extraction buffer containing 0.5% TritonX-100 at 37 ºC for 
5 minutes. Fixed neurons were stained with ankyrinG (green) 
and βIV-spectrin (magenta) antibodies. Scale bar = 20 µm. 
(B) Quantification of total ankyrinG and βIV-spectrin 
fluorescence intensity. *p < 0.05, ***p < 0.001, Mann 
Whitney test. Data in graphs were acquired from three 
independent experiments and represented as the mean ± 
SEM. 
 
Formins expression is not limited to neurons, 
but also expressed in glia cells (Gardberg et al., 
2010; Williams et al., 2018). In our co-culture 
model, both neurons and glia cells lost formins 
activity when samples were applied to the 
treatment with SMIFH2. To exclude that formins 
inhibition in glial cells could be responsible for 
the effects on AIS, 14 DIV neurons were placed 
in glia cell conditioned medium without astrocytes, before treatment with SMIFH2 for 3 h. A 
similar decrease trend of total ankyrinG intensity was observed after blocking formins activity 
(71.2 ± 1.89% vs 100 ± 1.75% in control neurons, Mann Whitney test, p < 0.0001; Fig. R3A). 
This trend was corroborated in the cumulative fraction plot of individual neuron values for total 
ankyrinG intensity (Fig. R3A). 
48 
 
We have shown that formins inhibition reduces AIS components expression. Given AIS is 
characterized by a dynamic short- and long-term structural plasticity, we tested whether neurons 
could recover AIS composition after SMIFH2 inhibition. Thus, a set of neurons, previously 
treated with SMIFH2 or DMSO for 3 h, were washed and transferred to new plates in glia cell 
conditioned medium containing astrocytes as feeder layer for another 6 h in the absence of 
SMIFH2. Other set of neurons were fixed after 3 h SMIFH2 or DMSO treatment and used as 
control neurons. Consistent with above observations, 3 h treatment with SMIFH2 clearly 
decreased total ankyrinG intensity (68.79 ± 2.72%, Fig. R3B). After additional 6 h in the 
absence of SMIFH2, ankyrinG expression was not recovered and instead another 15% 
significant decrease (53.86 ± 2.30%) was observed compared to neurons directly fixed after 
SMIFH2 treatment (68.79 ± 2.72%, Fig. R3B ). However, ankyrinG intensity in DMSO treated 
neurons did not change after 6 h (97.4 ± 3.17% vs 100 ± 2.79% in only 3 h DMSO treated 
neurons, Fig. R3B). 
Figure R3. Formins inhibition 
has long-term effects on 
ankyrinG decrease. (A) 14 
DIV hippocampal neurons were 
treated with DMSO or 15 µM 
SMIFH2 for 3 h in glia cell 
conditioned medium without 
astrocytes. Quantification of 
total ankyrinG fluorescence 
intensity. ***p < 0.0001, Mann 
Whitney test. In the right panel, 
a cumulative fraction plot 
shows a distribution of 
normalized total ankyrinG 
intensity. (B) Neurons were treated with DMSO or 15 µM SMIFH2 for 3 h. Then neurons were washed and cultured 
for another 6 h in glia cell conditioned medium containing astrocytes. Total ankyrinG intensity was quantified and 
normalized to DMSO treated neurons before maintenance in conditioned medium. n.s., not significant, **p < 0.01, 
***p < 0.001, Kruskal-Wallis, Dunn’s multiple comparison test. All data were acquired from three independent 
experiments and represented as the mean ± SEM. 
Together, all these immunofluorescence quantification data indicate that neuronal formins 
activity is required for AIS components maintenance. In order to ascertain this role of formins 
on AIS, we tested whether SMIFH2 inhibition had the same effect on ankyrinG-GFP expressing 
neurons. To this end, we first studied the impacts of formins on exogenous ankyrinG-GFP 
accumulation in the AIS. In brief, 10 DIV hippocampal neurons were transfected with a plasmid 
expressing ankyrinG-GFP, and after 48 h expression, neurons were treated with SMIFH2 for 3 h. 
AnkyrinG-GFP mainly accumulated in the AIS and decreased after formins inhibition (Fig. 
R4A-C), which further confirmed the results obtained from endogenous ankyrinG. Namely, total 
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GFP signal of ankyrinG-GFP in the AIS reduced by 34% (65.54 ± 6.50% vs 100 ± 6.93% in 
control neurons, unpaired t test, p = 0.0008, Fig. R4B). Analysis of the average GFP signal 
revealed the decrease profile along the AIS (Fig. R4C).  
Figure R4. Formins inhibition decreases ankyrinG-GFP accumulation in the AIS. (A) 10 DIV hippocampal 
neurons were transfected with ankyrinG-GFP for 48 h and then exposed to DMSO or 15 µM SMIFH2 for 3 h. The 
neurons were stained with MAP2 antibody (magenta). AnkyrinG-GFP was richly expressed in the AIS. AIS 
magnification and ankyrinG-GFP signal for each condition are shown in adjacent panels. Scale bar = 50 µm. (B) 
Quantification of total GFP fluorescence intensity in the AIS in vehicle (black) or SMIFH2 treated neurons (red). 
***p < 0.001, unpaired t test. (C) Normalized average GFP intensity profile along the AIS in the presence (red) or 
absence (black) of 15 µM SMIFH2 treatments. (D) Percentage of AIS ankyrinG-GFP fluorescence recovery for 120 s 
after photobleaching. Hippocampal neurons were transfected with ankyrinG-GFP plasmids at 8-9 DIV and kept in 
culture for 24 h before exposing them to DMSO (black) or 15 µM SMIFH2 (red) treatment for 1 h, and posterior 
FRAP experiments. (E) The graph represents the mean ± SEM of the maximal GFP recovery capability for each 
neuron. *p < 0.05, unpaired t test. All data were acquired from three independent experiments and represented as the 
mean ± SEM. 
After this confirmation, we took advantage of the possibility to analyze live ankyrinG-GFP 
expressing neurons after DMSO or SMIFH2 treatments. Thus, we performed FRAP experiments 
to analyze ankyrinG-GFP mobility at the AIS in DMSO or SMIFH2 treated neurons. 8-9 DIV 
neurons were transfected with ankyrinG-GFP and left for 24 h before being treated with DMSO 
or SMIFH2 for 1 h prior to confocal live imaging. Next, we performed ankyrinG-GFP 
photobleaching on a section of 5 µm of the AIS and analyzed GFP signal during the whole 
processes of live imaging. The maximal ankyrinG-GFP signal recovery was significantly lower 
in SMIFH2 treated neurons (36.6 ± 5.01% vs 54.77 ± 6.32% in DMSO treated neurons, 
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unpaired t test, p = 0.0305, Fig. R4D, E). These results suggest that formins inhibition affects 
ankyrinG-GFP diffusion and tethering at the AIS. Nevertheless, it may also reflect the 
possibility of alterations on ankyrinG traffic at the AIS. 
2. Formins inhibition alters AIS actin and microtubules cytoskeleton 
In view of our results, and taking in account that AIS cytoskeleton integrity and dynamics 
is essential for AIS components tethering and trafficking, we analyzed the AIS actin and 
microtubules cytoskeleton after formins inhibition. We first studied F-actin at the AIS using 
fluorescent Phallodin. To do so, 14 DIV neurons were treated with DMSO or SMIFH2 for 3 h 
and stained with Phalloidin. AIS identification was done by ankyrinG staining and F-actin 
intensity was quantified in the ankyrinG positive area in confocal sections of control or 
SMIFH2 treated neurons. Consistent with other reports (Jones et al., 2014), F-actin signal in the 
AIS was not high in mature neurons (Fig. R5A). AIS F-actin was distributed in patches along 
the AIS (Fig. R5A). Formins inhibition with SMIFH2 decreased 18% of total F-actin intensity at 
the AIS (81.59 ± 1.94% vs 100 ± 2.27% in control neurons, Mann Whitney test, p < 0.0001; Fig. 
R5B, C). In line with this, the average profile along the AIS also showed a reduction of F-actin 
intensity (Fig. R5D).  
Interestingly, the AIS contains an actin related structure, the cisternal organelle (CO) 
(Sanchez-Ponce et al., 2012a). To corroborate the above findings, we took advantage of this 
structure. To this end, we treated mature neurons at 21 DIV for 3 h and labeled CO using the 
synaptopodin marker. AIS was identified by ankyrinG staining. While 89.83 ± 2.50% of control 
neurons had an identificable synaptopodin positive CO, only 25.41 ± 4.61% of neurons treated 
with SMIFH2 were synaptopodin positive (p = 0.0022, Mann Whitney test; Fig. R5F). Thus, 
formins inhibition dramatically reduced synaptopodin intensity in the AIS (Fig. R5E, F), further 
suggesting a change on AIS F-actin cytoskeleton. 
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Figure R5. Formins inhibition decreases F-actin intensity in the AIS. (A) 14 DIV neurons were treated with 
vehicle DMSO or 15 µM SMIFH2 for 3 h. Neurons were fixed and stained with ankyrinG antibodies (green) for AIS 
identification. F-actin was labeled by Alexa Fluor 568 Phalloidin (magenta). Magnification of AIS in each condition 
is shown under each image. Scale bar = 20 µm. (B) Quantification of total F-actin intensity in the AIS in vehicle 
(black) or SMIFH2 treated neurons (red). (C) Graph represents mean ± SEM normalized total F-actin intensity of 
data represented in B. ***p < 0.0001, Mann Whitney test. (D) Normalized average F-actin intensity profile along the 
AIS in the presence (red) or absence (black) of 15 µM SMIFH2 treatments. (E) 21 DIV hippocampal neurons treated 
for 3 h with vehicle DMSO or 15 µM SMIFH2. Neurons were fixed and stained with synaptopodin (magenta) and 
ankyrinG antibodies (green). Synaptopodin puncta were used to identify cisternal organelles and ankyrinG signal was 
used to identify AIS. Magnification of AIS is shown under each image. Scale bar = 20 µm. (F) Quantification of the 
percentage of neurons with or without synaptopodin puncta in the AIS. **p < 0.01, Mann Whitney test. All data were 
acquired from three independent experiments and represented as the mean ± SEM. 
Next, we analyzed whether microtubule properties were modified on AIS after formins 
activity inhibition. It has been described that formins can stabilize microtubules and modify 
tubulin acetylation in different cell types (Qu et al., 2017; Thurston et al., 2012). Previous 
studies have demonstrated that tubulin acetylation at the AIS is important to maintain AIS 
composition and integrity (Tapia et al., 2010). We first analyzed α-tubulin acetylation in 
dendrites and the AIS. To do this, 14 DIV neurons treated with DMSO or SMIFH2 for 3 h and 
labeled with acetylated-α-tubulin and α-tubulin antibodies, as well as ankyrinG for AIS 
identification. We found a clear reduction of acetylated-α-tubulin / α-tubulin ratio in the AIS 
after blocking formins activity (0.82 ± 0.025 vs 1 ± 0.021 in DMSO treated neurons, unpaired t 
test, p < 0.0001; Fig. R6A). This reduction was detectable all along the AIS (Fig. R6B). To 
check whether this effect is only related to AIS or is a general phenotype in other neuronal 
compartments, we analyzed acetylated-α-tubulin / α-tubulin ratio in proximal dendrites. After 3 
52 
 
h formins inhibition this ratio did not significantly change (0.95 ± 0.027 vs 1 ± 0.018 in DMSO 
treated neurons, unpaired t test, p = 0.1484; Fig. R6C), which is in accordance with the profile 
of this ratio along dendrites (Fig. R6D). These results suggest that formins activity is important 
to regulate microtubules characteristics in the AIS. 
Figure R6. Formins inhibition reduces tubulin acetylation in the AIS. (A, C) 14 DIV neurons were treated with 
vehicle DMSO or 15 µM SMIFH2 for 3 h. Graphs represent the quantification of the total intensity ratio of 
acetylated-α-tubulin / α-tubulin in the AIS (A) or in the proximal dendrites (C) in the presence or absence of 15 µM 
SMIFH2 treatments. (B, D) Normalized average ratio of acetylated-α-tubulin / α-tubulin profile along the AIS (B) or 
the proximal dendrite in 40 µm (D). n.s., not significant, ***p < 0.0001, unpaired t test.  (E) Images of control and 
SMIFH2 treated 13 DIV neurons after detergent extraction. After treatment, neurons were extracted using extraction 
buffer containing 0.5% TritonX-100 at 37 ºC for 5 minutes before fixation. Fixed neurons were stained with 
acetylated-α-tubulin (green), ankyrinG (magenta) and βIV-spectrin (blue) antibodies. Scale bar = 10 µm. (F) 
Quantification of total acetylated-α-tubulin fluorescence intensity of neurons shown in E. ***p < 0.0001, Mann 
Whitney test. (G) Normalized ratio of total acetylated-α-tubulin / AIS length for each neuron. ***p < 0.0001, 
unpaired t test. All data were acquired from three independent experiments and represented as the mean ± SEM. 
To further ascertain this data, we took advantage of the stability and detergent extraction 
resistance of AIS proteins. Thus, 13 DIV neurons were treated for 3 h with SMIFH2 or DMSO 
and then incubated in extraction buffer for 5 min at 37 ºC and fixed. Neurons were stained with 
acetylated-α-tubulin antibodies, and ankyrinG or βIV-spectrin staining was used for AIS 
identification (Fig. R6E). We observed a clear reduction of acetylated α-tubulin after inhibiting 
formins activity (46.13 ± 3.85% vs 100 ± 7.77% in control neurons, Mann Whitney test, p < 
0.0001; Fig. R6F), which was accompanied by a lower intensity of ankyrinG and βIV-spectrin 
staining (Fig. R6E). To avoid differences due to variability of neuronal AIS length after 
extraction, we normalized each AIS data to its length. Normalized acetylated α-tubulin of every 
µm AIS showed a similar reduction by 50% (49.27 ± 2.84% vs 100 ± 6.87% in DMSO treated 
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neurons, unpaired t test, p < 0.0001; Fig. R6G). Together, all these data demonstrate that 
formins activity is necessary to maintain AIS cytoskeleton dynamics. The absence of formins 
activity may then affect neuronal polarity and axonal trafficking.  
3. Blocking formins activity results in loss of neuronal polarity and alterations in axonal 
trafficking 
The AIS is essential to maintain neuronal polarization and serves as a membrane and 
cytoplasmic barrier to exclude somatodendritic proteins from the axon (Hedstrom et al., 2008; 
Sobotzik et al., 2009; Winckler et al., 1999). Thus, we analyzed whether formins inhibition may 
affect the distribution of a main somatodendritic protein, MAP2. To do so, 13 DIV neurons were 
treated with DMSO or SMIFH2 for 3 h, and then washed in neuronal medium and maintained in 
new plates with astrocytes and conditioned medium for 6 h or 24 h. Neurons were fixed and 
stained for MAP2 and ankyrinG. No difference was found for the percentage of ankyrinG 
positive neurons after 3 h treatment (97.43% for SMIFH2 group vs 98.13% for vehicle group; 
Fig. R7B), although ankyrinG intensity was significantly reduced (Fig. R1B). After additional 6 
h in conditioned medium, ankyrinG intensity decreased even more (Fig. R3B), but we were not 
able to detect MAP2 entering the axon. However, after 24 h we found that lots of neurons lost 
ankyrinG staining in pre-treated SMIFH2 group (Fig. R7B). Only 23% of neurons showed 
detectable and low ankyrinG intensity, in which concomitantly MAP2 signal was detected in the 
axon (Fig. R7A-D). MAP2 intensity profile along the axon showed a high level of MAP2 signal, 
particularly in the proximal region (Fig. R7C). Cell to cell analysis of total ankyrinG and MAP2 
intensity within AIS revealed that control neurons had low MAP2 intensity and high ankyrinG 
intensity, while neurons pre-treated with SMIFH2 showed higher MAP2 intensity and lower 
ankyrinG intensity (Fig. R7D). 
 In order to ascertain that formins inhibition can affect AIS barrier and neuronal 
polarization, we treated neurons with SMIFH2 at 5 DIV, when the AIS barrier is in the process 
of maturation (Nakada et al., 2003). 5 DIV neurons were treated for 3 h and labeled with 
ankyrinG and the somatodendritic marker MAP2. In control neurons, ankyrinG was enriched at 
the AIS and cytoplasmic MAP2 defined the somatodendritic domain and was absent from the 
axon (Fig. R7E). However, MAP2 signal extended into the AIS and continued along the axon in 
54 
 
SMIFH2 treated neurons, meanwhile a reduced accumulation of ankyrinG was observed in the 
AIS (Fig. R7E). Combined, these results indicate that formins activity is required to exclude 
somatodendritic proteins and maintains AIS barrier functionality. 
Figure R7. Formins inhibition disrupts neuronal polarity. (A) 13 DIV neurons were treated with DMSO or 15 µM 
SMIFH2 for 3 h. Then neurons were washed and cultured for another 24 h in glia cell conditioned medium containing 
astrocytes. Neurons were stained with MAP2 (magenta) and ankyrinG antibodies (green). Magnification of boxed 
AIS regions are shown in adjacent panels. Red arrows indicate the MAP2 signal in the proximal axon. Scale bar = 20 
µm. (B) Quantification of the percentage of ankyrinG positive neurons in the AIS before and after maintenance in the 
conditioned medium for 24 h. (C) Normalized average MAP2 intensity profile along the proximal axon after 24 h 
maintenance in the conditioned medium. (D) Cell-to-cell analysis of the relationship between total ankyrinG intensity 
and total MAP2 intensity at the AIS after 24 h maintenance in the conditioned medium. (E) 5 DIV hippocampal 
neurons were treated with DMSO or 15 µM SMIFH2 for 3 h before AIS barrier completely forms. Fixed neurons 
were stained with MAP2 (magenta) and ankyrinG antibodies (green). Magnification of boxed regions including AIS 
in each condition is shown in adjacent panels. Scale bar = 100 µm. Data were acquired from three independent 
experiments and represented as the mean ± SEM. 
The AIS is also essential to control and allow the traffic of axonal cargoes (Song et al., 
2009). Kinesin-1 is one of the main proteins in charge of axonal cargoes transportation. Its 
entrance in the AIS depends on microtubules acetylation and detyrosination (Konishi and Setou, 
2009; Reed et al., 2006). Given our previous results revealed that misregulation of tubulin 
acetylation in the AIS redistributes kinesin-1 location (Tapia et al., 2010) and our above data 
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showed that formins inhibition decreased tubulin acetylation in the AIS, we investigated 
whether kinesin-1 is altered following the inhibition of formins activity. To this end, we 
analyzed KIF5C staining and distribution, a major kinesin-1 family member functioning in the 
axonal transportation (Nakata and Hirokawa, 2003; Tapia et al., 2010). 5 DIV neurons were 
treated with SMIFH2 or DMSO for 3 h and labeled with KIF5C antibody. To analyze KIF5C 
signal distribution, its intensity was traced along the axon and the integrated intensity of KIF5C 
in the soma was also measured. Our results showed that KIF5C was significantly increased in 
the soma of SMIFH2 treated neurons (124 ± 4.63% vs 100 ± 4.39% in control neurons, unpaired 
t test, p = 0.0003; Fig. R8A, B), while it was reduced along the axon (88.99 ± 3.97% vs 100 ± 
3.17% in control neurons, unpaired t test, p = 0.0418; Fig. R8A, C). To further analyze KIF5C 
distribution in the axon, the ratio of KIF5C intensity in the proximal versus distal 50 µm axon 
was evaluated in both conditions. A relatively higher KIF5C signal was observed in the 
proximal axon of SMIFH2 treated neurons (129.7 ± 9.79%) compared to the vehicle treated 
Figure R8. The absence of formins activity 
alters the distribution of KIF5C along the 
neuron. (A) 5 DIV neurons treated for 3 h with 
DMSO or 15 µM SMIFH2. Neurons were fixed 
and stained with KIF5C antibodies (green). 
KIF5C expression in the soma is magnified in the 
boxes. Scale bar = 100 µm. (B, C) Quantification 
of total KIF5C fluorescence intensity in the soma 
(B) or along the entire axon (C) in vehicle (black) 
or SMIFH2 treated neurons (red). *p < 0.05, ***p 
< 0.001, unpaired t test. (D) Quantification of 
KIF5C intensity ratio between proximal and 
distal 50 µm axon. *p < 0.05, Mann Whitney test. 
All data were acquired from three independent 





neurons (100 ± 8.42%, Mann Whitney test, p = 0.0231; Fig. R8D). Combined, these data 
indicate that formins activity is necessary to maintain proper axonal transportation. Taken 
together, formins inhibition affected AIS cytoskeleton and structural integrity and resulted in 
defects on AIS barrier and axonal traffic. Mammalian animals consist of 15 formins. Therefore, 




4. mDia1 localizes at the AIS 
Next, we asked which formin family members may mediate AIS regulation. Our 
knowledge of formins in brain is still very limited, and only a few works have revealed the role 
of formins in brain functions (Kawabata Galbraith and Kengaku, 2019). In this context, mDia1 
is able to regulate axon growth in cultured cerebellar granule neurons (Arakawa et al., 2003), 
and it is an important regulatory protein to maintain polarity in epithelial or neuroepithelial cells 
(Acharya et al., 2017; Thumkeo et al., 2011). Besides, mDia1 is ubiquitously expressed in 
neurons and has been detected in dendrites, axon, dendritic spines and synapses (Qu et al., 2017; 
Soykan et al., 2017). mDia1 exerts its functions through regulating actin dynamics and 
microtubules stability (Ishizaki et al., 2001). This makes mDia1 a suitable candidate among 
formin members for AIS regulation. First, we tested whether mDia1 localizes in the AIS. Mature 
neurons at 14 DIV were labeled with an mDia1 antibody that has been previously used in other 
studies (Neuhaus et al., 2017). Our results showed that mDia1 signal was observed mainly in 
the soma with a perinuclear staining, as well as, in dendrites and axon (Fig. R9A). Meanwhile, 
mDia1 puncta were also detected in the AIS along ankyrinG staining (Fig. R9A). To corroborate 
these findings, neurons were transfected at 10 DIV with a GFP-mDia1 plasmid, which harbors 
its constitutive active form (GFP-CA-mDia1), and neurons were kept for another 48 h in culture. 
GFP signal was detected in the soma with a perinuclear signal, but also in the AIS, along the 
axon and in dendrites (Fig. R9B), as found with mDia1 antibody staining. Indeed, GFP signal 
and mDia1 antibody staining were colocalized in the same regions, as observed in the AIS and 
axon (Fig. R9C).  
To further confirm mDia1 location at the AIS, we took advantage of the detergent 
resistance properties of AIS proteins. As actin and microtubules cytoskeleton dynamics are 
sensitive to temperature changes, we performed detergent extraction experiments at 4 and 37 ºC 
(Winckler et al., 1999). Detergent extraction was initially applied to 14 DIV using 0.5% 
TritonX-100 at 4 ºC. After extraction, mDia1 signal was detected as puncta in the AIS, identified 
by ankyrinG staining (Fig. R9D). Next, we extracted 20 DIV neurons at 37 ºC. Consistent with 
the findings at 4 ºC, mDia1 localized along the AIS as puncta (Fig. R9E). Together, these data 




Figure R9. mDia1 localizes at the AIS. (A) 14 DIV hippocampal neurons stained with mDia1 (green) and ankyrinG 
(magenta) antibodies. AIS region is magnified under the image. Scale bar = 20 µm. (B) GFP-CA-mDia1 transfected 
10 DIV hippocampal neurons stained with MAP2 (blue) and ankyrinG (magenta) antibodies. AIS region is magnified 
under the image. Scale bar = 20 µm. (C) GFP-CA-mDia1 transfected 9 DIV hippocampal neurons stained with 
MAP2 (blue) and mDia1 (magenta) antibodies. A representative image of proximal axon is shown. Scale bar = 20 µm. 
(D) Detergent extracted 14 DIV neurons at 4 ºC for 20 minutes. (E) Detergent extracted 20 DIV neurons at 37 ºC for 
5 minutes. Neurons were fixed and stained with mDia1 (green) and ankyrinG (magenta) antibodies. Scale bar = 20 
µm. 
5. mDia1 is necessary for AIS assembly 
AIS regulation includes AIS assembly and maintenance. AIS starts to assemble since axon 
specification at 3-4 DIV (Kaech and Banker, 2006) and turns to be premature when AIS barrier 
is formed at 10 DIV (Nakada et al., 2003). Thus, we questioned whether mDia1 plays roles in 
the AIS formation. Before addressing this question, we first examined the expression of mDia1 
in hippocampal neurons at 3 DIV and 7 DIV respectively. Similar to mature neurons, mDia1 
was mainly expressed in the soma with a perinuclear staining, as well as, in dendrites and in the 
nascent axon of hippocampal neurons (Fig. R10A, C). mDia1 staining was also observed in the 
AIS of 7 DIV neurons, identified by ankyrinG staining (Fig. R10C). However, we found a 
relatively higher signal of mDia1 in the axon compared to neurites at 3 DIV (Fig. R10A, B) and 
this difference disappeared at 7 DIV along dendrites development (Fig. R10C). These data 




Figure R10. mDia1 location in 
neuronal early developmental 
stages. (A) 3 DIV neurons were 
stained with mDia1 (green) and 
Tau1 (blue) antibodies. F-actin was 
labeled by Alexa Fluor 568 
Phalloidin (magenta). Scale bar = 
50 µm. (B) Normalized average 
mDia1 intensity along the axon or 
neurites (axon, n = 41; neurites, n = 
51). Data in graphs were acquired 
from three independent experiments. 
(C) 7 DIV neurons were stained 
with mDia1 (green), ankyrinG 
(magenta) and MAP2 (blue) 
antibodies. Scale bar = 50 µm. 
 
Previous studies reported that the complexity of neuronal morphology can affect AIS 
development (Hamada et al., 2016; Tapia et al., 2017). Moreover, the time window of AIS 
assembly matches with initial dendritic development. Therefore, it is necessary to study the 
contribution of mDia1 during axon and dendrites growth prior to AIS assembly study. We 
employed knockdown experiments to reduce endogenous mDia1 expression before neuronal 
polarization starts. First, we analyzed 4 different vectors harboring short hairpin RNAs specific 
for mDia1 that co-express the red fluorescent protein (RFP). As a control we used scrambled 
RNA sequences (scrRFP). After screening, we found two efficient vectors to knock down 
mDia1 (shmDia1-1 and shmDia1-2).  
Figure R11. Identification of efficient 
mDia1 interference shRNAs. (A) 10 
DIV hippocampal neurons were 
nucleofected with scrambled 
interference RNA (scrRFP) or mDia1 
interference RNA (shmDia1-1, 
shmDia1-2). Nucleofected neurons 
were identified based on RFP 
fluorescence (magenta). Neurons were 
stained with mDia1 (green) and MAP2 
(blue) antibodies. Scale bar = 20 µm. 
(B) Quantification of total mDia1 
fluorescence intensity in the soma of 10 
DIV hippocampal neurons nucleofected 
with scrRFP, shmDia1-1 or shmDia1-2 
plasmids. *p < 0.05, ***p < 0.001, 
One-way analysis of variance, Tukey’s 
multiple comparison test. Data in 
graphs were acquired from three independent experiments and represented as the mean ± SEM. 
Neurons were nucleofected before plating and fixed at 10 DIV. Nucleofected neurons were 
identified based on RFP fluorescence. Samples were labeled with mDia1 antibody and the total 
mDia1 intensity in the soma was measured to evaluate the knocking down efficiency. We found 
a significant reduction of mDia1 signal in shmDia1-1 nucleofected neurons (56.15 ± 2.82%) and 
59 
 
shmDia1-2 nucleofected neurons (70.85 ± 3.88%) compared to mDia1 signal in scrRFP 
nucleofected control neurons (100 ± 3.71%, One-way analysis of variance, Tukey’s multiple 
comparison test, p < 0.001; Fig. R11A, B). 
Next, we took advantage of the higher efficiency of shmDia1-1 vector capable of depleting 
mDia1 for axonal and dendritic studies. Neurons were nucleofected with scrRFP or shmDia1-1 
and fixed at 3 DIV and 7 DIV respectively. 3 DIV neurons were used for studying axon polarity 
and axon length. Axon polarity was assessed by the percentage of Tau1 positive nucleofected 
neurons among all the nucleofected neurons identified by RFP (Fig. R12A). We found that 
knocking down mDia1 has no effects on axon specification (Fig. R12A). 
Figure R12. Suppression of 
mDia1 by interference shRNAs 
has no effects on axon and 
dendrites growth in 
hippocampal neurons. (A) 3 DIV 
hippocampal neurons nucleofected 
with scrambled interference RNA 
(scrRFP) or mDia1 interference 
RNA (shmDia1-1). Neurons were 
stained with Tau1 (green) antibody. 
Scale bar = 50 µm. (B) 
Quantification of total axon length 
of 3 DIV hippocampal neurons 
nucleofected with scrRFP or 
shmDia1-1 plasmids. n.s., not 
significant, Mann Whitney test. (C) 
Quantification of total axon 
branches in the same neurons. n.s., 
not significant, Mann Whitney test. 
(D) 7 DIV hippocampal neurons 
nucleofected with scrRFP or 
shmDia1-1 plasmids. Neurons 
were stained with MAP2 (blue) 
antibody. Scale bar = 100 µm. (E) 
Quantification of total dendrites 
length of 7 DIV hippocampal 
neurons nucleofected with scrRFP 
or shmDia1-1 plasmids. n.s., not significant, Mann Whitney test. (F) Quantification of total dendrites branches of 7 
DIV hippocampal neurons nucleofected with scrRFP or shmDia1-1 plasmids. n.s., not significant, unpaired t test. 
Nucleofected neurons were identified based on RFP fluorescence (magenta). All data were acquired from three 
independent experiments and represented as the mean ± SEM. 
 No significant difference was observed in total axon length (278.3 ± 18.04 µm for 
shmDia1-1 nucleofected neurons vs 247.3 ± 14.64 µm for scrRFP nucleofected neurons, Mann 
Whitney test, p = 0.1907; Fig. R12B), neither a change was observed for the number of axonal 
branches (2.08 ± 0.13 for shmDia1-1 nucleofected neurons vs 1.91 ± 0.10 for scrRFP 
nucleofected neurons, Mann Whitney test, p = 0.3093; Fig. R12C). Meanwhile, 7 DIV neurons 
were used for dendritic study. Visually, we did not find any change of dendrites based on the 
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MAP2 staining (Fig. R12D). This was confirmed by our quantitative data showing comparable 
dendrites length (213.9 ± 10.89 µm for shmDia1-1 nucleofected neurons vs 235.5 ± 13.44 µm 
for scrRFP nucleofected neurons, Mann Whitney test, p = 0.4177; Fig. R12E) and total dendritic 
branches (4.15 ± 0.19 for shmDia1-1 nucleofected neurons vs 4.72 ± 0.24 for scrRFP 
nucleofected neurons, unpaired t test, p = 0.0669; Fig. R12F). 
We have shown that mDia1 reduction has no significant effects on initial axon and 
dendrites growth. Thus, we asked whether increasing mDia1 expression or enhancing mDia1 
activity on early neuronal development may have effects on neuronal growth. To this end, 
hippocampal neurons were nucleofected using a plasmid that expresses a constitutively active 
form of mDia1 (GFP-CA-mDia1). GFP was used as a control vector for nucleofection. 
Nucleofected neurons were fixed at 3 DIV and labeled with Tau1 for axon identification (Fig. 
R13A). Neurons expressing GFP-CA-mDia1 significantly reduced axon polarity, and 59.50 ± 
7.40% did not develop an axon compared to 9.79 ± 1.35% in GFP nucleofected neurons (Mann 
Whitney test, p = 0.0022).  
Figure R13. Expression of a 
constitutively active form of 
mDia1 decreases axon 
specification and axon 
growth. (A) 3 DIV 
hippocampal neurons 
nucleofected with GFP or 
GFP-CA-mDia1 plasmids. 
Nucleofected neurons were 
identified based by GFP 
signal. Neurons were stained 
with Tau1 (magenta) antibody. 
Arrows indicate axons of 
nucleofected neurons. Scale 
bar = 100 µm. (B) Percentage 
of neurons without or with 1, 
≥ 2 axons in 3 DIV 
hippocampal neurons 
nucleofected with GFP or 
GFP-CA-mDia1 plasmids. 
**p < 0.01, Mann Whitney 
test. (C) Quantification of 
total axon length in 3 DIV polarized GFP or GFP-CA-mDia1 positive neurons. ***p < 0.0001, unpaired t test. All 
data were acquired from three independent experiments and represented as the mean ± SEM. 
Meanwhile, 37.98 ± 7.21% developed one axon, and 2.52 ± 1.19% were able to develop 
two or more axons, compared to 70.24 ± 2.74% and 19.97 ± 3.67%, respectively, in GFP 
nucleofected neurons (Mann Whitney test, p = 0.0081 and p = 0.0022, respectively,  Fig. R13B). 
We further analyzed GFP-CA-mDia1 polarized neurons and we found a significant reduction of 
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total axon length (187.9 ± 13.40 µm vs 332.6 ± 23.04 µm in GFP polarized neurons, unpaired t 
test, p < 0.0001; Fig. R13A, C). These data suggest that mDia1 is not strictly necessary to 
develop the axon, but its enhanced expression and activity affect initial neuronal polarization. 
Given that knocking down mDia1 has no effects on early neuronal development in axon 
and dendrites, we took advantage of this approach to specifically study the role of mDia1 on 
AIS assembly. Neurons were nucleofected with two efficient mDia1 knockdown vectors 
shmDia1-1 and shmDia1-2, or scrRFP vector as control. Nucleofected neurons were cultured 
until 10 DIV when AIS diffusion barrier is formed. Fixed samples were labeled with ankyrinG 
antibody and its fluorescence intensity in the AIS along 30 µm was analyzed for comparing total 
ankyrinG expression. We found that ankyrinG intensity was reduced in both shmDia1-1 (65.09 
± 1.51%) and shmDia1-2 nucleofected neurons (78.31 ± 2.15%) compared to 100.0 ± 2.44% in 
scrRFP nucleofected neurons (p < 0.001; Fig. R14A, B). 
Figure R14. Suppression of mDia1 by interference shRNAs decreases AIS proteins accumulation. (A) 10 DIV 
hippocampal neurons nucleofected with scrambled interference RNA (scrRFP) or mDia1 interference RNAs 
(shmDia1-1, shmDia1-2). Nucleofected neurons were identified based on RFP fluorescence (magenta). Neurons were 
stained with ankyrinG (green) and MAP2 (blue) antibodies. Scale bar = 20 µm. (B) Quantification of total ankyrinG 
fluorescence intensity in the AIS of scrRFP, shmDia1-1 or shmDia1-2 10 DIV nucleofected hippocampal neurons. 
***p < 0.001, One-way analysis of variance, Tukey’s multiple comparison test. (C) Quantification of total ankyrinG 
fluorescence intensity in the AIS of 7 DIV hippocampal neurons nucleofected with plasmids of scrRFP, shmDia1-1 or 
shmDia1-2. *p < 0.05, ***p < 0.001, Kruskal-Wallis, Dunn’s multiple comparison test. (D) Cumulative fraction plot 
of the normalized total ankyrinG intensity of neurons quantified in C. (E) Quantification of total voltage gated 
sodium channels (PanNaCh) and βIV-spectrin fluorescence intensity in the AIS of 7 DIV hippocampal neurons 
nucleofected with scrRFP or shmDia1-1 plasmids. ***p < 0.001, Mann Whitney test. (F) Cumulative fraction plot 
shows the normalized total PanNaCh and βIV-spectrin intensity distribution of neurons quantified in E. All data were 
acquired from three independent experiments and represented as the mean ± SEM. 
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 The reduction of ankyrinG intensity in both mDia1 shRNAs was in line with the higher 
efficiency of shmDia1-1 to deplete mDia1 expression in hippocampal neurons (Fig. R11A, B). 
These data suggest that mDia1 is necessary to assemble AIS components. In order to ascertain 
this data, we analyzed ankyrinG expression in 7 DIV nucleofected neurons, when AIS diffusion 
barrier and AIS maturity is not complete (Nakada et al., 2003). Consistently, our data showed 
that total ankyrinG intensity in the AIS was significantly decreased in shmDia1-2 (87.13 ± 
2.29%) and even more in shmDia1-1 nucleofected neurons (73.89 ± 1.65%) compared to 100 ± 
3.54% in scrRFP nucleofected neurons (Kruskal-Wallis, Dunn’s multiple comparison test, p < 
0.001; Fig. R14C). The decrease trend was corroborated by the cumulative fraction plot of total 
ankyrinG intensity in individual neurons (Fig. R14D). In addition, we further analyzed other 
AIS components using 7 DIV nucleofected samples. We found a ~53% reduction of total 
PanNaCh (46.63 ± 5.84%, Mann Whitney test, p = 0.0003; Fig. R14E) and a ~67% reduction of 
total βIV-spectrin (32.99 ± 3.97%, Mann Whitney test, p < 0.0001; Fig. R14E) in shmDia1-1 
nucleofected neurons compared to scrRFP nucleofected neurons. The cumulative fraction plot of 
total PanNaCh and βIV-spectrin further confirmed the reduction of AIS components after 
knocking down mDia1 (Fig. R14F). These results suggest that mDia1 is involved in AIS 
modulation before and after the diffusion barrier is formed.  
We have shown that formins inhibition causes AIS structural disruption and mDia1 
suppression disturbs AIS structural integrity. To further ascertain that the effects of SMIFH2 on 
AIS are due to mDia1 inhibition, neurons were nucleofected with scrRFP or shmDia1-1 
plasmids and cultured until 10 DIV, followed by 3 h treatment with DMSO or 15 µM SMIFH2. 
Fixed neurons were labeled with ankyrinG antibody and total ankyrinG intensity in 30 µm AIS 
was quantified and analyzed. In line with above results, both, SMIFH2 treatment and mDia1 
suppression, alone or in combination, significantly decreased ankyrinG intensity (One-way 
analysis of variance, Tukey’s multiple comparison test, p < 0.001; Fig. R15A, B). SMIFH2 
treated neurons and shmDia-1-1 nucleofected neurons shared a similar reduction of ankyrinG 
level (68.32 ± 2.02% for neurons in scrRFP-SMIFH2 group vs 72.83 ± 3.17% for neurons in 
shmDia1-1-DMSO group, n.s.; Fig. R15A, B). Besides, when shmDia1-1 nucleofected neurons 
were treated with SMIFH2, no further reduction of total ankyrinG intensity was observed in 
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shmDia1-1 nuclefected neurons (66.85 ± 3.01% vs 72.83 ± 3.17% for neurons in shmDia1-1-
DMSO group, Fig. R15A, B). Together, these results indicate that mDia1 is the primary target of 
SMIFH2 in hippocampal neurons during AIS development. Thus, mDia1 is a regulator of AIS 
assembly and potentially involved in its maintenance. 
 
Figure R15. Formins inhibition does not 
further decrease ankyrinG intensity in 
neurons with decreased mDia1 expression. 
(A) 10 DIV hippocampal neurons were 
nucleofected with scrambled interference RNA 
(scrRFP) or mDia1 interference RNA 
(shmDia1-1) and then treated for 3 h with 
DMSO or 15 µM SMIFH2. Nucleofected 
neurons were identified based on RFP 
fluorescence (magenta). Neurons were stained 
with ankyrinG (green) antibody. Scale bar = 20 
µm. (B) Quantification of total ankyrinG 
fluorescence intensity in the AIS of 10 DIV 
hippocampal neurons in every experimental 
condition. n.s., not significant, ***p < 0.001, 
One-way analysis of variance, Tukey’s multiple 
comparison test. Data in graph were acquired 
from three independent experiments and 
represented as the mean ± SEM. 
 
6. mDia1 is required for AIS maintenance and plasticity in vitro 
Next, we asked whether mDia1 contributes to AIS maintenance. To address this question, 
neurons were left to develop AIS till 10 DIV and then transfected with plasmids expressing 
shmDia1-1 or scrRFP. Transfected neurons were fixed after 24 or 48 h before analyzing 
ankyrinG expression in the AIS. mDia1 interference RNA dramatically reduced ankyrinG 
expression after 48 h (Fig. R16A). Indeed, ankyrinG intensity was significantly reduced after 24 
h suppression of mDia1 (85.71 ± 4.32% vs 100 ± 3.83% for scrRFP transfected neurons, 
unpaired t test, p = 0.0148; Fig. R16B). AnkyrinG reduction was even higher after 48 h (72.37 ± 
3.70% vs 100 ± 4.58% for scrRFP transfected neurons, unpaired t test, p < 0.0001; Fig. R16B). 
To further decipher the role of mDia1 in the AIS maintenance, we transfected 10 DIV neurons 
with GFP-CA-mDia1 to constitutively express active form of mDia1. Transfected neurons were 
fixed after 24 or 48 h expression of exogenous plasmids GFP or GFP-CA-mDia1. After 48 h, 
GFP-CA-mDia1 transfected neurons had slightly lower ankyrinG intensity (87.24 ± 3.29% vs 
100 ± 3.85% for GFP transfected neurons, unpaired t test, p = 0.014; Fig. R16C, D). However, 
no significant difference of ankyrinG signal was observed after 24 h in GFP-CA-mDia1 
transfected neurons  (97.37 ± 7.31% vs 100 ± 6.78% for GFP transfected neurons, unpaired t 
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test, p = 0.7938; Fig. R16D). These results demonstrate that the appropriate expression and 
activity of mDia1 is essential to maintain AIS components integrity, suggesting again that 
mDia1 is a fine regulator of AIS.  
Figure R16. mDia1 interference shRNA or constitutively active mDia1 expression in hippocampal neurons 
after AIS development decreases ankyrinG intensity. (A, C) 10 DIV hippocampal neurons transfected with 
scrambled interference RNA (scrRFP) or mDia1 interference RNA (shmDia1-1) plasmids (A), and GFP or a 
constitutively active form of mDia1 (GFP-CA-mDia1) plasmids (C). Transfected neurons were identified based on 
RFP (magenta, A) or GFP (green, C) fluorescence. Neurons were stained with MAP2 (blue) and ankyrinG (green in A, 
magenta in B) antibodies. The boxed AIS region is amplified and shown under each image. Scale bar = 50 µm. (B, D) 
Quantification of total ankyrinG fluorescence intensity in the AIS. 10 DIV hippocampal neurons were transfected 
with scrRFP or shmDia1-1 plasmids (B) or  GFP or GFP-CA-mDia1 plasmids (D) and analyzed after 24 and 48 h. 
Data were normalized to their respective scrRFP or GFP transfected neurons at each interval. *p < 0.05, ***p<0.0001, 
unpaired t test in B, and n.s., not significant, *p < 0.05, unpaired t test in D. Data in graph were acquired from three 
independent experiments and represented as the mean ± SEM. 
AIS plasticity consists of the dynamic changes of molecular composition, length and 
location. Our results have highlighted that mDia1 is necessary to maintain AIS composition. To 
test whether mDia1 is a mediator on AIS length and position, we used 10 DIV neurons 
transfected with shmDia1-1 and scrRFP plasmids, and kept them for additional 48 h in culture 
due to the higher decrease of ankyrinG components in the AIS at that time. The average 
ankyrinG intensity profile obtained from all the normalized smooth data showed an overall 
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ankyrinG reduction along the AIS (Fig. R17A). To quantify whether AIS length is modified, we 
employed a well documented protocol (Grubb and Burrone, 2010), where ankyrinG profile from 
each neuron was smoothed into every 1  µm and a 33% of maximum fluorescence intensity 
reference was applied to define the AIS start and end position. Using this approach, we first 
analyzed AIS length in the average ankyrinG intensity profile of scrRFP and shmDia1-1 
transfected neurons (Fig. R17A). We found that AIS length was reduced after knocking down 
mDia1 (Fig. R17A), as observed in shmDia1-1 transfected neurons (Fig. R16A).  
Figure R17. mDia1 suppression or inhibition shortens AIS length. (A, D) Normalized average ankyrinG intensity 
profile along the AIS of 12 DIV hippocampal neurons transfected at 10 DIV (A) with scrambled interference RNA 
(scrRFP, black) or mDia1 interference RNA (shmDia1-1, red), and the same profile for 10 DIV hippocampal neurons 
in the presence (red) or absence (black) of 15 µM SMIFH2 (D) treatments. A 33% of maximum fluorescence 
intensity reference was applied to define the AIS start and end position in the profile. (B, E) Quantification of AIS 
length in transfected neurons shown in A or inhibited neurons shown in D. ***p < 0.0001, unpaired t test. (C, F) 
Quantification of AIS starting, maximum intensity and end positions in transfected (C) or inhibited neurons (F) 
shown in B or E, n.s., not significant, *p < 0.05, ***p < 0.0001, Mann Whitney test in C, and n.s., not significant, 
Mann Whitney test; ***p < 0.0001, unpaired t test in F.  (G) Quantification of AIS length in 12 DIV hippocampal 
neurons transfected at 10 DIV with GFP (black) or GFP-CA-mDia1 (green) plasmids. n.s., not significant, Mann 
Whitney test. (H) Quantification of AIS length in 10 DIV hippocampal neurons nucleofected with scrRFP (black) or 
shmDia1-1 (red) plasmids. n.s., not significant, Mann Whitney test. All data were acquired from three independent 
experiments and represented as the mean ± SEM. 
To ascertain this data, AIS length was analyzed independently neuron by neuron in their 
own ankyrinG intensity smooth profile. A significant reduction was observed after knocking 
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down mDia1 (20.21 ± 0.72 µm vs 25.43 ± 0.63 µm for scrRFP transfected neurons, unpaired t 
test, p < 0.0001; Fig. R17B). Next, in order to further analyze whether the change in length is 
related to changes in ankyrinG distribution along the AIS, we analyzed the start, maximum 
intensity and end position in each neuron. Our study revealed that AIS end position remarkably 
shifted towards the soma in shmDia1-1 transfected neurons (21.17 ± 0.70 µm vs 26 ± 0.64 µm 
for scrRFP transfected neurons, Mann Whitney test, p < 0.0001; Fig. R17C), accompanied by 
slightly significant movement of maximal ankyrinG intensity position (7.10 ± 0.47 µm for 
shmDia1-1 transfected neurons vs 8.33 ± 0.46 µm for scrRFP transfected neurons, Mann 
Whitney test, p = 0.0487; Fig. R17C). No change was found for AIS starting position (Mann 
Whitney test, p=0.4389; Fig. R17C). In order to corroborate these results, we analyzed AIS 
length after mDia1 inhibition with SMIFH2. 10 DIV neurons were treated for 3 h with DMSO 
or 15 µM SMIFH2. Fixed samples were labeled with ankyrinG antibody for AIS length and 
position analysis. Using the same analysis procedures, we found a decrease of AIS length in the 
average ankyrinG intensity profile of SMIFH2 treated neurons, accompanied by a reduction of 
ankyrinG intensity along AIS (Fig. R17D). AIS length from every neuron was analyzed and a 
similar reduction was found in SMIFH2 treated neurons (21.15 ± 0.72 µm vs 27.86 ± 0.79 µm 
for control neurons, unpaired t test, p < 0.0001; Fig. R17E). Consistent with mDia1 knockdown 
experiments, AIS end position shifted forward to the soma in SMIFH2 treated neurons (21.83 ± 
0.70 µm vs 28.21 ± 0.80 µm for DMSO treated neurons, unpaired t test, p < 0.0001; Fig. R17F). 
No significant change was found in ankyrinG maximal fluorescence position (Mann Whitney 
test, p = 0.0984), but it was slightly closer to the soma as happened in transfected neurons (6.58 
± 0.37 µm vs 7.79 ± 0.44 µm for DMSO treated neurons; Fig. R17F). No significant difference 
was found in AIS starting position (Mann Whitney test, p = 0.9784; Fig. R17F). 
Given mDia1 suppression or inhibition decreases AIS length, we next analyzed the effects 
of increased mDia1 expression and activity on AIS plasticity. 10 DIV neurons were transfected 
with GFP-CA-mDia1 or GFP and fixed after 48 h. AIS length analysis showed that no 
significant change was found in GFP-CA-mDia1 transfected neurons (22.40 ± 0.70 µm vs 24.53 
± 0.82 µm for GFP transfected neurons, Mann Whitney test, p = 0.0821; Fig. R17G). These data 
suggest that mDia1 lack of function on AIS has detrimental consequences for AIS length, but 
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increasing its expression does not modify AIS length at short-term. 
Next, we asked whether mDia1 participates in the long-term AIS plasticity. To do so, 
neurons were nucleofected with shmDia1-1 or scrRFP and cultured until 10 DIV. AIS length 
was checked in shmDia1-1 or scrRFP nucleofected neurons. We found that AIS length was 
similar in both conditions and the difference did not reach statistical significance (Mann 
Whitney test, p = 0.2864; Fig. R17H). This result indicates that mDia1 is related with short-term 
changes in AIS length and some other mechanisms may compensate AIS length changes at 
long-term.  
In view of our results, short-term mDia1 suppression or inhibition decreased both AIS 
components and AIS length. Thus, we explored whether AIS components reduction were related 
to the shortening of AIS length in the same set of neurons used for AIS length analysis. To test 
this hypothesis, cell to cell analysis was performed regarding to the AIS length and the total 
ankyrinG intensity within AIS. First, we examined the relation between AIS length and total 
ankyrinG intensity after blocking mDia1 activity. 10 DIV neurons were treated with SMIFH2 or 
DMSO for 3 h. AIS length and total ankyrinG intensity within AIS were measured. Our results 
showed that there was a positive correlation between these two parameters in SMIFH2 treated 
neurons (Pearson r = 0.4319, p = 0.0027; Fig. R18A) and a similar correlation was also found in 
DMSO treated neurons (Pearson r = 0.468, p = 0.001; Fig. R18A). Then, we analyzed the ratio 
of normalized total ankyrinG intensity within AIS / AIS length. Our statistical analysis of this 
ratio revealed a significant reduction after SMIFH2 treatment (87.24 ± 3.01% vs 100 ± 2.76%, 
unpaired t test, p = 0.0024; Fig. R18B). Next, we explored the relationship between AIS length 
and total ankyrinG intensity after knocking down mDia1. 10 DIV neurons were transfected with 
scrRFP or shmDia1-1 and fixed after 48 h. We also found a positive correlation of these two 
parameters both in scrRFP transfected neurons (Pearson r = 0.627, p < 0.0001; Fig. R18D) and 
shmDia1-1 transfected neurons (Pearson r = 0.7085, p < 0.0001; Fig. R18D). To further analyze 
these data, we compared the ratio of normalized total ankyrinG intensity within AIS / AIS 
length. Although the difference of this ratio did not reach statistical significance (unpaired t test, 
p = 0.0672), a decrease trend was found in shmDia1-1 transfected neurons (90.61 ± 3.32% vs 
100 ± 3.81% for scrRFP transfected neurons; Fig. R18E). 
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Figure R18. AnkyrinG decrease caused by mDia1 inhibition or suppression is partially due to AIS length 
shortening. (A, D) Cell-to-cell analysis of the relationship between normalized total ankyrinG intensity and AIS 
length of 10 DIV hippocampal neurons in the presence (red) or absence (black) of 15 µM SMIFH2 treatments (A) 
and 12 DIV hippocampal neurons transfected at 10 DIV (D) with interference RNAs scrRFP (black) or shmDia1-1 
(red). Data fit a normal distribution and Pearson correlation test was performed. The number of neurons, Pearson r 
coefficient and p values are indicated in the graph. (B, E) Quantification of the ratio of normalized total ankyrinG 
intensity within AIS versus AIS length. Quantified neurons are from (A or D). n.s., not significant, p = 0.0672, **p < 
0.01, unpaired t test. (C, F) Graphs show the normalized ankyrinG intensity within AIS and AIS length. Quantified 
neurons are from (A or D). ***p < 0.0001, unpaired t test. All data were acquired from three independent experiments 
and represented as the mean ± SEM. 
To explore the reason that leads to the statistical difference of the ratio between mDia1 
inhibition and mDia1 suppression, we re-analyzed ankyrinG intensity within AIS and AIS 
length in both conditions. We found a ~21% decrease of AIS length after SMIFH2 acute 
treatment (78.69 ± 2.52%; Fig. R18C) and mDia1 short-term suppression (79.47 ± 2.85%; Fig. 
R18F). However, SMIFH2 treated neurons showed 68.33 ± 2.54% of total ankyrinG intensity 
within AIS (n=46; Fig. R18C), while mDia1 suppressed neurons had 72.37 ± 3.70% of total 
ankyrinG intensity within AIS (n=55; Fig. R18F). A slightly less reduction of total ankyrinG 
intensity leads to the statistical difference of average ankyrinG intensity between mDia1 
knockdown experiments and mDia1 inhibition experiments. Combined, the total ankyrinG 
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intensity is positively correlated with AIS length in all the conditions. In addition, an AIS length 
independent ankyrinG decrease was also observed, as shown in the reduction of average 
ankyrinG intensity in mDia1 inhibited or suppressed neurons. 
Together, all these data demonstrate that mDia1 expression and activity are required to 
maintain AIS structural integrity and plasticity in hippocampal neurons. 
7. mDia1 activity is essential for AIS structural plasticity in vivo 
Our data in cultured hippocampal neurons demonstrate that loss of mDia1 activity and 
expression decreases AIS components and shortens AIS length. To further understand whether 
mDia1 has the same function in more complex brain models, we employed brain slices and 
blocked mDia1 activity through acute SMIFH2 treatment using 15 µM or 30 µM concentrations. 
Coronal sensorimotor cortex slices (300 µm) from mice P26-P30 were treated with SMIFH2 or 
DMSO for 3 h in a solution buffer equilibrated with 95% O2-5% CO2. Fixed brain slices were 
labeled with ankyrinG antibody and bisBenzimide to stain nuclei and to identify specific regions of 
cerebral cortex and hippocampus. We analyzed AIS length and ankyrinG staining. Images were 
acquired from 40x oil objective of confocal microscope (1024 × 1024 pixels) spanning 35 μm 
thickness with a 0.5-μm step size. 
AIS was first traced one by one in the z-projected image of cerebral cortex. Taken into 
account that AIS may differ in different layers, first we explored the total ankyrinG intensity and 
AIS length in three regions of the cerebral cortex (layers II/III, layer IV and layers V/VI). In 
control brain slices, no significant change was observed in ankyrinG intensity between these 
regions using layers II/III as a reference (layers II/III, 100 ± 4.30%; layer IV, 107.5 ± 3.68%; 
layers V/VI, 107.2 ± 2.52%; Kruskal-Wallis, Dunn’s multiple comparison test; Fig. R19B). 
However, AIS length were significantly different in all the categorized layers (19.39 ± 0.41 µm 
for layers II/III, 21.49 ± 0.48 µm for layer IV, 23.04 ± 0.28 µm for layers V/VI, Kruskal-Wallis, 





Figure R19. Formins inhibition decreases ankyrinG intensity and shortens AIS length in brain slices of 
cerebral cortex. (A) Coronal sensorimotor cortex slices (300 µm) from P30 mice were treated with DMSO or 30 µM 
SMIFH2 for 3 h. Fixed brain slices were labeled with ankyrinG (green) antibody and bisBenzimide (blue) to stain 
nuclei. Layers were categorized into layers II/III, layer IV and layers V/VI, as shown in images. Scale bar = 100 µm. 
(B) Quantification of total ankyrinG intensity in layers II/III, layer IV and layers V/VI of coronal sensorimotor cortex 
in P30 mice. n.s., not significant, Kruskal-Wallis, Dunn’s multiple comparison test. In the right panel, a cumulative 
fraction plot shows a distribution of normalized total ankyrinG intensity. (C) Quantification of AIS length based on 
ankyrinG intensity in layers II/III, layer IV and layers V/VI of coronal sensorimotor cortex in P30 mice. **p < 0.01, 
***p < 0.001, Kruskal-Wallis, Dunn’s multiple comparison test. In the right panel, a cumulative fraction plot shows a 
distribution of AIS length. (D) Quantification of total ankyrinG intensity in the presence or absence (dark) of 15 µM 
(magenta) or 30 µM (light blue) SMIFH2 in layers II/III, layer IV and layers V/VI of coronal sensorimotor cortex in 
P30 mice. *p < 0.05, **p < 0.01, ***p < 0.001, Kruskal-Wallis, Dunn’s multiple comparison test. (E) Quantification 
of AIS length based on ankyrinG intensity in the presence (red) or absence (dark) of 30 µM SMIFH2 in layers II/III, 
layer IV and layers V/VI of coronal sensorimotor cortex in P30 mice. ***p < 0.0001, Mann Whitney test. (F) 
Quantification of the ratio of normalized total ankyrinG intensity / AIS length in the presence (red) or absence (dark) 
of 30 µM SMIFH2 in layers II/III, layer IV and layers V/VI of coronal sensorimotor cortex in P30 mice. ***p < 





To precisely evaluate the SMIFH2 effects on AIS, we compared AIS intensity and length 
according to the categorized layers. We found that 15 µM SMIFH2 treatment significantly 
decreased ankyrinG intensity in all the layers (Kruskal-Wallis, Dunn’s multiple comparison test; 
Fig. R19D) and the decrease was even higher in 30 µM SMIFH2 treated brain slices (layers 
II/III, 63.11 ± 2.94% vs 74.22 ± 2.34% for 15 µM SMIFH2 treated brain slices; layer IV, 70.19 
± 2.76% vs 84.52 ± 3.24% for 15 µM SMIFH2 treated brain slices; layers V/VI, 70.24 ± 2.79% 
vs 83.34 ± 1.99% for 15 µM SMIFH2 treated brain slices; Fig. R19D). Thus, 30 µM SMIFH2 
was used for the following experiments in brain slices. 30 µM SMIFH2 treatment significantly 
reduced AIS length in layers II/III (88.53 ± 0.84% vs 100 ± 2.11% for DMSO treated neurons, 
Mann Whitney test, p < 0.0001), layer IV (87.19 ± 0.84% vs 100 ± 2.21% for DMSO treated 
neurons, Mann Whitney test, p < 0.0001) and layers V/VI (88.50 ± 0.69% vs 100 ± 1.20% for 
DMSO treated neurons, Mann Whitney test, p < 0.0001; Fig. R19E). A similar AIS length 
decrease was observed in all layers of treated neurons (Fig. R19E). To study the average 
ankyrinG intensity versus AIS length, the ratio of normalized total ankyrinG intensity / AIS 
length was analyzed. We found a ~25% reduction of this ratio in all the analyzed layers after 
SMIFH2 treatment (Mann Whitney test, p < 0.0001; Fig. R19F). 
In order to ascertain the data from cerebral cortex, CA1 regions of hippocampi were used 
for ankyrinG intensity analysis. As above described, images were acquired from 40x oil 
objective of SP5 spanning 35 μm thickness with a 0.5-μm step size. The whole AIS regions 
were selected from one z-projected images according to ankyrinG staining and background was 
subtracted, due to the complexity of analyzing individual AIS in hippocampi. We found that 30 
µM SMIFH2 dramatically reduced ankyrinG intensity of CA1 regions after 3 h treatment (Fig. 
R20A). Corrected total fluorescence intensity showed that SMIFH2 treated neurons had lower 
ankyrinG intensity (79.11 ± 5.22%) compared to DMSO treated neurons (100 ± 3.00%, 
unpaired t test, p = 0.0022; Fig. R20B). To exclude the influence of selected area size, correct 
mean fluorescence intensity was measured. Consistently, our results showed a significant 
reduction of average ankyrinG intensity in SMIFH2 treated neurons (79.77 ± 3.95% vs 100 ± 
3.51% for DMSO treated neurons, unpaired t test, p = 0.0005; Fig. R20C). Combined, these 
data demonstrate that mDia1 inhibition disrupts AIS structural integrity and plasticity in vivo at 
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short-term. This raises the question that how mDia1 is regulated and contributes to the 
regulation of AIS. 
Figure R20. Formins inhibition decreases ankyrinG intensity of hippocampal AISs in brain slices. (A) Brain 
slices (300 µm) containing hippocampi from P26-P30 mice were treated with DMSO or 30 µM SMIFH2 for 3 h. 
Fixed brain slices were labeled with ankyrinG (green) antibody and bisBenzimide (blue) to stain nuclei. Scale bar = 
100 µm. (B) Quantification of corrected total fluorescence intensity (CTF) in CA1 regions. **p < 0.01, unpaired t test. 
(C) Quantification of correct mean fluorescence intensity (CMF) in CA1 regions. ***p < 0.001, unpaired t test. All 
data were acquired from three independent experiments and represented as the mean ± SEM. 
8. Deciphering mDia1 mediated AIS regulation pathway 
8.1. Rho is not the upstream regulator of mDia1 for AIS regulation 
Our above data have demonstrated that mDia1 regulates AIS components through 
downstream cytoskeleton regulation. This leads us to question which is the mDia1 upstream 
regulator. Previous studies have shown that RhoA-mDia1 signaling participates in many 
physiological processes both in neurons and in non-neuronal cells through actin and 
microtubules regulation (Qu et al., 2017; Zilberman et al., 2011). Furthermore, RhoA is 
involved in both neuro-epithelial and epithelial apico-basal polarity regulation (Acharya et al., 
2017; Herder et al., 2013; Herzog et al., 2011). Taken all these into account, we investigated 
whether RhoA is the upstream regulator of mDia1 on AIS regulation. Given RhoA affects early 
neuronal development (Chen and Firestein, 2007; Fujita and Yamashita, 2014), we modified 
RhoA expression and activity after AIS had already formed. 10 DIV hippocampal neurons were 
transfected with RhoA plasmids and its mutants coupled to EGFP protein and fixed at 12 DIV. 
RhoA-T19N is a dominant negative construct and RhoA-Q63L is a constitutively active construct. 
Neurons were stained with ankyrinG antibody and total intensity was analyzed. We did not find 
any change of ankyrinG intensity in neurons with over-expressed RhoA (93.49 ± 4.40%), 
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neither in the case of RhoA-T19N (97.95 ± 4.95%) or RhoA-Q63L (97.83 ± 4.41%) compared to 
GFP transfected neurons (100 ± 4.05%, One-way analysis of variance, Tukey’s multiple 
comparison test, n.s.; Fig. R21A). 
Figure R21. RhoA is not the 
upstream regulator of mDia1 for 
ankyrinG accumulation. (A) 
Quantification of total ankyrinG 
fluorescence intensity of 12 DIV 
hippocampal neurons transfected at 
10 DIV with plasmids of GFP, RhoA 
wild-type (RhoA-WT), RhoA 
dominant negative form (RhoA-T19N) 
and RhoA constitutively active form 
(RhoA-Q63L). n.s., not significant, 
One-way analysis of variance, 
Tukey’s multiple comparison test. (B) 
Quantification of total ankyrinG 
fluorescence intensity of 13-15 DIV 
hippocampal neurons treated with 
vehicle or 40 µM Y27632 (ROCK 
inhibitor) for 3 h. n.s., not significant, Kruskal-Wallis, Dunn’s multiple comparison test. (C) Quantification of total 
ankyrinG fluorescence intensity of 15 DIV hippocampal neurons treated for 3 h with 1.0 µg/ml CT04 (Rho inhibitor), 
15 µM SMIFH2 or the combination of both. *p < 0.05, ***p < 0.001, Kruskal-Wallis, Dunn’s multiple comparison 
test. All data were acquired from three independent experiments and represented as the mean ± SEM. 
To corroborate these data, we took advantage of the canonical RhoA effector, Rho-
associated kinase (ROCK) (Schmandke et al., 2007). 13-15 DIV neurons were treated with 40 
µM Y27632 (ROCK inhibitor) for 3 h. Two commercial Y27632 drugs were employed and we 
did not find any change of ankyrinG intensity in Y27632 treated neurons (96.08 ± 1.54% for 
TOCRIS drug treated neurons, 96.62 ± 1.76% for SIGMA drug treated neurons) compared to 
control neurons (100 ± 1.53%, Kruskal-Wallis, Dunn’s multiple comparison test, n.s.; Fig. 
R21B). 
Our data exhibited that it was not RhoA that signals mDia1 to regulate AIS integrity (Fig. 
R21A, B). However, previous studies have shown that apart from RhoA, RhoB and RhoC can 
also bind to mDia1 in its N-terminal region (Watanabe et al., 1999). Besides, RhoB and RhoC 
can remodel cellular cytoskeleton (Fernandez-Borja et al., 2005; Luo et al., 2017). Thus, we 
employed a general Rho inhibitor CT04 to explore whether other Rho proteins are mDia1 
upstream regulators. 15 DIV neurons were treated for 3 h and total ankyrinG intensity was 
analyzed. We found that ankyrinG intensity showed a slightly significant decrease after 
treatment with 1.0 µg/ml CT04 (92.93 ± 1.56%) compared with vehicle treated neurons (100 ± 
1.62%, p < 0.05; Fig. R21C). SMIFH2 treatment decreased ankyrinG intensity (87.42 ± 1.69%), 
while neurons co-treated with SMIFH2 and CT04 remarkably decreased ankyrinG accumulation 
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in the AIS (72.69 ± 1.30%, p < 0.001; Fig. R21C). Statistical analysis revealed that ankyrinG 
intensity in co-treated neurons was significantly lower compared to either CT04 treated neurons 
or SMIFH2 treated neurons (Kruskal-Wallis, Dunn’s multiple comparison test, p < 0.001; Fig. 
R21C). Together, our data suggest that Rho is not the upstream modulator of mDia1 in the 
process of AIS regulation. Further study is needed to decipher the upstream regulator and 
perfect mDia1 cell signaling. 
8.2. mDia1 mediated AIS components loss is independent of calpain signaling 
Previous studies reported that calcium-dependent calpain signaling is responsible for AIS 
components degradation (Schafer et al., 2009). Inhibition of calpain activity by 50 nM MDL 
28170 can rescue AIS composition loss caused from calcium influx (Del Puerto et al., 2015). 
Therefore, we investigated whether the loss of ankyrinG caused by mDia1 inhibition is related 
to calpain activation. 14 DIV neurons were pre-treated with 50 nM or 1 µM MDL 28170 or 
DMSO for 1 h, followed by 3 h treatment with 15 µM SMIFH2. Consistent with previous 
results, we found a significant reduction of total ankyrinG intensity in SMIFH2 treated neurons 
(80.87 ± 2.31% vs 100 ± 2.11% for vehicle treated neurons, p < 0.001; Fig. R22A). However, 
MDL 28170 pre-treatment did not block ankyrinG decrease after SMIFH2 treatment (78.01 ± 
2.07% for 50 nM MDL 28170 pre-treated neurons, 76.44 ± 2.03% for 1 µM MDL 28170 pre-
treated neurons vs 80.87 ± 2.31% for only SMIFH2 treated neurons, Kruskal-Wallis, Dunn’s 
multiple comparison test, n.s.; Fig. R22A). This was confirmed by the cumulative fraction plot 
of total ankyrinG intensity (Fig. R22B). 
Figure R22. Calpain inhibition does not 
avoid ankyrinG decrease induced by 
formins inhibition. (A) Quantification of 
total ankyrinG fluorescence intensity. 14 
DIV hippocampal neurons were treated 
with vehicle DMSO or 50 nM or 1 µM 
MDL 28170 (MDL, calpain inhibitor) for 
1 h prior to 3 h treatment with vehicle 
DMSO or 15 µM SMIFH2. n.s., not 
significant, ***p < 0.001, Kruskal-Wallis, 
Dunn’s multiple comparison test. (B) A 
cumulative fraction plot shows a 
distribution of normalized total ankyrinG 
intensity quantified in A of vehicle, 
SMIFH2, 50 nM MDL-SMIFH2 and 1 
µM MDL -SMIFH2 conditions. Data were 
acquired from three independent 




8.3. mDia1 mediated AIS integrity is related with F-actin dynamics regulation 
 In view of these results, we decided to assess whether AIS cytoskeleton regulatory factors 
may be linked to mDia1 AIS regulation. AIS cytoskeleton modulation contributes to AIS 
assembly and maintenance (Berger et al., 2018; Tapia et al., 2010). Our results have shown that 
mDia1 inhibition destabilized F-actin (Fig. R5) and microtubules (Fig. R6). We systematically 
studied how stabilization/destabilization of actin or microtubules contributes to AIS integrity in 
relation to mDia1. First, we analyzed actin dynamics. For this purpose, we used an F-actin 
stabilizing agent, Jasplakinolide, and and actin destabilizing agent, Latrunculin A. We found that 
F-actin destabilization triggered by Latrunculin A decreased ankyrinG intensity (85.09 ± 1.63% 
for 0.5 µM Latrunculin A treated neurons, 86.10 ± 1.48% for 1 µM Latrunculin A treated 
neurons vs 100 ± 1.41% for DMSO treated neurons; One-way analysis of variance, Tukey’s 
multiple comparison test, p < 0.001; Fig. R23A-C). Interestingly, enhancement of F-actin 
stability by Jasplakinolide also significantly reduced ankyrinG accumulation in the AIS (89.74 ± 
1.07% for 10 nM Jasplakinolide treated neurons, 86.27 ± 1.30% for 25 nM Jasplakinolide 
treated neurons vs 100 ± 1.09% for DMSO treated neurons; Kruskal-Wallis, Dunn’s multiple 
comparison test, p < 0.001; Fig. R23A, D, E). Given our results that actin dynamics are essential 
to maintain AIS structural integrity and mDia1 inhibition destabilizes actin filaments, we tested 
whether AIS deficiency in SMIFH2 treated neurons could be ameliorated through stabilizing F-
actin. 14 DIV neurons were treated with 15 µM SMIFH2, 10 nM Jasplakinolide or both reagents 
for 3 h and total ankyrinG intensity in 30 µm AIS was quantified. We found that ankyrinG 
intensity did not change between SMIFH2 treated neurons (91.05 ± 2.34%) and SMIFH2-
Jasplakinolide co-treated neurons (86.90 ± 2.20%, n.s.; Fig. R23F). Taken into account that 
sequence of drugs application might affect F-actin stabilization efficiency, we first stabilized F-
actin 1 h in advance using Jasplakinolide and then treated with SMIFH2 for another 3 h. 
Similarly, Jasplakinolide pre-treatment failed to rescue ankyrinG reduction in SMIFH2 treated 
neurons (90.68 ± 1.24% vs 88.43 ± 1.27% for only SMIFH2 treated neurons, n.s.; Fig. R23G). 
Due to this unexpected result and in order to get a better understanding of actin in the AIS, we 
analyzed whether an AIS actin related structure, the cisternal organelle (CO), was affected by 




Figure R23. Disruption of actin dynamics leads to ankyrinG reduction. (A) Hippocampal neurons were cultured 
for 14 DIV and then treated for 3 h with vehicle DMSO, 0.5 µM Latrunculin A (LatA, actin destabilizing agent) or 10 
nM Jasplakinolide (Jasp, F-actin stabilizing agent). Neurons were fixed and stained with MAP2 (magenta) and 
ankyrinG antibodies (green). Scale bar = 50 µm. (B, C) Quantification of total ankyrinG fluorescence intensity of 14 
DIV neurons treated for 3 h with vehicle DMSO, 0.5 µM or 1 µM Latrunculin A. n.s., not significant, ***p < 0.001, 
One-way analysis of variance, Tukey’s multiple comparison test. (D, E) Quantification of total ankyrinG fluorescence 
intensity of 14 DIV neurons treated for 3 h with vehicle DMSO, 5 nM, 10 nM or 25 nM Jasplakinolide. n.s., not 
significant, ***p < 0.001, Kruskal-Wallis, Dunn’s multiple comparison test. (F, G) Quantification of total ankyrinG 
fluorescence intensity of 14 DIV hippocampal neurons treated for 3 h with 10 nM Jasplakinolide, 15 µM SMIFH2 or 
the combination of both (F), or treated with vehicle DMSO or 10 nM Jasplakinolide for 1 h prior to 3 h treatment 
with vehicle DMSO or 15 µM SMIFH2 (G), n.s., not significant, *p < 0.05, **p < 0.01, Kruskal-Wallis, Dunn’s 
multiple comparison test in F, or n.s., not significant, ***p < 0.001, One-way analysis of variance, Tukey’s multiple 
comparison test in G. (H) Quantification of the percentage of synaptopodin puncta positive neurons in the AIS. 21 or 
22 DIV hippocampal neurons were treated for 3 h with 10 nM Jasplakinolide, 15 µM SMIFH2 or the combination of 
both. **p < 0.01, Mann Whitney test. All data were acquired from three independent experiments and represented as 




To test this, 21 or 22 DIV hippocampal neurons were treated with SMIFH2, Jasplakinolide 
or the combination of both reagents for 3 h and the percentage of CO positive neurons in the 
AIS was evaluated. CO was identified by synaptopodin marker and ankyrinG staining was used 
to identify the AIS. SMIFH2 treatment significantly decreased CO positive neurons in the AIS 
(21.93 ± 2.38% vs 85.13 ± 1.44% for vehicle treated neurons, Mann Whitney test, p = 0.005), 
which was partially rescued by the co-treatment of SMIFH2 and Jasplakinolide (59.15 ± 5.45%, 
Mann Whitney test, p < 0.01; Fig. R23H). Indeed, more percentage of neurons had CO in the 
AIS after Jasplakinolide treatment (93.65 ± 1.16% vs 85.13 ± 1.44% for vehicle treated neurons, 
Mann Whitney test, p = 0.0081; Fig. R23H). These data propose a participation of mDia1 in 
actin dynamics regulation at the AIS such as modulating actin related structures, the cisternal 
organelle. However, the fact that ankyrinG intensity is not recovered by F-actin stabilization, 
which suggests that other AIS cytoskeleton components may participate on mDia1 mediated 
modulation. 
8.4. Microtubule properties contribute to AIS components loss caused by mDia1 
inhibition or suppression 
As aforementioned, mDia1 inhibition decreased tubulin acetylation in the AIS (Fig. R6). 
Thus, we asked whether balancing the level of acetylated tubulin can rescue AIS deficiency 
caused by mDia1 inhibition. HDAC6 is a tubulin deacetylase and functions in the AIS 
regulation through tubulin deacetylation (Tapia et al., 2010). To increase the level of acetylated 
tubulin, we used 10 µM Tubastatin A, an inhibitor of HDAC6. 14 DIV neurons were treated 
with SMIFH2, Tubastatin A, SMIFH2-Tubastatin A or vehicle for 3 h. We analyzed ankyrinG 
intensity, as well as, AIS length. Acute Tubastatin A treatment did not change ankyrinG intensity 
(101 ± 1.80%) compared to vehicle treated neurons (100 ± 1.51%), while SMIFH2 treated 
neurons showed a significant reduction (81.33 ± 1.45%, p < 0.001; Fig. R24A). However, 
ankyrinG intensity was rescued by Tubastatin A in SMIFH2 treated neurons (95.69 ± 1.63%) 
compared to SMIFH2 treated neurons (81.33 ± 1.45%, p < 0.001; Fig. R24A). Consistently, the 
ratio of normalized total ankyrinG intensity within AIS / AIS length revealed that Tubastatin A 
treatment prevented ankyrinG decrease in SMIFH2 treated neurons along AIS (106 ± 2.59% for 
co-treated neurons vs 84.13 ± 1.99% for SMIFH2 treated neurons, p < 0.001; Fig. R24B). These 
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data suggest that microtubules regulation through HDAC6 is related to mDia1 and at least 
regulates ankyrinG expression at the AIS.  
Figure R24. HDAC6 inhibition or suppression rescues ankyrinG loss in hippocampal neurons after mDia1 
inhibition or knockdown. (A) Quantification of total ankyrinG fluorescence intensity in 14 DIV hippocampal 
neurons treated for 3 h with 10 µM Tubastatin A (Tuba, HDAC6 inhibitor), 15 µM SMIFH2 or the combination of 
both. n.s., not significant, ***p < 0.001, One-way analysis of variance, Tukey’s multiple comparison test. (B) Mean ± 
SEM ratio of normalized total ankyrinG intensity within AIS / AIS length. Quantified neurons are from A. n.s., not 
significant, ***p < 0.001, Kruskal-Wallis, Dunn’s multiple comparison test. (C) AIS length of neurons quantified in 
B. n.s., not significant, *p < 0.05,**p < 0.01, Kruskal-Wallis, Dunn’s multiple comparison test. (D) Quantification of 
total ankyrinG fluorescence intensity of 7 DIV hippocampal neurons nucleofected with mDia1 interference RNA 
(shmDia1-1), HDAC6 interference RNA (shHDAC6) or the combination of both. Neurons nucleofected with 
scrambled interference RNA (scrRFP) are used as control. n.s., not significant, *p < 0.05, ***p < 0.001, Kruskal-
Wallis, Dunn’s multiple comparison test. (E) Normalized average ankyrinG intensity profile along the AIS of 7 DIV 
hippocampal neurons nucleofected with scrRFP, shmDia1-1, shHDAC6 or the combination of shmDia1-1 and 
shHDAC6. (F) Quantification of the percentage of synaptopodin puncta positive neurons in the AIS. 21 or 22 DIV 
hippocampal neurons were treated for 3 h with 10 µM Tubastatin A, 15 µM SMIFH2 or the combination of both. n.s., 
not significant, **p < 0.01, Mann Whitney test. All data were acquired from three independent experiments and 
represented as the mean ± SEM. 
Next, we explored whether Tubastatin A can recover AIS length due to mDia1 inhibition. 
Our previous results have shown that AIS length shortens after SMIFH2 treatment in 10 DIV 
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neurons (Fig. R17D-F). In this set of experiments, SMIFH2 treatment also significantly 
decreased AIS length in 14 DIV neurons (28.49 ± 0.68 µm vs 31.71 ± 0.95 µm for vehicle 
treated neurons, p < 0.05; Fig. R24C). However, Tubastatin A treatment did not rescue AIS 
length shortening in SMIFH2 treated neurons (27.80 ± 0.61 µm for co-treated neurons vs 28.49 
± 0.68 µm for SMIFH2 treated neurons, n.s.; Fig. R24C). 
To corroborate these results, instead we used interference RNA plasmids for HDAC6 and 
mDia1. Neurons were nucleofected with interference RNA plasmids: shHDAC6-GFP, shmDia1-
1-RFP, shHDAC6 and shmDia1-1 in combination or scrRFP and fixed at 7 DIV. As happened 
with HDAC6 inhibition using Tubastatin A in SMIFH2 treated neurons, we found that co-
nucleofected neurons expressing shmDia1-1 and shHDAC6 plasmids prevented ankyrinG 
decrease observed in shmDia1-1 nucleofected neurons (62.16 ± 3.54%) compared to 97.72 ± 
5.80% in shmDia1-1/shHDAC6 nucleofected neurons (p < 0.001; Fig. R24D). In contrast to the 
results that 3 h inhibition of HDAC6 had no effect on ankyrinG (Fig. R24A, B), shHDAC6 
nucleofection decreased ankyrinG intensity after 7 DIV (79.17 ± 4.33%, p < 0.05) compared to 
control scrRFP nucleofected neurons (100 ± 4.71%; Fig. R24D). These results and the 
difference in ankyrinG intensity were confirmed, as observed in the plot profile of average 
ankyrinG intensity along the AIS (Fig. R24E). 
To assess whether this rescue mediated by increasing acetylated tubulin has relation with 
actin filaments integrity, 21 or 22 DIV hippocampal neurons were treated with SMIFH2, 
Tubastatin A or combined reagents for 3 h and the percentage of CO positive neurons in the AIS 
was evaluated, as previously performed for the study of actin dynamics (Fig. R23H). Neurons 
were labeled with synaptopodin and ankyrinG antibodies to identify CO and AIS respectively. A 
significant decrease of CO positive neurons in the AIS was found both in SMIFH2 treated 
neurons (20.02 ± 1.70%) and SMIFH2-Tubastatin A co-treated neurons (25.48 ± 1.99%) 
compared to vehicle treated neurons respectively (84.90 ± 1.26%, Mann Whitney test, p < 0.01; 
Fig. R24F). The percentage of CO positive neurons in the AIS did not show any difference 
between SMIFH2 and Tubastatin A co-treated neurons and SMIFH2 treated neurons (Mann 
Whitney test, p = 0.0649; Fig. R24F), indicating that microtubules modifications might not be 
related to cisternal organelle alterations due to mDia1 inhibition, in contrast to what observed in 
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actin related experiments. 
8.5. mDia1 inactivity induced ankyrinG loss can be rescued by exogenous EB1 
expression or dynein inhibition 
All above data point to that mDia1 modulation of AIS is through regulation of actin and 
microtubules structure and functions. As described in the introduction section, formins and 
specifically, mDia1, is able to modulate actin dynamics and tubulin acetylation (Acharya et al., 
2017; Bartolini et al., 2016). Thus, in order to understand whether an AIS component common 
to actin and microtubules is linked to mDia1 mediated AIS regulation, we studied EB1 as a 
potential link to mDia1. End binding (EB) protein EB1 has been reported to contribute to the 
maintenance of the AIS structure and participation in the AIS assembly (Freal et al., 2016; 
Leterrier et al., 2011). EB1 stabilizes microtubules and promotes actin filaments elongation 
through directly or indirectly binding to mDia1 (Henty-Ridilla et al., 2016; Wen et al., 2004). 
Thus, we transfected 9-11 DIV hippocampal neurons with EB1-GFP or GFP respectively and 
maintained neurons for another 48 h. Neurons were treated with SMIFH2 or DMSO for 3 h 
before fixation. Total ankyrinG intensity in 30 µm AIS was analyzed. We found that EB1-GFP 
expression prevented ankyrinG reduction observed in GFP transfected neurons after SMIFH2 
treatment (89.84 ± 3.74% for EB1-SMIFH2 neurons vs 65.40 ± 4.24% for GFP-SMIFH2 
neurons, p < 0.01; Fig. R25A). EB1-GFP expression had no effect on ankyrinG accumulation in 
the AIS (97.58 ± 3.76% for EB1-GFP-DMSO neurons vs 100 ± 4.23% for GFP-DMSO neurons; 
Fig. R25A). This effect was confirmed along the AIS in the average ankyrinG intensity plot 
profile (Fig. R25B). 
Figure R25. Over-expression of EB1 
rescues ankyrinG loss induced by 
mDia1 inhibition in hippocampal 
neurons. (A) Quantification of total 
ankyrinG fluorescence intensity in the 
AIS. 9-11 DIV hippocampal neurons 
were transfected with GFP or EB1-
GFP for 48 h and then exposed to 
DMSO or 15 µM SMIFH2 for 3 h. n.s., 
not significant, **p < 0.01, ***p < 
0.001, Kruskal-Wallis, Dunn’s multiple 
comparison test. (B) Normalized 
average ankyrinG intensity profile 
along the AIS of hippocampal neurons 
shown in A. All data were acquired 
from three independent experiments 




Then, we took advantage of this normalized smooth ankyrinG intensity profile and assessed AIS 
length according to the reference of 33% of maximal ankyrinG intensity. However, AIS length 
was not rescued in EB1 transfected neurons after SMIFH2 treatment as happened after HDAC6 
inhibition (~34 µm, ~23 µm, ~33 µm, ~25 µm for neurons in conditions of GFP-DMSO, GFP-
SMIFH2, EB1-GFP-DMSO, and EB1-GFP-SMIFH2 respectively; Fig. R25B). 
Our data have shown that mDia1 inhibition mediated ankyrinG loss at the AIS can be recovered 
by increased acetylation of microtubules and EB1 expression. Moreover, our results showed that 
KIF5C distribution is modified in neurons after mDia1 inhibition. Thus, one potential cause of 
ankyrinG loss is the alteration of the AIS cytoskeleton properties to control traffic towards the 
axon. Thus, we hypothesized that compensating the lack of anterograde transport of AIS 
components could reverse ankyrinG loss by inhibiting retrograde transport and keeping 
ankyrinG at the AIS. One of the important mediators of retrograde transport at the AIS is dynein 
(Kuijpers et al., 2016). Dynein participates on neuronal polarity maintenance avoiding the 
axonal entry of somatodendritic proteins through their retrograde transport in the AIS (Klinman 
et al., 2017; Kuijpers et al., 2016). In fact, dynein and its accessory complex dynactin interact 
with EB1 (Baumbach et al., 2017; Berrueta et al., 1999). Thus, we investigated whether dynein 
inhibition with Ciliobrevin D could rescue ankyrinG reduction in mDia1 inhibited neurons 
(Firestone et al., 2012). 14 DIV neurons were treated with 15 µM SMIFH2 and 20 µM 
Ciliobrevin D (Sainath and Gallo, 2015), SMIFH2-Ciliobrevin D or vehicle for 3 h and 
ankyrinG intensity was then analyzed. We found that Ciliobrevin D application partially 
prevented the reduction of ankyrinG intensity in SMIFH2 treated neurons (87.17 ± 1.56% vs 
75.82 ± 1.38% for SMIFH2 treated neurons and 100 ± 1.41% for vehicle treated neurons, One-
way analysis of variance, Tukey’s multiple comparison test, p < 0.001, Fig. R26A). AnkyrinG 
intensity in Ciliobrevin D treated neurons was comparable to vehicle treated neurons after 3 h 
acute treatment (Fig. R26A). The partial rescue effect was corroborated by the average 
ankyrinG intensity along the AIS (Fig. R26B). However, Ciliobrevin D failed to rescue AIS 
length shortening according to the final smooth profile pooled from all the neurons in the 
corresponding conditions (~30 µm in SMIFH2 or SMIFH2-Ciliobrevin D treated neurons, ~34 
µm in vehicle or Ciliobrevin D treated neurons; Fig. R26B). Combined, dynein inhibition 
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partially rescued AIS components integrity after loss of mDia1 activity. 
Figure R26. Dynein inhibition 
partially rescues ankyrinG loss in 
mDia1 inhibited hippocampal 
neurons. (A) Quantification of total 
ankyrinG fluorescence intensity of 
14 DIV hippocampal neurons treated 
for 3 h with 20 µM Ciliobrevin D 
(CilioD, dynein inhibitor), 15 µM 
SMIFH2 or the combination of both. 
n.s., not significant, ***p < 0.001, 
One-way analysis of variance, 
Tukey’s multiple comparison test. (B) 
Normalized average ankyrinG 
intensity profile along the AIS of 
hippocampal neurons shown  in A. 
 
 
All together, AIS components loss mediated by mDia1 inactivation can be recovered 
through cytoskeleton modulation as well as axonal motors regulation, in which both actin and 
microtubules are involved. However, the shortening of AIS length can not be rescued in our 
work, suggesting that a complex mechanism related with AIS stability and axonal traffic 
contributes to mDia1 mediated AIS integrity and plasticity. Although Rho proteins somewhat 
affect ankyrinG in the AIS, they are not the upstream regulator of mDia1. Additional studies are 
required to elucidate the cell signaling of mDia1 mediated AIS regulation. 
9. Formins inhibition decreases intrinsic excitability 
All these data suggest that changes in mDia1 expression and formins activity are important 
for the regulation of AIS composition and voltage gated sodium channels localization at the AIS, 
implicating a role of formins in the modulation of neuronal excitability. To corroborate the data 
obtained in hippocampal cultured neurons or brain slices and consolidate this latter hypothesis, 
hippocampal slice cultures containing the entorhinal cortex were used. Slices were treated with 
30 µM SMIFH2 or DMSO, and kept for 2 hours before testing the electrophysiological 
properties of the neurons (Fig. R27). CA3 pyramidal neurons were used to analyze neuronal 
excitability and action potential number in current clamp. In accordance with our previous 
results showing an ankyrinG reduction after SMIFH2 treatment (Fig. R20), SMIFH2 treated 
neurons showed a significant reduction in the number of action potentials (Fig. R27A) and a 
higher rheobase (Fig. R27B), indicating that SMIFH2 treated neurons need a higher minimum 
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current to launch an action potential. 
Figure R27. Formins inhibition decreases neuronal intrinsic excitability in hippocampal neurons. 350 µm brain 
slices containing the entorhinal cortex were used from P26-P30 mice. Intrinsic excitability was measured by current 
clamp in CA3 hippocampal neurons treated with 30 µM SMIFH2 or its vehicle DMSO for 2 h. (A) Input-output 
curves for control DMSO and SMIFH2 treated neurons. (B) Graph represents the mean ± SEM of the smallest 




















































The AIS is essential for action potential generation (Kole et al., 2008; Stuart et al., 1997) 
and neuronal polarity maintenance (Hedstrom et al., 2008; Sobotzik et al., 2009; Winckler et al., 
1999). However, these functions require a fine regulation of its complex structure. Due to the 
complexity of AIS study, the knowledge of its molecular composition is still uncompleted, and it 
is still elusive how AIS performs its complex structural and functional regulation. Previous 
works have described some aspects of actin and microtubules structure at the AIS (Nirschl et al., 
2017), however only a limited number of studies have proposed some potential regulatory 
mechanisms of AIS actin (Berger et al., 2018; Zhang et al., 2019) or microtubules cytoskeleton 
(Leterrier et al., 2011; Tapia et al., 2010). In this work, we have studied the potential role of 
formins on AIS regulation, as proteins that modulate both, actin and microtubules cytoskeletons. 
We demonstrate that formins take a role on maintaining AIS integrity. Formins inhibition 
decreases AIS expression of structural and functional proteins, such as, voltage-gated sodium 
channels. Among formins, mDia1 is the most studied formin family member. mDia1 is 
necessary to maintain cell polarity (Acharya et al., 2017; Herzog et al., 2011), cell growth and 
morphology (Arakawa et al., 2003; Ishizaki et al., 2001) in different cell models and tissues. In 
this sense, we identified mDia1 expression at the AIS and its function as a regulator of AIS 
assembly and axonal polarity maintenance. Moreover, unbalanced mDia1 activity or expression 
not only alters AIS assembly, integrity and plasticity, but also modifies action potential 
generation. Furthermore, AIS components loss after inhibition of mDia1 activity can be rescued 
by modulating AIS cytoskeleton and cytoskeleton related proteins. All these findings 
demonstrate that mDia1 participates in AIS integrity and function regulation. 
1. Formins activity maintains AIS structure 
This study demonstrates that formins activity inhibition disrupts AIS structure, modifying 
the expression of AIS scaffold proteins, such as ankyrinG and βIV-spectrin, and functional 
proteins, such as voltage gated sodium channels (Fig. R1). The data suggest that this 
modification is due to alterations on AIS microfilaments and microtubules cytoskeleton 
properties and structure (Fig. R5, 6). Formins are a group of large proteins with multiple 
domains, of which FH2 is the most conserved domain (Higgs and Peterson, 2005) and the core 
functional component (Bartolini and Gundersen, 2010; Courtemanche, 2018). In our work, we 
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used a potent FH2 domain inhibitor, SMIFH2 (Rizvi et al., 2009), to inhibit FH2 domain 
dependent formins activity. Indeed, SMIFH2 has been validated as a general formin inhibitor in 
previous studies in neurons (Ganguly et al., 2015; Qu et al., 2017) and nonneuronal cells (Rao 
and Zaidel-Bar, 2016). We found that formins activity is essential to keep AIS components both 
in vitro (Fig. R1-4) and in vivo (Fig. R19, 20). In fact, ankyrinG, βIV-spectrin, sodium channels 
and pMLC expression was significantly reduced in the AIS after SMIFH2 inhibition. This effect 
was observed as soon as 30 min (Fig. R1), strongly supporting a direct effect of SMIFH2 on 
AIS, not mediated by further transcriptional machinery. 
AIS components reduction has been observed in different pathological conditions using in 
vivo animal models. Following ischemic injury, ankyrinG, βIV-spectrin and sodium channels 
are lost from the AIS in the cerebral cortex neurons (Schafer et al., 2009). Sodium channel Nav 
1.6 reduces in the AIS of layer II/III neurons in primary visual cortex of aged rats (Ding et al., 
2018). In addition, enhanced neuronal excitability induced by high concentration of 
extracellular KCl leads to a reduction of ankyrinG and pMLC in cultured hippocampal neurons 
(Berger et al., 2018). Interestingly, some neuronal receptors expression and activity also 
contribute to the maintenance of AIS components. For example, purinergic P2X7 receptor over-
expression or hyperactivity decreases ankyrinG and sodium channels concentration in the AIS 
(Del Puerto et al., 2015). Conversely, loss of expression of purinergic receptor P2Y1 blocks AIS 
early development with reduction of ankyrinG, βIV-spectrin, sodium channels and pMLC 
expression (Zhang et al., 2019). In fact, a previous work from our laboratory has shown that 
P2Y1 suppression alters actin structures at the AIS (Zhang et al., 2019). Furthermore, 
cannabinoid receptors inhibition or suppression also decreases ankyrinG expression at the 
developing AIS (Tapia et al., 2017). It will be of interest to determine whether formins activity 
are been regulated by those receptors.  
Our knowledge of formins in neurons is very limited. However, structures with similar 
function in other cells are regulated by formins. In this context, epithelial tight junctions or 
adherent junctions are important for establishing epithelial cells polarity, separating apical and 
basolateral domins (Grikscheit and Grosse, 2016), that were previously thought to be equivalent 
to axons and dendrites. These junctions participate in the control of polarized traffic and 
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maintenance of cell polarity. Indeed, formins are involved in the maintenance of these junctions 
and the expression of different proteins on them. It is reported that formins activity inhibition 
decreases E-cadherin at epithelial junctions (Rao and Zaidel-Bar, 2016). E-cadherin is a main 
protein to maintain adherent junctions and has been shown to interact with ankyrinG in 
epithelial cells in early embryos (Kizhatil et al., 2007). mDia1 knockdown decreases β-catenin 
in cell-cell junctions of epithelial cells (Carramusa et al., 2007). Interestingly, phosphorylated β-
catenin localizes in the AIS of hippocampal neurons (Tapia et al., 2013). In addition, knocking 
down mDia1 or FMNL3 reduces E-cadherin at the adherens junctions of epithelial cells and 
weakens cell-cell adhesion and polarity (Rao and Zaidel-Bar, 2016). mDia1 knockdown also 
decreases vinculin, non-muscle myosins II A/B, and even another formin member mDia2 at 
epithelial junctions (Acharya et al., 2017). Non-muscle myosin II is an actin-binding protein 
that has actin cross-linking and contractile properties and is activated via MLC phosphorylation 
(pMLC) (Heissler and Sellers, 2014). pMLC is enriched at the AIS and involved in the activity-
dependent plasticity of the AIS via actin destabilization during depolarization (Berger et al., 
2018). In our work, we found a reduction of pMLC after formins inhibition (Fig. R1). Moreover, 
the junctional levels of epithelial constituent proteins, ZO-1, occludin, and Par3 all are reduced 
after losing mDia1 expression (Acharya et al., 2017). In neuroepithelial cells of mouse 
ventricular zone, loss of mDia1 activity results in the loss of apical N-cadherin and 
neuroepithilium organization is disrupted (Herzog et al., 2011). Together with our findings, this 
suggests that formins have capacity to maintain structural proteins in cellular specific 
compartments, such as the axon initial segment. 
On the other hand, formins inducing ankyrinG loss leads to the loss of voltage gated 
sodium channels, which are highly enriched at the AIS and their high concentration is required 
for initiating action potentials (Kole et al., 2008; Zhou et al., 1998). AnkyrinG is required for 
normal action potential firing through clustering voltage gated sodium channels in the AIS 
(Zhou et al., 1998). Other studies have demonstrated that ankyrinG loss affects sodium channels 
concentration at the AIS (Hedstrom et al., 2007; Jenkins and Bennett, 2001). Accordingly, our 
data reveal an overall reduction of sodium channels in cultured neurons (Fig. R1). It is widely 
reported that loss of sodium channels in the AIS disables action potential generation and lowers 
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neuronal excitability (Del Puerto et al., 2015; Tapia et al., 2013). Consistently, we found a 
decrease in intrinsic neuronal excitability of hippocampal neurons after inhibiting formins 
activity in P26-P30 mice brain slices (Fig. R27), which is correlated with the fact that ankyrinG 
expression is reduced on these brain slices (Fig. R19, 20). 
2. AIS cytoskeleton and formins 
AnkyrinG, βIV-spectrin and sodium channels anchorage at the AIS depend on the integrity 
of AIS cytoskeleton (Berger et al., 2018; Tapia et al., 2010). Previous studies have shown that 
formins activity inhibition disrupts deep F-actin network in axons (Ganguly et al., 2015) and 
blocks synaptic vesicles endocytosis mediated by actin assembly (Soykan et al., 2017). In the 
case of microtubules, formins are featured to induce microtubule acetylation (Thurston et al., 
2012). Formins inactivation or suppression results in microtubule instability (Qu et al., 2017). 
Moreover, formins’ function can happen in actin or microtubules independently. Consistently, in 
our work, loss of formins activity destabilizes F-actin (Fig. R5) and alters microtubules 
properties (Fig. R6) in the AIS. Acute inhibition of formins activity for only 3 h remarkably 
disrupts microtubule stability, understood as a decrease in tubulin acetylation. While this 
happens in the AIS, no effect is detected in proximal dendrites (Fig. R6). Microtubules in the 
AIS are distinctive from other neuronal regions and they are tightly packed into fascicles (Palay 
et al., 1968), which may explain this different sensitivity of microtubules in the AIS and 
dendrites in our study. Previous studies showed that AIS assembly and integrity are tightly 
related with microtubule acetylation at the AIS. Enhanced microtubule acetylation in the distal 
axon by tubulin deacetylase HDAC6 inhibition or suppression, impairs the AIS to have specific 
local higher microtubules acetylation (Tapia et al., 2010). Similarly, the inhibition of Casein 
kinase 2, an AIS protein, also increases tubulin acetylation and decreases AIS composition 
(Sanchez-Ponce et al., 2011b). Some microtubules associated proteins, such as, microtubule 
cross-linking factor 1 (MTCL1) and TRIM46, are necessary to maintain microtubules bundles 
stability in the AIS, as a consequence of ankyrinG tethering (Satake et al., 2017; van Beuningen 
et al., 2015). In our work, we found that tubulin acetylation decreases in the AIS after formins 
activity inhibition, which is accompanied by a reduction of ankyrinG and βIV-spectrin in the 
AIS (Fig. R6). Interestingly, inhibiting or suppressing the activity of HDAC6 deacetylase we 
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were able to impair ankyrinG reduction in AIS (Fig. R24). HDAC6 inhibition has been 
previously shown as a way to protect neurons from external insults (Rivieccio et al., 2009). All 
these data demonstrate that microtubule dynamics in the AIS play an essential role in the AIS 
regulation, and our results suggest that formins play a role on these microtubules regulation. 
In our work, we also found that actin dynamics play vital roles on AIS integrity (Fig. R23). 
Actin destabilization induced by Latrunculin A or enhanced actin stability induced by 
Jasplakinolide leads to a reduction of ankyrinG intensity. This phenomenon is also observed in 
actin trails in the axon using the same reagents (Ganguly et al., 2015). Here, we provide new 
insights of how actin cytoskeleton and related structures are modified by actin dynamic 
alterations mediated by formins. In fact, several studies have previously pointed out that actin 
related regulation is important for AIS components assembly and maintenance. For example, a 
previous study from our laboratory showed that stabilizing F-actin with Jasplakinolide recovers 
AIS components reduction due to P2Y1 receptor-mediated F-actin loss (Zhang et al., 2019). 
This actin loss is accompanied by a reduction of pMLC, an actin motor myosin II activator. In 
addition, it has been shown that pMLC reduction at the AIS, happens concomitantly with 
alterations in the space and organization of actin rings, and a decrease of ankyrinG expression in 
the AIS caused by enhanced neuronal excitability (Berger et al., 2018). 
As mentioned in introduction section, different types of F-actin structures have been 
described in the AIS. Actin rings, actin patches and actin trails are involved in varied functions 
in the AIS, such as, structural maintenance or traffic control (Ganguly et al., 2015; Watanabe et 
al., 2012; Xu et al., 2013). In our data, we found that formins inhibition generates an overall 
reduction of F-actin signal in the AIS identified by phalloidin-bound fluorophore (Fig. R5). F-
actin signal reduction contributes to the loss of the actin related structure termed cisternal 
organelles (Fig. R5). While the cisternal organelle is not necessary to maintain action potential 
generation, it has been shown that its size is modified with AIS plasticity during development. 
We found that cisternal organelles partially recovered at the AIS when stabilizing actin, but not 
when recovering tubulin acetylation, and after formins inhibition. Thus, further investigations 
will be necessary to better understand this proposed regulatory element in the AIS. However, a 
study described that actin patches are not modified by formins inhibition in mature neurons, 
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even if the formin FMN2 is expressed in the AIS of these cortical neurons. Instead, the study 
proposes that the actin nucleator Arp2/3 is required to maintain those actin patches in the AIS 
(Balasanyan et al., 2017). In fact, Arp2/3 and formins can cooperate for F-actin filaments 
formation and regulation, but can also act independently one from the other (Young et al., 2015). 
In this sense, we have identified the mDia1 formin at the AIS, which may function as a regulator 
of AIS actin structures as shown by other data using interference shRNAs. Other F-actin 
structures are localized at the AIS, short and stable actin filaments, as well as, longer dynamic 
actin filaments that can cooperate with other AIS enriched proteins to maintain AIS integrity 
(Jones et al., 2014). Given the longer dynamic actin filaments are sensitive to actin destabilizing 
drugs, and AIS enriched proteins decrease in our work, losing formins activity may at least 
reduce longer dynamic actin filaments. Using electron microscopy in the future in the context of 
formins and AIS will help to address this question. 
In addition, actin rings are currently identified in the AIS (Xu et al., 2013). It is reported 
that actin rings are resistant to F-actin perturbations, although the overall amount of F-actin 
markedly decreases (Abouelezz et al., 2019). These rings in the AIS are connected by βIV-
spectrins and potentially stabilize AIS structure and ankyrinG tethering (Leterrier et al., 2015; 
Zhong et al., 2014). In our work, ankyrinG reduction caused by the actin destabilizing reagent 
Latrunculin A is lower than that generated by the loss of formins activity (Fig. R1, 23). It will be 
of interest to determine whether actin rings in the AIS are affected after losing formins activity, 
but this will need a further STORM analysis. 
3. mDia1 role on AIS regulation 
Most of the data described above are based on pharmacological experiments using a 
general formins inhibitor. Taking advantage of the knowledge of mDia1 in epithelial cell 
polarity and the potential similarity with AIS, we found that mDia1 is expressed in patches 
along the AIS (Fig. R9). Although mDia1 is ubiquitously expressed along the neuron (Qu et al., 
2017), a relatively higher expression of mDia1 was observed in the axon of early developing 
neurons (Fig. R10). Moreover, we could detect mDia1 signal after detergent extraction at the 
AIS (Fig. R9). mDia1 signal colocalizes with the signal of GFP-CA-mDia1 and ankyrinG, and 
we confirmed that AIS regulation observed in formins pharmacological experiments are due to 
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mDia 1 inhibition.  
Previous studies have shown that axon growth or dendritic growth has a relation to AIS 
plasticity (Hamada et al., 2016; Tapia et al., 2017). Our work demonstrates that silencing mDia1 
does not affect axon specification or dendrites growth in hippocampal neurons (Fig. R12). 
However, other studies have proposed that mDia1 silencing decreases axon elongation in 
cerebellar granule neurons (Arakawa et al., 2003) and dendrites length as well as dendritic 
arborization in hippocampal neurons (Hong et al., 2018). Conversely, mDia1 depletion increases 
dendritic complexity in post-developmental hippocampal neurons (Qu et al., 2017). These 
discrepancies may be the result of different times of mDia1 depletion or the varied percentage 
of mDia1 reduction in each study. In our work, we quantified a 30-40% reduction of 
endogenous mDia1, which probably allows axon development and AIS formation. Interestingly, 
constitutively active mDia1 expression is able to diminish axon and dendrites differentiation and 
growth during initial development of hippocampal neurons (Fig. R13). This is consistent with 
previous studies showing that axon length decreases after mDia1 hyperactivation in cultured 
cerebellar granule neurons (Arakawa et al., 2003) and which suggests that the control of mDia1 
activity is essential to maintain a proper morphological neuronal development.  
Regarding functions of mDia1 at the AIS, our results show that mDia1 participates in the 
AIS assembly (Fig. R14), maintenance (Fig. R16) and plasticity (Fig. R17). In fact, mDia1 
suppression in neuronal early development leads to a decrease of AIS components, such as 
ankyrinG, βIV-spectrin and voltage gated sodium channels. This is the first study to describe a 
role of mDia1 in the AIS. Some studies have shown an early function of mDia1 in neuronal 
proliferation and migration in developmental cerebral cortex in mDia1/mDia3 knock-out mice 
model (Shinohara et al., 2012; Thumkeo et al., 2011). mDia1 homozygous loss in humans leads 
to microcephaly due to reduced neuronal cell precursors proliferation (Al-Maawali et al., 2016; 
Ercan-Sencicek et al., 2015). Thus, cultured hippocampal neurons in vitro is a good model to 
explore mDia1 functions in neuronal morphology development and AIS assembly and 
maintenance through modifying mDia1 expression. In fact, our results show that early 
suppression of mDia1 affects AIS properties along with the axonal and dendritic development. 
Taken these data, we hypothesized that mDia1 over-expression could increase AIS components. 
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However, the expression of a constitutively active mDia1 construct also slightly decreases 
ankyrinG expression (Fig. R16). In fact, the same effects are produced by increasing or 
decreasing mDia1 activity in other cell models, such as the axon length shortening in cultured 
cerebellar granule neurons (Arakawa et al., 2003).  
4. Formins and AIS plasticity 
Recent studies have highlighted the importance of AIS plasticity in the regulation of 
neuronal function in response to physiological or pathological changes affecting neuronal input. 
AIS plasticity occurs during neuronal development (Gutzmann et al., 2014) and after alterations 
of neuronal activity in mature neurons (Grubb and Burrone, 2010; Kuba et al., 2010). Structural 
AIS plasticity requires a re-arrangement of actin and microtubules cytoskeleton that is not well 
known neither understood. AIS elongation or movement away from the soma can only be 
understood following this re-arrangement. In this context, formins, and specifically mDia1, are 
known by their mechanosensitive function (Jegou et al., 2013; Zimmermann et al., 2017). 
Formins and mDia1 can sense forces and promote actin polymerization, but also modulate 
efficient contractile ring assembly. It has been described that pulling force of myosin II 
propagates through the actin filament impeding formin-mediated actin filament elongation in 
yeast (Zimmermann et al., 2017). Our study shows important changes in cytoskeleton after 
formins inhibition, which may be involved in AIS plasticity. In fact, our work demonstrates that 
short-term mDia1 inhibition or knockdown in mature neurons shortens AIS length (Fig. R17), as 
happens in cortical neurons in brain slices after formins inhibition (Fig. R19). However, long 
term knocking down mDia1 before AIS forms, does not change AIS length, but only decreases 
AIS components accumulation (Fig. R14, 17). This could be due to homeostatic compensation 
that may occur for 10 days in vitro before AIS is analyzed (Kuba et al., 2010; Schluter et al., 
2017).  
AIS plasticity can happen at short- or long-term (Grubb et al., 2011), involving other 
mechanisms, such as calcium regulation or channels expression. Moreover, the regulation of 
AIS structural plasticity and AIS composition may be mediated through different pathways. In 
fact, our results show that AIS composition can be recovered, while AIS length is not rescued 
(Fig. R24-26). Different mechanisms have been related to AIS structural or compositional 
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plasticity. For example, calcium-calpain activation through P2X7 activation decreases ankyrinG 
and sodium channels, but does not alter AIS length (Del Puerto et al., 2015), while KCl 
depolarization induces AIS movement or AIS length shortening in different cell types (Evans et 
al., 2015; Grubb and Burrone, 2010), without changing AIS components expression after 48 h. 
AIS plasticity also happens during development and seems to be related to changes in cisternal 
organelle (Schluter et al., 2017). In our work, we found a dramatic reduction of cisternal 
organelle clusters after short period of mDia1 inhibition together with AIS shortening (Fig. R5). 
In pyramidal neurons of layers II/III in visual cortex, visual deprivation leads to the size 
increase of cisternal organelle clusters, as well as AIS length increase (Schluter et al., 2017). 
However, loss of cisternal organelles due to synaptopodin knockout results in AIS length 
shortening after visual deprivation (Schluter et al., 2017). The increase of cisternal organelle 
clusters in number and size is also observed in retinal ganglion cells after sensory deprivation 
(Schluter et al., 2019). It would be interesting to determine whether cisternal organelles are 
involved in mDia1 mediated AIS length shortening in future studies. Moreover, the cisternal 
organelle is thought to regulate calcium, which intracellular increase is related to P2X7 
mediated AIS components loss (Del Puerto et al., 2015). 
Thus, formins may regulate AIS plasticity through the regulation of actin filaments 
elongation and shortening, affecting actin related strucutures and microtubules. How changes in 
neuronal input can modify AIS cytoskeleton needs further research.  
5. Potential mechanisms for mDia1 mediated AIS regulation 
To understand how formins regulate intrinsic neuronal excitability through AIS regulation, 
it is important to know which molecules or signaling pathways act as upstream regulators or 
play a parallel role as formins in AIS regulation. mDia1 is typically autoinhibited through DID 
and DAD interaction. In different models, it has been shown that the binding of GTP-bound 
RhoGTPases to GBD displaces the DAD domain and activates formins (Kuhn and Geyer, 2014). 
However, formins can also be regulated by other mechanisms, such as, phospholipids 
interaction, myristoylation, farnesylation or phosphorylation (Grikscheit and Grosse, 2016). 
Specifically, besides RhoGTPases regulation, activation and localization of mDia1 is regulated 
by phospholipids (Ramalingam et al., 2010). Rho-mDia1 pathway is involved in the regulation 
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of Golgi complex architecture and dynamics in HeLa cells and its polarization in hippocampal 
neurons (Hong et al., 2018; Zilberman et al., 2011). Indeed, this signal is also linked with many 
physiological functions, such as cell polarity, cell adhesion, cell migration, neuronal stem cell 
pool maintenance and axon growth (Arakawa et al., 2003; Herzog et al., 2011; Yamana et al., 
2006; Zaoui et al., 2008). ROCK is another canonical effector of Rho and cooperates with 
mDia1 for cell adhesion and tangential migration of interneuron precursors through actin 
dynamics regulation (Acharya et al., 2017; Shinohara et al., 2012). However, we found that the 
expression of RhoA, activated RhoA or dominant negative RhoA plasmids has no effects on AIS 
modulation (Fig. R21). Furthermore, ROCK deactivation has no influence on AIS components 
(Fig. R21). However, mDia1 can interact with other Rho proteins, such as RhoB or RhoC 
(Wallar and Alberts, 2003). RhoA-C inhibition with CT04 slightly decreases ankyrinG intensity 
at the AIS compared to SMIFH2, and the double inhibition generates a much higher effect (Fig. 
R21). This may indicate parallel mechanisms of AIS regulation mediated by Rho and formins, 
not being Rho as the upstream regulator of mDia1. Other RhoGTPases could be responsible for 
mDia1 activation. In fact, RhoGTPase Rif binds to the N-terminal GBD domain of mDia1 (Fan 
et al., 2010). Through direct interaction within filopodia, Rif with mDia1 instead of with mDia2 
regulates filopodial protrusion in the N1E115 mouse neuroblastoma cell line (Goh et al., 2011). 
In addition to RhoGTPase, tyrosine kinases src also has access to regulate formins activity (Rao 
and Zaidel-Bar, 2016). mDia1 activation is sufficient to rescue the effects of Src inhibition on E-
cadherin levels at adherent junctions and prevent the loss of lateral junctions in epithelial cells 
(Rao and Zaidel-Bar, 2016). Regarding phospholipids regulation, N-terminal phospholipid-
binding sites help to anchor mDia1 at the plasma membrane, and the interaction with 
phospholipids in the C-terminal functions as a switch for transient inactivation (Ramalingam et 
al., 2010). In this sense, AIS is characterized by a characteristic membrane that controls protein 
and lipids diffusion (Nakada et al., 2003). Future studies are needed to elucidate the cell 
signaling of mDia1 mediated AIS regulation. 
Some studies have described that calcium regulation related receptors, such as, IP3R3 can 
regulate actin cytoskeletal reorganization through a signaling pathway including mDia1 
(Vautrin-Glabik et al., 2018). In fact, IP3R1 is localized at the AIS (Sanchez-Ponce et al., 2011a). 
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As previously described, calcium-calpain mechanisms have been shown to modulate AIS 
composition. However, calpain inhibition is not able to impair ankyrinG decrease, excluding the 
possibility that formins regulation on AIS through calpain mechanisms. Given actin stabilization 
partially recovers the cisternal organelle after formins inhibition (Fig. R23), we can not exclude 
calcium involvement in these regulatory mechanisms. 
Microtubules regulation and microtubules binding proteins related to formins may be an 
alternative way of AIS regulation by formins. Both, actin and microtubules act in a complex 
interplay for cytoskeleton regulation in different cellular structures (Dogterom and Koenderink, 
2019). EB1 not only interacts with microtubules but may serve as a link to actin cytoskeleton 
(Dugina et al., 2016). End bind proteins EB1 and EB3 are expressed at the AIS and interact with 
ankyrinG (Leterrier et al., 2011). Moreover, mDia1 directly interact with EB1, which occurs 
independently of actin filaments and microtubules (Wen et al., 2004), suggesting a potential 
mechanisms for mDia1 location at the AIS. Previous studies have shown that EB proteins have 
access to associate with giant ankyrinG, and this interaction is crucial for AIS formation (Freal 
et al., 2016). In our work, EB1 over-expression recovers AIS components loss induced by acute 
inhibition of mDia1 activity (Fig. R25). EB1 over-expression may act by modulating AIS 
cytoskeleton and impairing changes produced by formins inhibition or somewhat contributing to 
ankyrinG stabilization. 
In addition, local acetylation of microtubules in the AIS contributes to recruitment of AIS 
components (Tapia et al., 2010). The reduction of acetylated tubulin in the AIS inflicted by 
mDia1 inhibition might contribute to the deficiency of AIS assembly. Consistently, silencing 
HDAC6 rescues ankyrinG reduction caused by mDia1 knockdown during AIS formation (Fig. 
R24). It will be of interest to determine whether there exists a mutual regulation between mDia1 
and HDAC6 and how they cooperates to maintain this local higher acetylated tubulin in the AIS. 
For instance, a relation between HDAC6 and mDia2 has been described in podosomes 
(Destaing et al., 2005). 
In view of the AIS cytoskeleton modifications caused by formins inhibition, a final balance 
of AIS components due to changes in anterograde or retrograde traffic may contribute to AIS 
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integrity maintenance. AIS formation and maintenance rely on the proper axonal transportation 
(Kuijpers et al., 2016; Tapia et al., 2010; van Beuningen et al., 2015). Kinesin-1 is the primary 
motor for anterograde transportation of axons (Nakata and Hirokawa, 2003). KIF5C is one of 
identified kinesin-1 family members in the axon and AIS (Nakata and Hirokawa, 2003; Tapia et 
al., 2010). We found that KIF5C expression is disrupted both in the soma and axon in mDia1 
inhibited neurons (Fig. R8). It is reported that microtubule acetylation or detyrosination 
promotes kinesin-1 binding and transport into axon (Konishi and Setou, 2009; Reed et al., 2006). 
Consistently, AIS components loss is corrected by increasing tubulin acetylation in mDia1 
inactivated or suppressed neurons (Fig. R24). Currently, an AIS enriched microtubule binding 
protein TRIM46 is identified and functions in the formation and maintenance of parallel 
microtubule arrays. Loss of ankyrinG leads to a dramatic redistribution of TRIM46 (van 
Beuningen et al., 2015). Given the remarkable effects of mDia1 on AIS ankyrinG, TRIM46 may 
also be affected in our work and which could be another reason of anterograde disability in the 
axon. 
Apart from anterograde transportation, we found a possible involvement of retrograde 
transportation in mDia1 mediated AIS regulation. Cytoplasmic dynein is responsible for 
microtubule-based transportation in a minus end direction (Hirokawa, 1998). In the AIS, dynein 
and its regulators control axonal cargos transportation through excluding somatodendritic 
proteins (Klinman et al., 2017; Kuijpers et al., 2016). Consistent with this, we found that mDia1 
inhibition disrupts neuronal polarity with MAP2 entrance into the axon (Fig. R7), although we 
can not exclude contributions from F-actin destabilization and ankyrinG loss in our study 
(Sobotzik et al., 2009; Song et al., 2009; Winckler et al., 1999). However, dynein inhibitor 
Ciliobrevin D partially rescues AIS components loss inflicted by mDia1 inhibition (Fig. R26). 
Previous studies showed that actin filament depolymerization induces retrograde reorganization 
of the axonal cytoplasm, which is rescued by treatment with Ciliobrevin D (Sainath and Gallo, 
2015). Together with our results and previous studies, we propose that formins inhibition can 
affect both anterograde and retrograde transport, generating an imbalance in AIS trafficking, 
which leads to reduced AIS proteins accumulation together with loss of these proteins tethering 
at the AIS. Additional studies are needed to elucidate the role of mDia1 on protein 
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transportation to the AIS. 
In conclusion, we have demonstrated that mDia1 activity and expression is necessary for 
AIS assembly, maintenance and plasticity both in cultured hippocampal neurons and in brain 
slices. However, further studies are necessary to completely understand the mechanisms and 
how they are involved in neuronal excitability regulation and diseases. Homozygous mutations 
of DIAPH1, the gene coding mDia1, in humans generate microcephaly, but no study has 
focused on further neuronal activity in adults. In mice models, it has been observed that mice 
lack of mDia1 and mDia3 altogether causes impaired tangential migration of cortical 
interneurons as well as neuroblasts migration from the subventricular zone to the granule cell 
layer of the olfactory bulb (Shinohara et al., 2012). Double knockout mice also show aberrant 
midline crossing of axons of corticospinal neurons and spinal cord interneurons (Toyoda et al., 
2013). In addition, loss of mDia1 and mDia3 in mice disrupts integrity of neuroepithelium and 
causes periventricular dysplasia (Thumkeo et al., 2011). However, these phenotypes can not be 
observed in mDia1 knockout mice (Ercan-Sencicek et al., 2015). To some extent, in mice 
models, mDia1 is redundant with mDia3 and lacking mDia1 or mDia3 alone in mice has no 
apparent abnormality (Shinohara et al., 2012; Toyoda et al., 2013). 
Regarding Alzheimer’s disease, mDia1 suppression or inhibition diminishes 
synaptotoxicity induced by oligomeric amyloid β1-42 by increasing microtubule dynamics (Qu 
et al., 2017). mDia1 regulates tau phosphorylation through affecting microtubules stability (Qu 
et al., 2017). Besides, the recent involvement of AIS as a potential link to Alzheimer’s disease, 
AIS modifications by formins in this disease models are lacking. In addition, some other formin 
family members are related to brain disorders. For example, formin FMN2 is deregulated in 
post-traumatic stress disorder (PTSD) and Alzheimer’s disease. The loss of FMN2 leads to 
accelerated age-associated memory impairment and amyloid-induced deregulation of gene 
expression (Agis-Balboa et al., 2017). Finally, more studies are necessary to understand the role 
of formins and their mechanisms on neurons or glial cells. Together, our current findings 
provide novel molecular insights into AIS regulation, which might suggest new therapeutic 




































1. Formins activity is required for axon initial segment (AIS) cytoskeleton maintenance. 
Inhibition of formins activity decreases overall F-actin intensity and microtubules acetylation in 
the AIS. 
2. Formins activity is essential to maintain AIS protein composition. Loss of formins 
activity decreases the concentration of structural and functional AIS proteins in cultured neurons 
and brain slices.  
3. Formins activity is required to maintain AIS mediated neuronal polarity. Lack of formins 
activity allows the somatodendritic protein MAP2 to enter the axon. 
4. One of formin family members, mDia1, is localized at the AIS. 
5. mDia1 knockdown alters early AIS assembly, by decreasing the recruitment of AIS 
components.  
6. Formins activity and mDia1 are required to maintain AIS composition integrity after AIS 
is fully assembled.  
7. Alterations in formins activity or mDia1 expression generate AIS plasticity and lead to 
AIS shortening. 
8. AIS integrity loss by formins inhibition can be recovered through increasing tubulin 
acetylation, over-expressing the microtubule associated protein EB1 or inhibiting retrograde 















































        1. La actividad de las forminas es necesaria para el mantenimiento del citoesqueleto del 
segmento inicial del axón (AIS). La inhibición de la actividad de las forminas disminuye la 
intensidad general de F-actina y la acetilación de los microtúbulos en el AIS. 
        2. La actividad de las forminas es esencial para mantener la composición proteíca del AIS. 
La pérdida de la actividad de las forminas disminuye la concentración de proteínas estructurales 
y funcionales del AIS en neuronas en cultivo y rodajas de cerebro. 
        3. Se requiere la actividad de las forminas para mantener la polaridad neuronal mediada 
por el AIS. La falta de actividad de las forminas permite que la proteína somatodendrítica 
MAP2 entre en el axón. 
        4. Uno de los miembros de la familia de las forminas, mDia1, está localizado en el AIS. 
        5. La disminución de la expresión de mDia1 altera el ensamblaje temprano del AIS, al 
disminuir el reclutamiento de componentes del AIS. 
        6. La actividad de las forminas y mDia1 son necesarias para mantener la integridad de la 
composición del AIS, cuando el AIS está completamente ensamblado. 
        7. Las alteraciones en la actividad de las forminas o la expresión de mDia1 generan 
plasticidad en el AIS y conducen a su acortamiento. 
        8. La pérdida de integridad del AIS por la inhibición de las forminas se puede recuperar 
aumentando la acetilación de la tubulina, sobreexpresando la proteína EB1 asociada a los 
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Morphological and functional polarization of neurons depends on the generation and
maintenance of the axon initial segment (AIS). This axonal domain maintains axonal
properties but is also the place where the action potential (AP) is generated. All these
functions require the AIS, a complex structure that is not fully understood. An integrated
structure of voltage-gated ion channels, specific cytoskeleton architecture, as well as,
scaffold proteins contributes to these functions. Among them, ankyrinG plays a crucial
role to maintain ion channels and membrane proteins. However, it is still elusive how
the AIS performs its complex structural and functional regulation. Recent studies reveal
that AIS is dynamically regulated in molecular composition, length and location in
response to neuronal activity. Some mechanisms acting on AIS plasticity have been
uncovered recently, including Ca2+, calpain or calmodulin-mediated modulation, as
well as post-translational modifications of cytoskeleton proteins and actin-associated
proteins. Neurons are able to respond to different kind of physiological and pathological
stimuli from development to maturity by adapting their AIS composition, position and
length. This raises the question of which are the neuronal receptors that contribute to
the modulation of AIS plasticity. Previous studies have shown that purinergic receptor
P2X7 activation is detrimental to AIS maintenance. During initial axonal elongation,
P2X7 is coordinated with P2Y1, another purinergic receptor that is essential for proper
axon elongation. In this study, we focus on the role of P2Y1 receptor on AIS development
and maintenance. Our results show that P2Y1 receptor activity and expression are
necessary during AIS initial development, while has no role once AIS maturity is achieved.
P2Y1 inhibition or suppression results in a decrease in ankyrinG, βIV-spectrin and
voltage-gated sodium channels accumulation that can be rescued by actin stabilization
or the modulation of actin-binding proteins at the AIS. Moreover, P2X7 or calpain
inhibition also rescues ankyrinG decrease. Hence, a dynamic balance of P2Y1 and
P2X7 receptors expression and function during AIS assembly and maturation may
represent a fine regulatory mechanism in response to physiological or pathological
extracellular purines concentration.
Keywords: axon initial segment, purinergic receptors, P2Y1, ankyrinG, axon, myosin
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INTRODUCTION
The axon initial segment (AIS) plays a crucial role in neuronal
physiology, being responsible for the coordination of the whole
set of inputs that a neuron receives. This unique axonal
domain generates the action potential (AP; Stuart et al., 1997;
Kole et al., 2008) and has a high degree of plasticity that
allows the control of AP amplitude and frequency. In fact,
the AIS may undergo lengthening or shortening, changes in
its composition and can move away from soma to control
AP response (Grubb and Burrone, 2010; Kuba et al., 2010,
2015; Del Puerto et al., 2015). Further, axonal identity and
neuronal polarity depend on AIS integrity (Schafer et al., 2009).
Different mental disorders (e.g., bipolar disorder, schizophrenia)
and genetic diseases (e.g., Angelman syndrome) are related to
AIS alterations (Kaphzan et al., 2011; van der Werf et al.,
2017; Zhu et al., 2017), as well as neurodegeneration related
diseases, such as stroke, brain injury or Alzheimer’s disease
(Schafer et al., 2009; Sun et al., 2014; Del Puerto et al., 2015).
Despite the importance of AIS, our knowledge is far from
a complete understanding of its whole composition, structure
and plasticity. In this sense, it remains mostly unknown
which receptors and extracellular factors participate on AIS
development, maintenance and modulation.
The AIS comprises around the first 20–60 microns of the
axon, depending on the type of neuron and developmental stage
(for a review see Leterrier, 2018). It is composed by a high
density of voltage-gated sodium, potassium and calcium ion
channels, and also contains among others, GABA, dopamine
and serotonin receptors, which contribute to modulate APs
(Rasband, 2010). These voltage-gated ion channels are anchored
through interactions with AIS enriched scaffold proteins, such
as AnkyrinG or PSD-93 (Garrido et al., 2003; Pan et al., 2006;
Ogawa et al., 2008). AnkyrinG is the most important structural
protein in the AIS and AnkyrinG suppression drives to the
loss of polarity and axonal identity. Scaffold proteins also serve
to anchor other membrane proteins, such as L1, neurofascin
or ADAM-22 (Jenkins and Bennett, 2001; Ogawa et al., 2010).
Other extracellular proteins, such as Lgi1 (Seagar et al., 2017)
or brevican (Hedstrom et al., 2007) also contribute to this dense
protein structure. This functional and structural membrane and
submembranous scaffold are anchored to a complex cytoskeleton
by βIV-spectrin (Komada and Soriano, 2002), which interacts
with the actin cytoskeleton (Rasband, 2010). Although recent
studies have contributed to a better knowledge of this actin
cytoskeleton, whose roles in AIS maintenance, development and
function are not well understood. The AIS contains regular
actin rings and actin patches (Watanabe et al., 2012; Leterrier
et al., 2015). Some AIS actin-interacting proteins are α-actinin-
2 (Sánchez-Ponce et al., 2012), synaptopodin (Bas Orth et al.,
2007) or myosins (Evans et al., 2017; Janssen et al., 2017).
Also, the AIS contains a synaptopodin and actin-associated
structure, the cisternal organelle (Benedeczky et al., 1994),
which function is still elusive despite, changes in cisternal
organelle structure occurs during development and AIS plasticity
(Schlüter et al., 2017). Finally, a differential microtubules
cytoskeleton supports this whole structure and contributes
to axonal trafficking. This microtubules cytoskeleton contains
acetylated and detyrosinated tubulin that confers a higher degree
of stability to this cytoskeleton (Konishi and Setou, 2009;
Tapia et al., 2010).
While our knowledge of this complex interplay between
important structural and functional proteins of the AIS
increases, we still have little information about the external
regulatorymechanismsmodulating the AIS and its structural and
composition plasticity.
Recent studies have highlighted the role of some receptors
at the AIS and outside the AIS on the control of AIS
composition, integrity and structural plasticity. The function
and plasticity of AIS seem to depend on the excitatory or
inhibitory profile of hippocampal neurons, as well as the input
they receive and their developmental stage (Grubb et al., 2011).
However, the extracellular factors, receptors, and mechanisms
controlling these adaptive modifications are unknown. This
raises the question of what factors contribute to a physiological
development and maintenance of the AIS. Recent results show
that neurotransmitter receptors participate in AIS regulation.
Dopamine, through D3R receptors, modulates T-type Ca2+
channels at the AIS contributing to neuronal output (Bender
et al., 2010; Clarkson et al., 2017). Serotonin receptors (5-HT1A)
also contribute to the control of AP threshold by modulating
AIS cyclic-nucleotide-gated channels (HCN1) in the medial
superior olive (Ko et al., 2016). In addition, 5-HT1A receptors
modulate Nav1.2 voltage-gated sodium channels in the AIS of
cortical neurons, decreasing the success rate of AP generation
(Yin et al., 2017). Cannabinoid receptor 1 (CB1R) is necessary
to achieve a proper ankyrinG clustering at the AIS in the
early developmental stages of AIS (Tapia et al., 2017). Other
neurotransmitters such as ATP, through the purinergic receptor
P2X7, modulate AIS composition (Del Puerto et al., 2015).
Purinergic receptors are a wide family of receptors expressed
in neurons and glial cells and are important regulators of
neuronal excitability. They can be divided into three subfamilies,
adenosine, P2X and P2Y receptors, all activated by different
neuronal and glial secreted purines (Del Puerto et al., 2013).
They have an important role not only in physiological but also
in pathological processes (Burnstock, 2017). Among them, the
ionotropic P2X7 receptors are activated by high concentrations
of extracellular ATP, while the metabotropic P2Y1 receptor is
preferentially activated by ADP (Burnstock, 2007). P2X7 and
P2Y1 purinergic receptors have an antagonistic role and are
coordinated during initial axon elongation (del Puerto et al.,
2012). While P2X7 has a detrimental effect on axonal elongation,
P2Y1 promotes axonal elongation during the first stages of
axonal growth. These antagonistic actions are regulated by
P2X7-mediated calcium entry that inhibits adenylate cyclase
5 (AC5), and P2Y1-mediated Gq-PKCζ activation of AC5.
This generates a balance that controls cAMP production and
modulates PI3K-Akt-GSK3 pathway activity. Our previous work
demonstrated that P2X7 activation is detrimental for ankyrinG
and voltage-gated sodium channels accumulation in AIS of
mature neurons (Del Puerto et al., 2015). However, P2Y1 role
on AIS regulation has not been studied. The objective of our
study was to investigate whether P2Y1 purinergic receptor
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participates on AIS development or modulation. Our results
show that P2Y1 activity is necessary for initial AIS development
and ankyrinG accumulation while having no significant role in
mature neuron AIS. Decreased ankyrinG accumulation due to
P2Y1 suppression can be prevented through P2X7 or calpain
inhibition, revealing the crosstalk of P2Y1 and P2X7 during
AIS development. Further, P2Y1 suppression alters F-actin
distribution in AIS and decreases phosphorylation of myosin
light chain (pMLC) and ankyrinG which can be prevented by
F-actin stabilizing agent Jasplakinolide or protein phosphatase
1 and 2A inhibitor Calyculin A. Together with previous results
on purinergic regulation (del Puerto et al., 2012; Del Puerto et al.,
2015), our results suggest a necessary role for P2Y1 for the early
development of the AIS. However, with neuronal maturation, the
importance of P2Y1 decreases while P2X7 gains and increasing
relevance in AIS maintenance and modulation.
MATERIALS AND METHODS
Reagents and Plasmids
Reagents were obtained from the following manufacturers:
Adenosine 5’-diphosphate sodium ADP (A2754),
P2X7 antagonist, BBG (B0770), AC5 inhibitor, NKY80
(N2165) and PP1/PP2A phosphatases inhibitor calyculin A
(C5552) were obtained from Sigma-Aldrich. P2Y Antagonist
II (BPTU; 504187) was obtained from EMD Millipore.
2-Methylthioadenosine diphosphate trisodium salt (2-MeSADP;
1624), (N)-methanocarba-2MeSADP (MRS 2365; 2157), the
calpain inhibitor MDL 28170 and jasplakinolide were obtained
from Tocris. P2Y1 shRNA and scrambled shRNA plasmids have
been previously published and validated (del Puerto et al., 2012).
Animals
Animals were housed in a room at controlled temperature
and relative humidity with alternating 12 h light and dark
cycles and free access to food and water ‘‘ad libitum.’’ Animal
care protocols used in our laboratory are in conformity with
the appropriate national legislation (53/2013, BOE no. 1337)
and guidelines of the Council of the European Communities
(2010/63/UE). All protocols were previously approved by the
CSIC bioethics committee.
Neuronal Culture
Mouse hippocampal neurons were prepared as previously
described (del Puerto et al., 2012; Del Puerto et al., 2015).
Neurons were obtained from E17 mouse hippocampi, which
were incubated in a 0.25% trypsin solution in Ca2+/Mg2+
free Hank’s buffered salt solution (HBSS) and dissociated
using fire-polished Pasteur pipettes. The cells were plated
on polylysine-coated coverslips (1 mg/ml) at a density of
5,000 cells/cm2 for 2 h in plating medium [minimum
essential medium (MEM), 10% horse serum, 0.6% glucose and
Glutamax-I]. Then coverslips were inverted and transferred to
culture dishes containing astrocytes. Astrocytes medium was
replaced by neuronal culture medium 24 h before neuronal
culture (Neurobasal medium, B27 supplement, Glutamax-I).
To avoid contact between neurons and astrocytes, paraffin
beads were placed on coverslips before neuronal plating. Five
micromolar 1-β-D-arabinofuranosylcytosine (AraC) was added
after 2 days in culture to avoid glial cells proliferation. One-third
of neuronal medium was replaced every week. Pharmacological
treatments were applied as described in the ‘‘Results’’ section.
In the case of pharmacological treatments in the absence of
glial cell layer, coverslips were transferred to plates containing
glial cells-conditioned medium. Primary hippocampal neurons
were nucleofected using the Amaxa nucleofector kit for primary
mammalian neural cells (Amaxa Bioscience) according to the
manufacturer’s instructions. Nucleofection was performed using
3 µg of total DNA and 3 × 106 cells for each nucleofection.
Neurons were plated at a density of 10,000 cells/cm2 as described
above. Nucleofection efficiency was ∼15% of neurons, based on
the number of GFP-positive neurons. For lipofection, neurons
were plated at a density of 20,000 cells/cm2 and transfected at
7 or 10 DIV. Lipofection was performed using Lipofectamine
2000 (Life Technologies) and 3 µg of total DNA following
manufacturer instructions.
Immunofluorescence
Neurons from each experiment, containing all experimental
conditions to be compared, were fixed in 4% PFA. To standardize
staining, all these coverslips were treated at the same time
for immunofluorescence following the same conditions. Briefly,
coverslips were treated for 10 min with 50 mM NH4Cl and
incubated in blocking buffer (0.22% gelatine, 0.1% Triton X-100
in PBS) for 30 min, before incubation with primary antibodies
for 1 h at room temperature in blocking buffer. The primary
antibodies used were: chicken anti-MAP2 (1:10,000, Abcam,
ab5392), mouse anti-ankyrinG (1:100) from NeuroMab (clone
N106/36), mouse anti-pan sodium channel (1:100) from Sigma
(clone K58/35), rabbit anti-pMLC (1:200) from Thermo Fisher
(PA5-17727) and rabbit βIV-spectrin (1:1,000; a gift from Dr.
M. Rasband, Baylor College of Medicine, Houston, TX, USA).
The secondary antibodies used were a goat or donkey anti-
mouse, anti-rabbit or anti-chicken Alexa-Fluor 488, 594, or 647
(1:1,000). Phalloidin Alexa-Fluor 594 was used at a concentration
of 1:100. Images from each immunofluorescence were acquired
on a Leica SP5 confocal microscope maintaining the same
acquisition parameters to compare intensities. Figures were
prepared for presentation using the Adobe CS4 software.
Dendrites and AIS Measurements
Quantification of fluorescence intensity at the AIS was performed
on confocal images of neurons from at least three independent
experiments. Neurons were randomly acquired without any bias
by scanning each coverslip from top to bottom. All confocal
images within the same experiment and immunofluorescence
were acquired using exactly the same parameters of laser
intensity, excitation and emission detection during the same
working session for each Alexa fluorophore. Parameters were set
in control neurons and maintained for the other experimental
groups. After completing images acquisition of all conditions,
ankyrinG and other AIS proteins staining were quantified using
ImageJ software. We drew a line starting at the limit of neuronal
soma identified by MAP2 staining and extended it along the
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ankyrinG staining or the GFP signal of the axon. Data from every
0.16µmalong the first 40µmwere obtained and smoothed using
the Sigmaplot software to obtain average ankyrinG fluorescence
intensity every 1 µm. Data were normalized in each neuron,
within the same immunofluorescence, considering the value of
maximum mean fluorescence in control neurons to be 100%.
Total fluorescence intensity for each neuron was obtained by
adding ankyrinG fluorescence values from 0 to 40 µm. In
some experiments, the total ankyrinG intensity was calculated
within each AIS length and data normalized to AIS length
of each neuron. AIS start, end and maximum fluorescence
intensity were determined following the criteria described in
Grubb and Burrone (2010). Taking 100% fluorescence as the
maximum fluorescence intensity point, start and end points
were defined as the points were fluorescence intensity is lower
than 33%. For actin patches quantification, neurons were stained
with Phalloidin-Alexa 594 (1:100) and ankyrinG to detect
the AIS. Puncta of relatively uniform diameter of less than
3 µm within AIS were considered to be patches (Balasanyan
et al., 2017). To avoid any possible loss of actin patches by
lower F-actin intensity, image intensity was increased for the
purpose of identification and quantification of all possible
actin patches.
Dendrites lengths were obtained based on MAP2 staining
using NeuronJ software to measure the length of the dendritic
arbor in each neuron. All dendrites and ramifications in each
neuron were traced using NeuronJ and their total length added.
GFP signal of neurons under analysis allowed discriminating
from crossing dendrites from other neurons. In order to study
correlations between dendrites and AIS fluorescence, both data
were obtained from the same neurons.
Statistical Analysis
All statistical analyses were carried out in Sigmaplot v12.5 (Systat
Software Inc.) and Prism 5 (GraphPad Software, Inc., La Jolla,
CA, USA). Data for each independent sample were obtained from
at least three independent experiments. For pharmacological
experiments, data from each experiment were collected from at
least 30 cells (between 30 and 50 cells) in each experimental
condition. For nucleofection or lipofection experiments around
25 neurons from each experiment in each experimental condition
were analyzed. Statistical analysis was performed by t-test for
two group comparisons and one-way ANOVA for multiple
group comparisons. When data were non-normally distributed,
non-parametric tests were used: Mann-Whitney Rank test for
two independent samples and Kruskal-Wallis for analysis of
multiple groups. In the analysis of multiple comparisons, a
post hoc analysis was performed using Dunn’s test. All p-values
were adjusted to account for multiple comparisons. Cell-to-
cell analysis of dendrite length and ankyrinG fluorescence was
performed using Prism 5 and Sigmaplot v12.5. First, we tested
the normality of data distribution on each variable using a
Shapiro-Wilk or Kolmogorov-Smirnov normality test. As not all
data passed normality test, the correlation was analyzed using the
Pearson correlation function or Spearman correlation function
when data failed normality test. Differences were considered
significant when p < 0.05.
RESULTS
ADP Activation of P2Y1 Increases
AnkyrinG Levels in the Developing Axon
Initial Segments
A previous study demonstrated that the AIS of mature
cultured hippocampal neurons (21 DIV) is regulated by
ATP and P2X7 receptor (Del Puerto et al., 2015). Due
to the coordinated action of ATP and ADP during initial
axon elongation, we have investigated whether ADP and
P2Y1 play a role in AIS regulation. Hippocampal neurons
were treated with vehicle or ADP 10 µM during the 3 days
prior fixation at 10, 14 or 21 DIV. AnkyrinG levels were
then analyzed after immunofluorescence (Figures 1A–D). ADP
treatment increased ankyrinG fluorescence intensity at the
AIS in neurons treated from 7 to 10 DIV (146.74 ± 2.48%)
compared to 10 DIV control neurons (100 ± 1.76%). However,
ADP treatment in 14 DIV neurons had no significant
effect in ankyrinG levels (113.74 ± 3.81%) vs. 14 DIV
control neurons (100 ± 3.78%), as also happened for ADP
treatment in 21 DIV neurons (110.38 ± 3.89% vs. AIS
of 10 and 21 DIV neurons (Figures 1B,C). Next, we
treated neurons with two more P2Y1 agonists, 2MeSADP
(10 µM) and MRS-2365 (10 µM). Both agonists also increased
significantly ankyrinG intensity at the AIS of 7–10 DIV
treated neurons (Figures 1E,F), suggesting a P2Y1 mediated
effect of ADP.
P2Y1 Receptor Suppression or Inhibition
Decreases AnkyrinG Accumulation at the
AIS During Initial Developmental Stages
In order to ensure that ADP effect was due to P2Y1 receptor
activation, we nucleofected neurons before plating using
scrambled (shscr) or P2Y1 (shP2Y1) interference RNAs that
also express GFP. Neurons were left in culture for 4, 7, 14 or
21 DIV, fixed and stained with MAP2 and ankyrinG antibodies
(Figures 2A–D). P2Y1 interference RNA significantly decreased
ankyrinG intensity between 4 and 14 DIV (Figure 2E), with
the maximum reduction found at 7 DIV (77.07 ± 3.79%)
compared to 100 ± 4.75% in sh scrambled 7 DIV control
neurons. Fourteen DIV neurons recovered when compared to
7 DIV neurons (86.58 ± 2.36%), and no significant change was
observed in 21 DIV neurons. To ascertain that ADP treatment
has no effect on ankyrinG intensity after P2Y1 suppression,
nucleofected 7 DIV neurons were treated with ADP 10 µM for
3 days. Neurons nucleofected with scramble shRNA increased
ankyrinG intensity after ADP treatment, while those expressing
shP2Y1 did not respond to ADP treatment (Figure 2F). Next,
we checked whether the fluorescence intensity of ankyrinG
interacting proteins, βIV-spectrin and voltage-gated sodium
channels, was also reduced in 7 DIV neurons (Figure 2G). Both
proteins significantly decreased their expression at the AIS after
P2Y1 suppression (72.19± 5.67%, panNaCh and 70.69± 6.46%,
βIV-spectrin) and the percentage was similar to ankyrinG
(Figure 2E). To rule out the possibility that shP2Y1 efficiency was
progressively lost during in vitro development, we introduced
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FIGURE 1 | ADP and P2Y1 agonists potentiates ankyrinG expression during early axon initial segment (AIS) development. (A) Normalized ankyrinG fluorescence
intensity in 10, 14 and 21 DIV hippocampal neurons. Neurons were treated with ADP for 3 days before fixation (blue symbols). Data were acquired from three
independent experiments (30 neurons/experimental condition in each experiment). Same pool of neurons was used for each experiment and fixed at different times.
All images were acquired by confocal microscopy using the same fluorescence parameters. Statistical differences were analyzed by a Kruskal-Wallis test followed by
a Dunn’s multiple comparisons post-test. Adjusted p values: ∗∗∗p < 0.001. (B,C) Normalized AnkyrinG intensity profile along the AIS of 10 DIV (B) and 21 DIV (C)
hippocampal neurons in the presence (green line) or absence (black line) of 10 µM ADP treatments. (D) Control and ADP treated 10 DIV and 21 DIV neurons stained
with MAP2 (blue) and ankyrinG antibodies (green). Scale bar = 100 µm. Four times-magnification of the ankyrinG staining (green) at the AIS is shown below images.
(E) Normalized ankyrinG intensity at the AIS of 10 DIV neurons treated with ADP and P2Y1 agonists 2-methylthioadenosine diphosphate trisodium salt (2MeSADP) or
MRS-2365 from 7 to 10 DIV. Data were acquired from three independent experiments (30 neurons/experimental condition in each experiment). ∗∗∗p < 0.001, two-tail
t-test. (F) 10 DIV hippocampal neurons stained with MAP2 (blue) and ankyrinG antibodies (green) treated with 2MeSADP (10 µM) or MRS-2365 (10 µM). Data in
graphs are represented as the mean ± SEM.
control scrambled shRNA and P2Y1 shRNA by lipofection in
7 or 10 DIV neurons. Neurons were left 2–3 days and ankyrinG
signal was analyzed (Figure 2H). Lipofected neurons expressing
shP2Y1 did not show any reduction of ankyrinG levels at
neither 10 or 12 DIV, confirming that in cultured hippocampal
neurons P2Y1 exerts its action only during the initial steps of
AIS development. This timing correlates with the stages prior
to which the AIS diffusion barrier is developed at 10 DIV
(Brachet et al., 2010).
In view of these results, we next checked whether
P2Y1 pharmacological inhibition was enough to
reduce ankyrinG levels. For this purpose, we used the
non-nucleotide allosteric and none ADP-competitive P2Y1
antagonist, BPTU (1-(2-(2-(tert-butyl)phenoxy)pyridin-3-yl)
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FIGURE 2 | P2Y1 receptor is necessary to maintain ankyrinG density during early stages of AIS development. (A–D) 4, 7, 14 and 21 DIV hippocampal neurons
nucleofected with scrambled and P2Y1 shRNAs. After nucleofection neurons were kept in culture for 4 (A), 7 (B), 14 (C) and 21 days (D) and stained with MAP2
(blue) and ankyrinG (red) antibodies. Nucleofected neurons were identified by GFP expression (green). Inserts show magnifications of AISs (gray) of each neuron.
(E) Normalized ankyrinG intensity at different days post-nucleofection with scrambled shRNA (shscr, black) or P2Y1 shRNA (shP2Y1, red). shP2Y1 data are
normalized to their respective shscr controls at each developmental stage. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, two-tail t-test. (F) Normalized ankyrinG intensity in
10 DIV neurons expressing shscr or shP2Y1 plasmids, treated with vehicle or ADP from 7 to 10 DIV. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, two-tail t-test. Data were
acquired from three independent experiments (30 neurons/experimental condition in each experiment). (G) βIV-spectrin and voltage-gated sodium channels
(PanNaCh) normalized intensity in 7 DIV control shscr and shP2Y1 expressing neurons. ∗p < 0.05, ∗∗∗p < 0.001, two-tail t-test. Data were acquired from three
independent experiments (at least 25 neurons/experimental condition in each experiment). (H) Normalized ankyrinG intensity in 10 and 12 DIV hippocampal
transfected at 7 or 10 DIV, respectively, to express shscr or shP2Y1 interference RNAs. Data were acquired from three independent experiments (at least
20 neurons/experimental condition in each experiment). n.s., not significant, two tail t-test. Data in graphs are represented as the mean ± SEM.
-3-(4-(trifluoromethoxy)phenyl)urea; Mañé et al., 2016). First,
we determined the most efficient dose in cultured hippocampal
neurons. Seven DIV neurons were treated for 3 days with
BPTU at concentrations of 0.5, 1, 2, 5, 7, 10 and 20 nM and
ankyrinG levels were evaluated (Figure 3A). AnkyrinG levels
decreased linearly with increasing BPTU concentration. BPTU
doses under 10 nM did not affect neuronal viability, but
concentrations higher than 10 nM had a detrimental effect
on neuronal survival due to alterations on glial cell layer
morphology and viability (data not shown). Consequently,
we decided to inhibit P2Y1 using 5 nM BPTU treatments
in 7 DIV neurons for 3 days (Figure 3C). While 7–10 DIV
neurons increased ankyrinG levels after ADP treatment, 5 nM
BPTU reduced ankyrinG levels (Figure 3B) to similar levels
(75.21 ± 1.54%) than those observed in shP2Y1 neurons
(77.07 ± 3.79%, Figure 2E, or 63.86 ± 4.95%, Figure 3E). No
difference was observed between the ADP and BPTU vehicles,
water and DMSO, respectively (Figure 3B). Moreover, BPTU
treatment impaired the positive effect of ADP on ankyrinG
(Figure 3D). Finally, we combined shP2Y1 with BPTU and again
assessed ankyrinG. 10 DIV neurons expressing shP2Y1 had
decreased ankyrinG expression (63.86 ± 4.95%), which was
significantly reduced (49.38 ± 2.76%) by BPTU treatment in
shP2Y1 neurons (Figure 3E). The fact that BPTU has an additive
effect with P2Y1 suppression may be explained by the fact that
still some P2Y1 receptors are available and BPTU is a potent
P2Y1 inhibitor. shP2Y1 has an efficiency of 70% reducing
P2Y1 expression in cell lines (del Puerto et al., 2012). On the
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FIGURE 3 | P2Y1 pharmacological inhibition decreases ankyrinG accumulation at the AIS. (A) Normalized ankyrinG intensity on 10 DIV hippocampal neurons
treated from 7 DIV with increasing concentrations of the P2Y1 antagonist, BPTU (0.5, 1, 2, 5, 7 and 10 nM). Concentrations higher than 10 nM affected the
morphology of supporting glial cells and were discarded to avoid secondary effects on neurons. (B) AnkyrinG intensity profile along the AIS of hippocampal neurons
treated from 7 to 10 DIV with vehicle black line), DMSO (BPTU vehicle, gray line), ADP (green line) and BPTU (red line). (C) 10 DIV neurons stained with MAP2 (blue)
and ankyrinG antibodies (green) and treated with vehicle (control) or 5 nM BPTU from 7 to 10 DIV. Inserts show a magnification of the respective AIS. (D) Normalized
ankyrinG intensity on 10 DIV hippocampal neurons treated from 7 DIV with 10 µM ADP and BPTU 5 nM, alone or in combination. (E) Normalized ankyrinG intensity
on 10 DIV shscr or shP2Y1 nucleofected hippocampal neurons treated with BPTU from 7 DIV. Data were acquired from three independent experiments (at least
30 neurons/experimental condition in each experiment). ∗∗p < 0.01, ∗∗∗p < 0.001, n.s. not significant, two-tail t-test. Data in graphs are represented as the
mean ± SEM.
other hand, it is the first time that BPTU is used in neurons. We
can not discard that BPTU is partially affecting other purinergic
receptors. However, BPTU impairs ADP-mediated increase
of ankyrinG fluorescence. Therefore, our results suggest that
P2Y1 activation is necessary to maintain ankyrinG levels at
the AIS during the first stages of AIS development. This led
to the question which are the mechanisms or developmental
events that are under P2Y1 regulation that contribute to AIS
proteins accumulation.
AnkyrinG and Dendrites or AIS Length do
Not Correlate in Neurons Lacking
P2Y1 Receptor
P2Y1 receptor is not detected at the AIS but is located in
dendrites, distal axon and presynaptic terminals in cultured
hippocampal neurons (del Puerto et al., 2012). We recently
demonstrated that ankyrinG decrease at AIS was correlated
with impaired dendrite development mediated by CB1R
inhibition (Tapia et al., 2017) and previous studies demonstrated
that P2Y1 modulate neuronal morphology during the initial
stages of development (del Puerto et al., 2012). Dendrites
start their development in cultured hippocampal neurons
at 4 DIV (Dotti et al., 1988). In order to test whether
P2Y1 may control dendrite development and also influence
AIS development, we measured the cell-to-cell dendritic
length and ankyrinG fluorescence intensity in 7 DIV shscr
and shP2Y1 nucleofected neurons (Figures 4A,B). As
happened when CB1 expression was reduced (Tapia et al.,
2017), dendrites of 7 DIV shP2Y1 neurons were shorter
(320.2 ± 14.1 µm) than in control neurons (397.1 ± 20.37 µm,
Figures 4C,E). Moreover, ankyrinG expression at the AIS
was also reduced by 20% (Figures 4D,E). Even though
a similar percentage reduction of dendrites length and
ankyrinG was observed (Figure 4E), we analyzed both
parameters in each individual neuron (Figure 4F). While
we found a significant correlation between dendritic arbor
length and ankyrinG expression in sh scrambled control
neurons (Spearman r = 0.3037, p = 0.0055), there was
no significant correlation in shP2Y1 neurons (Spearman
r =−0.1522, p = 0.1955).
On the other hand, the AIS is known to respond to
stimulus or absence of stimulus with plasticity mechanisms
that include changes in composition, length and position
(Grubb and Burrone, 2010; Kuba et al., 2010; Del Puerto
et al., 2015). Therefore, we analyzed AIS length in 7 and
14 DIV shscr and shP2Y1 neurons (Figure 5). No significant
AIS length differences were found in 7 DIV shP2Y1 neurons
(26.06 ± 1.03 µm) compared to control 7 DIV sh scrambled
neurons (23.52 ± 0.97 µm), neither in AIS position or
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FIGURE 4 | No correlation between P2Y1 suppression-mediated decrease of dendrites length and ankyrinG density. (A,B) Representative images of 7 DIV
hippocampal neurons nucleofected with scrambled or P2Y1 shRNAs. After nucleofection neurons were kept in culture for 7 DIV and stained with MAP2 (blue) and
ankyrinG (red) antibodies. Nucleofected neurons were identified by GFP expression (green). (C,D) Box-plots represent total dendritic length (C) and ankyrinG
intensity (D) of 7 DIV scrambled sh (sh scr) or shP2Y1 nuclefected neurons from the same pools in three different experiments. Line inside the box represents the
median, and upper and bottom lines represent the maximum and minimum values. ∗∗p < 0.01, ∗∗∗p < 0.001, two-tail t-test. (E) Normalized mean ± SEM of
dendrites length and ankyrinG intensity of data represented in (C,D). (F) Correlation graph of dendrites length and ankyrinG intensity for each individual neuron
analyzed in the study. Control neurons (shscr) are represented in black and neurons expressing P2Y1 interference RNA (shP2Y1) are in red. Data were analyzed first
with two normality tests (Shapiro-Wilk and Kolmogorov-Smirnov). Not all data sets did fit a normal distribution and a non-parametric correlation test (Spearman) was
performed. Regression lines are shown for shscr (black) and shP2Y1 (red) neurons. The number of neurons, Spearman r coefficient and p values are indicated in (F).
A positive correlation is observed in control neurons, while there is no significant correlation in neurons expressing shP2Y1 interference RNA.
maximum ankyrinG intensity position (Figures 5A,B). No
significant change in AIS length was also obtained in 14 DIV
neurons, being AIS length around 33 µm in sh scrambled and
shP2Y1 neurons (Figure 5E). However, in 14 DIV neurons,
P2Y1 suppression generated a significant proximal shift of
ankyrinG maximum intensity of 2–3 µm (7.37 ± 0.41 µm vs.
9.58 ± 0.53 µm in sh scrambled neurons, Figure 5I), which
can be observed in the mean profile of ankyrinG expression
along the AIS (Figure 5J). Despite no AIS length mean changes
were observed between scrambled sh and shP2Y1 neurons,
there is variability of AIS length within each experimental
group. Thus, we analyzed ankyrinG intensity within the AIS
length of each neuron (Figures 5C,F). Our results show a
significant reduction of the mean ratio ankyrinG/AIS length
in shP2Y1 neurons at 7 DIV (around 30%, Figure 5D) and
14 DIV (around 10%, Figure 5G). Furthermore, we analyzed
whether AIS length and ankyrinG intensity are correlated in
14 DIV scrambled sh and shP2Y1 neurons (Figure 5H). Both
parameters were significantly correlated in control scrambled
sh neurons, while no significant correlation was found
in shP2Y1 neurons, demonstrating that ankyrinG intensity
reduction in shP2Y1 neurons is not related to changes in AIS
length. This data suggest that besides neuronal morphology
regulation, P2Y1 receptor maintain other mechanisms to
regulate AIS development.
P2X7 Inhibition Recovers AnkyrinG
Expression
Our previous results showed that P2Y1 suppression produced
a shorter axon, which was recovered by P2X7 inhibition with
BBG (del Puerto et al., 2012). P2Y1-Gq and P2X7-mediated
calcium entry are coordinated through AC5 activation
(P2Y1) or inhibition (P2X7). This generates a cAMP balance
that modulates the PI3K/Akt/GSK3 pathway. In addition,
P2X7 modulate ankyrinG expression at the AIS through a
calcium-calpain-dependent mechanism (Del Puerto et al., 2015).
In order to test whether the same coordinated pathway is
also related to AIS modulation, we treated neurons from 7 to
10 DIV with the adenylate cyclase inhibitor NKY80 (10 µM)
and analyzed ankyrinG (Figure 6A). NKY80 significantly
reduced ankyrinG expression by around 10%, suggesting
a coordinated action of P2Y1 and P2X7. Next, 6 DIV
sh scrambled and shP2Y1 neurons were treated for 24 h
with BBG (100 nM), a well-characterized P2X7 inhibitor
(Figures 6B,D). P2X7 inhibition resulted in a non-significant
trend to increase ankyrinG fluorescence in sh scrambled neurons
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FIGURE 5 | No correlation between P2Y1 suppression-mediated decrease of ankyrinG density and AIS length. (A) Graph represents AIS length of each 7 DIV
neuron nucleofected with scrambled sh (black dots) or shP2Y1 (red dots). Lines represent the mean ± SEM. (B) Graph represents the mean ± SEM of AIS start
point, maximum intensity point and end point of AIS in 7 DIV scrambled shRNA or P2Y1 shRNA nucleofected neurons. (C) Normalized ankyrinG intensity within the
respective AIS length of neurons represented in (A). (D) Normalized AnkyrinG/AIS length ratio for each 7 DIV scrambled shRNA or P2Y1 shRNA nucleofected
neuron. (E) Graph represents AIS length of each 14 DIV neuron nucleofected with scrambled sh (black dots) or shP2Y1 (red dots). Lines represent the mean ± SEM.
(F) Normalized ankyrinG intensity within the respective AIS length of neurons represented in (E). Adjacent graph represents the mean ± SEM. (G) Normalized
AnkyrinG/AIS length ratio for each 14 DIV scrambled shRNA or P2Y1 shRNA nucleofected neuron. Adjacent graph represents the mean ± SEM. (H) Correlation
graph of AIS length and ankyrinG intensity for each individual 14 DIV neuron nucleofected with scrambled (black dots) or P2Y1 (red dots) shRNAs. Values are the
same represented in (E,F). Data were analyzed first with two normality tests (Shapiro-Wilk and Kolmogorov-Smirnov). All data sets did fit a normal distribution and a
Pearson correlation test was used. Regression lines are shown for shscr (black) and shP2Y1 (red) neurons. The number of neurons, Pearson r coefficient and p
values are indicated in (H). A positive correlation is observed in control neurons, while there is no significant correlation in neurons expressing shP2Y1 interference
RNA. (I) Graph represents the mean ± SEM of AIS start point, maximum intensity point and end point of AIS in 14 DIV scrambled shRNA or P2Y1 shRNA
nucleofected neurons. Note a significant proximal shift of the maximum intensity point. (J) AnkyrinG profile along AIS length of 14 DIV neurons, indicating the
proximal shift of the maximum ankyrinG intensity. Data are represented as the mean ± SEM of ankyrinG intensity every 1 micron. ∗p < 0.05, ∗∗p < 0.01,
∗∗∗p < 0.001, n.s., non-significant.
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FIGURE 6 | P2X7 inhibition recovers ankyrinG density in shP2Y1 nucleofected neurons. (A) Scatter plot showing normalized ankyrinG intensity in 10 DIV control
neurons or treated with the adenylate cyclase 5 (AC5) inhibitor NKY80 (10 µM) from 7 to 10 DIV. Mean ± SEM for each condition is shown in the adjacent graph.
∗∗∗p < 0.001, n.s. no significant, two-tail t-test. (B) Scatter plot of normalized ankyrinG intensity in 7 DIV transfected with scrambled shRNA or P2Y1 shRNA and
treated with the P2X7 antagonist, BBG (100 nM) from 6 to 7 DIV. Mean ± SEM for each condition is shown in the adjacent graph. Statistical differences were
analyzed by a Kruskal-Wallis test followed by a Dunn’s multiple comparisons post-test. ∗p < 0.05, ∗∗∗p < 0.001, n.s., non-significant. (C) Mean ± SEM of normalized
ankyrinG intensity in 7 DIV nucleofected with scrambled shRNA or P2Y1 shRNA and treated with the calpain inhibitor, MDL-28170 (50 nM) from 6 to 7 DIV. Statistical
differences were analyzed by a Kruskal-Wallis test followed by a Dunn’s multiple comparisons post-test. ∗p < 0.05, ∗∗∗p < 0.001, n.s., non-significant. (D)
Representative images of scrambled shRNA or P2Y1 shRNA treated with the P2X7 antagonist, BBG (100 nM). Neurons were stained with MAP2 (blue) and ankyrinG
(red) antibodies. Nucleofected neurons were identified by GFP signal (green). Axon initials segments were magnified and presented in panels below.
(105.0 ± 4.59%), while P2Y1 suppression (shP2Y1 neurons)
reduced ankyrinG fluoresecence around 25% (74.13 ± 3.98%).
Interestingly, 24 h inhibition of P2X7 recovered ankyrinG
intensity to control levels (92.7 ± 4.71%, Figures 6B,D).
Further, 24 h treatment with the calpain inhibitor MDL-28170
(50 nM) recovered ankyrinG fluorescence (95.1 ± 4.49%) in
shP2Y1 neurons (Figure 6C). This data suggests a coordinated
and antagonistic action of P2Y1 and P2X7 receptors during
initial stages of AIS development, which may depend on
the amount of ATP and ADP in extracellular medium and
their expression levels during AIS development. However,
P2X7 inhibition did not completely recover ankyrinG
intensity as previously observed in mature neurons (Del
Puerto et al., 2015), suggesting that P2X7 participation
is limited in young neurons. Thus, other AIS intrinsic
mechanisms may be regulated by P2Y1 in AIS initial
developmental stages.
P2Y1 Suppression Modifies AIS Actin
Cytoskeleton and Myosin II Light Chain
Phosphorylation
Recently, actin dynamics at the AIS were related to AIS
plasticity (Berger et al., 2018). Activity-dependent AIS plasticity
can produce a dramatic reorganization of the actin periodic
structure (Berger et al., 2018) and P2Y1 signaling pathways
can activate the RhoGTPase Rac, which modulates actin
dynamics in migration and differentiation processes (Soulet
et al., 2005). To understand whether our results can be
attributable to actin cytoskeleton modifications mediated by
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FIGURE 7 | P2Y1 suppression alters AIS F-actin. (A,B) Representative images of 7 DIV neurons nucleofected with scrambled (A) or P2Y1 (B) shRNAs. AISs were
identified by ankyrinG staining (blue) and Phalloidin-Alexa594 served to identify F-actin (red). Nucleofected neurons were identified by their GFP expression (green).
Panels show AIS region of the respective neurons and a 2.5× magnification of AIS. Gray scale images show phalloidin staining at the respective AISs. (C) Graph
represents the mean ± SEM number of actin patches identified in scrambled (black, n = 20) and shP2Y1 (red, n = 20) AISs. ∗p < 0.05, two-tail t-test. (D) Total AIS
F-actin intensity based on Phalloidin-Alexa 594 fluorescence intensity along ankyrinG signal in 7 DIV shscr and shP2Y1 neurons. ∗p < 0.05, two-tail t-test. (E) Plot
profile of F-actin intensity along AIS in 7 DIV scrambled shRNA (n = 24, black) or P2Y1 shRNA (n = 22, red) neurons. Data are represented as the mean ± SEM of
values every micron. (F) Scatter plot and mean ± SEM representing normalized ankyrinG intensity of each 7 DIV scrambled shRNA (sh scr) or P2Y1 shRNA (shP2Y1)
nucleofected neuron, treated or not with the actin stabilizer jasplakinolide (10 nM) during 4 h prior to fixation. Statistical differences were analyzed by a Kruskal-Wallis
test followed by a Dunn’s multiple comparisons post-test. ∗p < 0.05, ∗∗∗p < 0.001, n.s., non-significant.
P2Y1 receptor, we stained neurons 7 DIV scrambled sh and
shP2Y1 neurons with fluorescence phalloidin (Figures 7A,B)
and quantified F-actin intensity along the AIS, as well as
the number of actin patches (Figures 7C,D). Total F-actin
intensity was reduced by around 30% in shP2Y1 neurons
(Figure 7D), and so was ankyrinG intensity (Figure 7F).
Besides, the F-actin intensity decrease in the AIS was confirmed
by the profile (Figure 7E). While actin patches were visible
in control AISs, these were highly reduced in intensity and
visibility in shP2Y1 neurons (Figures 7A,B). Actin patches
quantification, independently of their intensity, showed that
scrambled sh neurons contained 4.8 ± 0.48 actin patches, while
shP2Y1 neurons only 3.2 ± 0.41 patches (Figure 7C). If loss of
P2Y1-dependent stabilization of the actin cytoskeleton results
in the decrease in ankyrinG, then it may be recovered by actin
stabilization. Thus, we treated scrambled and shP2Y1 neurons
with an F-actin stabilizing agent, Jasplakinolide (10 nM) for
4 h (Figure 7F). AnkyrinG expression in shP2Y1 neurons was
significantly recovered by Jasplakinolide treatment (90.6± 4.7%)
when compared to shP2Y1 neurons with no treatment
(65.27 ± 2.59%, p = 0.0002). After recovery, the level was
equivalent to sh scrambled control neurons (100 ± 4.36%).
In control sh scrambled neurons, Jasplakinolide generated a
decrease in ankyrinG expression (around 14%), which may
be due to a deregulation of actin dynamics and higher
actin stabilization.
How can actin cytoskeleton instability resulting from lack of
P2Y1 activity modify ankyrinG in the AIS? Recently published
work has highlighted the role of myosin II and myosin light
chain phosphorylation (pMLC) on AIS (Evans et al., 2017;
Berger et al., 2018). In platelets, ADP and P2Y1 activity
contribute to shape changes by increasing pMLC levels in
a calcium-calmodulin dependent manner (Paul et al., 1999).
Therefore, we analyzed pMLC levels and localization in 7 DIV
shP2Y1 neurons (Figure 8A). As previously demonstrated
(Berger et al., 2018), pMLC was localized at the AIS in
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FIGURE 8 | P2Y1 is necessary to maintain myosin light chain (MLC) phosphorylation at the AIS. (A) Representative images of 7 DIV scrambled shRNA or
P2Y1 shRNA nucleofected neurons showing phosphorylation of MLC (pMLC) staining in the AIS. Neurons were stained with MAP2 (blue) and pMLC (red) antibodies.
Nucleofected neurons were identified by GFP signal (green). pMLC staining at axon initials segments was magnified and presented in panels below (red). (B) Scatter
plot for each neuron (left) and mean ± SEM (right) representing normalized pMLC intensity at the AIS of 7 DIV neurons nucleofected with scrambled shRNA or
P2Y1 shRNA. ∗∗∗p < 0.001, two-tail t-test. (C) Scatter plot representing normalized pMLC intensity at the AIS of 7 DIV neurons nucleofected with scrambled shRNA
or P2Y1 shRNA and treated with 1 nM calyculinA (CalyA) for 3 h before fixation. Mean ± SEM of these values is represented in the adjacent graph. (D) Scatter plot
representing normalized ankyrinG intensity at the AIS of 7 DIV neurons nucleofected with scrambled shRNA or P2Y1 shRNA and treated with 1 nM calyculinA (CalyA)
for 3 h before fixation. Mean ± SEM are represented in the adjacent graph. Statistical differences in (C,D) were analyzed by a Kruskal-Wallis test followed by a
Dunn’s multiple comparisons post-test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
7 DIV control neurons. However, pMLC staining in the
AIS was 20% lower in shP2Y1 neurons (Figure 8B). Next,
we analyzed whether treating neurons with CalyculinA to
inhibit PP1/PP2A, the phosphatases acting on pMLC, could
recover pMLC levels and, consequently, ankyrinG. Calyculin
A (1 nM) treatment for 3 h increased pMLC intensity at
the AIS of control neurons by 40%, while in non-treated
shP2Y1 neurons it was reduced by 31% (Figure 8C). Calyculin
A treatment in shP2Y1 neurons increased pMLC intensity by
25% when compared to control neurons without Calyculin A
treatment. AnkyrinG intensity analysis in the same experimental
conditions revealed a recovery of ankyrinG in shP2Y1 neurons
treated with Calyculin A (87.82 ± 4.01%) compared to
shP2Y1 neurons (72.04 ± 3.08%), which did not completely
reach reference control levels (100 ± 4.16%, Figure 8D).
Interestingly, 3 h treatment of calyculin A in control neurons
reduced ankyrinG intensity (78.5 ± 3.89%). This may suggest
that increased pMLC levels are also detrimental to ankyrinG
clustering at the AIS, as happened with F-actin stabilization with
jasplakinolide (Figure 7F).
Altogether, our results underscore the role of
P2Y1 as one of the receptors that contribute to AIS
plasticity during early events of AIS maturation. Further
investigations are required to completely understand the
signaling pathway and interactions with other receptors
and neurotransmitters.
DISCUSSION
Relevant studies have recently underscored the importance of
AIS in neurodevelopmental disorders and neurodegenerative
diseases (Kaphzan et al., 2011; Sun et al., 2014; van der Werf
et al., 2017). Changes in AIS protein composition have been
detected in models of disease, such as Angelman syndrome or
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Alzheimer’s disease (Kaphzan et al., 2011; Sun et al., 2014).
However, our understanding of AIS composition, development
and regulation is still limited. Which are the extrinsic and
intrinsic mechanisms that modulate the AIS? The AIS has
been proven to respond to external stimuli with a high
degree of structural plasticity. However, our knowledge of
the receptors, neurotransmitters and extracellular factors that
modulate AIS remains limited. Understanding how the AIS
can be deregulated may contribute to control and recover
physiological neuronal function.
Prior studies demonstrated that the purinergic receptor
P2X7 modulates AIS composition under pathological conditions
(Del Puerto et al., 2015). Due to its relation with the
P2Y1 receptor, the objective of our study was to decipher
whether the purinergic receptor P2Y1 plays a role in AIS
development andmaintenance. Our results show that ADP-P2Y1
receptor contributes to the initial accumulation of ankyrinG
at the AIS. P2Y1 suppression or inhibition decreases ankyrinG
levels, as well as, voltage-gated sodium channels, βIV-spectrin
and pMLC. P2Y1 is necessary for a proper elongation of the
axon in early stages and is expressed in dendrites and axon
terminals in cultured hippocampal neurons (del Puerto et al.,
2012). P2Y1 expression is not detected in AIS, as previously
mentioned for P2X7 (Del Puerto et al., 2015). Previous studies
demonstrated a correlation between dendrites length or caliber
and AIS properties (Hamada et al., 2016; Tapia et al., 2017).
Our results show that, in control neurons, dendrites length
and ankyrinG density is correlated, albeit there is no statistical
correlation between both parameters after P2Y1 suppression.
This suggests that P2Y1-mediated ankyrinG density regulation
entails additional mechanisms triggered by P2Y1 alone or in
coordination with other receptors. In fact, ankyrinG levels can
be recovered through ATP-P2X7 receptor inhibition in neurons
lacking P2Y1 receptor. A previous study demonstrated that
high extracellular concentrations of ATP decrease ankyrinG
density through P2X7 and calpain activation in mature cultured
hippocampal neurons (Del Puerto et al., 2015). Here, we show
that extracellular ADP or P2Y1 inhibition do not modify
ankyrinG density in these mature neurons. However, through
P2Y1 receptor, ADP is necessary to maintain ankyrinG density
in young cultured hippocampal neurons. The P2Y1 regulation
coincides with the initial stages of AIS development, between
4 and 10 DIV, when the diffusion barrier is being generated
(Brachet et al., 2010) and is lost once the AIS achieve a
certain degree of maturity and stability, around 10–14 DIV. In
fact, P2Y1 suppression or ADP treatment after 7 DIV has no
effect on ankyrinG density, while P2Y1 inactivation at 7 DIV
or before decreases ankyrinG density. As happened during
early axonal elongation (del Puerto et al., 2012), BBG-mediated
P2X7 inhibition reverts the effects of P2Y1 suppression on
ankyrinG density. However, P2X7 inhibition mediated recovery
was not as high as previously observed in mature neurons
(Del Puerto et al., 2015), suggesting that P2Y1 receptors
decrease their expression or function during AIS development,
while the importance of P2X7 increases. This recovery can
be the result of decreased P2X7-mediated calcium entry and
reduced calpain activation, but other mechanisms may also
participate in this regulation. P2Y1 and P2X7 receptors are
important regulators of neuronal excitability. P2Y1 receptors
are expressed postsynaptically on dendrites of pyramidal cells
and presynaptic terminals and participate in the regulation
of neuronal plasticity (Barańska et al., 2017). Interestingly,
P2X7 and P2Y1 are balanced over the regulation of cAMP
and PKA activity, where P2Y1 contributes to increased cAMP
levels (del Puerto et al., 2012). It was postulated that a PKA
and phosphatases PP1 and calcineurin loop may regulate
sodium channels phosphorylation modulating spike firing that
correlates with AIS length in dentate granule cells (DGCs).
In this study (Evans et al., 2015), PKA activation did
not modify AIS length but did reverse the depolarization-
induced changes in sodium channels properties, increasing
their phosphorylation and decreasing conductance. Our results
show P2Y1 inhibition or suppression does not alter AIS
length, but rather proximally shifts the maximum ankyrinG
intensity while decreasing ankyrinG density. It remains to be
determined whether this shift is due to PKA activity levels or
modifications of sodium channels conductance. Nevertheless,
our results show that PP1/PP2A inhibition with calyculin A
is able to counteract the lack of P2Y1 expression, which
may balance PKA-phosphatases loop. On the other hand,
P2Y1 may participate in AIS modulation through regulation
of its actin cytoskeleton. In support, P2Y1 regulates Rac and
actin cytoskeleton in other cell types (Soulet et al., 2005). We
show that F-actin distribution and intensity in AIS is modified
after P2Y1 suppression, and actin cytoskeleton stabilization with
jasplakinolide recovers ankyrinG density. In fact, short-time
treatment with potassium chloride decreases ankyrinG density
at the AIS while at the same time actin is destabilized (Berger
et al., 2018). This may be caused by decreased phosphorylation
of myosin II light chain ( pMLC) at the AIS (Berger et al.,
2018). Our results demonstrate that P2Y1 suppression decreases
pMLC levels at the AIS at the same time that ankyrinG density
is reduced in a similar percentage. The lack of P2Y1 receptor
is compensated by inhibition of MLC phosphatase using
calyculin A. Interestingly, P2Y1 agonist, 2MeSADP, increases
pMLC phosphorylation in platelets generating a shape change
(Getz et al., 2010), through a Gq dependent mechanism.
All these data suggest that P2Y1 receptor participate in the
global regulation of AIS cytoskeleton dynamics during its
initial development.
CONCLUSION
In conclusion, our work demonstrates that P2Y1 receptor
participates only during initial AIS development. This may
represent decreased expression or function during neuronal
maturation, while other receptors, such as P2X7, increase
their participation and function in more mature neurons.
P2Y1 expression levels or functional activation/deactivation
in coordination with other receptors and mechanisms may
participate in the fine modulation of AIS development. Future
work will be necessary to completely understand the molecular
mechanisms underlying P2Y1 receptor; both at the level of
plasticity and the modulation of AIS cytoskeleton.
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primary neurons can enter M-phase
Chaska C. Walton  , Wei Zhang, Iris patiño-parrado, estíbaliz Barrio-Alonso,  
Juan-José Garrido & José M. Frade
Differentiated neurons can undergo cell cycle re-entry during pathological conditions, but it remains 
largely accepted that M-phase is prohibited in these cells. Here we show that primary neurons at 
post-synaptogenesis stages of development can enter M-phase. We induced cell cycle re-entry by 
overexpressing a truncated Cyclin E isoform fused to Cdk2. Cyclin E/Cdk2 expression elicits canonical 
cell cycle checkpoints, which arrest cell cycle progression and trigger apoptosis. As in mitotic cells, 
checkpoint abrogation enables cell cycle progression through S and G2-phases into M-phase. Although 
most neurons enter M-phase, only a small subset undergo cell division. Alternatively, neurons can exit 
M-phase without cell division and recover the axon initial segment, a structural determinant of neuronal 
viability. We conclude that neurons and mitotic cells share S, G2 and M-phase regulation.
Neurons that are not fully differentiated can enter M-phase and undergo cell division1–6, and they may keep 
dividing even after full differentiation7–9. In contrast, in the absence of dedifferentiation10, fully differentiated 
neurons do not undergo M-phase entry and cell division upon acute induction of cell cycle re-entry1,11–14. In 
pathologies such as Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (AML) 
or brain injury, neuronal cell cycle re-entry is associated to increased susceptibility to cell death instead of cell 
division15,16. This observation has led to suggest that M-phase entry is prohibited in neurons16, and that the cell 
cycle machinery becomes pro-apoptotic in these cells17. However, the neuron-specific mechanisms that block 
M-phase entry remain unidentified. Furthermore, whether M-phase entry is irreversibly prohibited remains to 
be determined as well.
The block on M-phase entry could be explained by the presence of canonical cell cycle checkpoints. In mitotic 
cells, non-physiological cell cycle re-entry activates checkpoints that arrest the cell cycle18–20 and can result in 
cell death to prevent potentially cancerous cell division18,21. Cell cycle checkpoint abrogation in mitotic cells can 
prevent cell death, and enable M-phase entry and cell division18,19,22. This suggests that, by abrogating cell cycle 
checkpoint activity, neuronal M-phase entry and cell division in neurons that undergo cell cycle re-entry should 
be possible. This possibility remains untested.
To study whether cell cycle checkpoints regulate cell cycle progression in neurons as in mitotic cells, we 
induced neuronal cell cycle re-entry with a low molecular weight (LMW) Cyclin E isoform (Cyclin ET1), which 
shows higher oncogenic potential when compared to full length Cyclin E23, fused to Cdk2 (t1EK2). This fusion 
protein is similar to a Cyclin E/Cdk2 chimeric protein previously shown to be active24. t1EK2 overexpression was 
coupled with genetic and pharmacological checkpoint signaling abrogation. We assessed cell cycle progression 
through each of its phases. We show that the regulation of S, G2 and M phases in neurons is as in standard mitotic 
cells. Neurons readily enter M-phase and a small subset can undergo cell division. We also assessed the integrity 
of the axon initial segment (AIS) after M-phase exit without cell division in multinucleated neurons. We show 
that multinucleated neurons recover the AIS, indicating that aberrant cell cycle re-entry is not necessarily fatal.
Results
t1EK2 induces DNA synthesis in differentiated neurons. Cyclin E is the canonical late G1 cyclin that 
triggers transition into S-phase by activating Cyclin-dependent kinase 2 (Cdk2)25 and is necessary for cell cycle 
re-entry from quiescence26. Strikingly, Cyclin E is highly expressed in neurons under physiological conditions27, 
and Cyclin E upregulation is associated to aberrant neuronal cell cycle re-entry14,28–34 and in AD35,36. Under phys-
iological conditions, Cyclin E forms catalytically inactive complexes with Cdk5 to promote synapse maturation27. 
However, Cdk5 deregulation is associated to neuron diseases37. To avoid interfering with endogenous Cdk5 sig-
naling by off target binding of Cyclin ET1 to Cdk5, we generated a t1EK2 fusion product and used it to induce 
neuronal cell cycle re-entry.
t1EK2 or control LacZ were co-lipofected with red fluorescent protein (RFP) in hippocampal cultures 
maintained for 15 days in vitro (DIV), a stage in which dendritic spines and synapses have already been devel-
oped and neurons are electrophysiologically active38,39. Transfected neurons were identified by MAP2-specific 
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labeling in RFP-positive cells. We studied cell cycle S-phase entry by assessing 5-bromo-2′-deoxyuridine (BrdU) 
incorporation 1, 1.5, and 2 days post-transfection (dpt). Transfected control neurons never incorporated BrdU 
(n = 491) (Fig. 1a,b), confirming that neurons in primary culture at these stages of maturation do not spon-
taneously re-enter the cell cycle. In contrast, t1EK2 induced DNA synthesis in neurons (Fig. 1a,b). At 1 dpt, 
52.3% t1EK2-expressing neurons incorporated BrdU (t152 = 12.906, p < 0.001). This increased at 1.5 dpt to 58.9% 
(t128 = 13.548, p < 0.001), and then declined to 46.8% at 2 dpt (t93 = 9.047, p < 0.001). The apparent decrease in 
BrdU incorporation from 1.5 to 2 dpt likely reflected selective death of t1EK2 transfected neurons since, at 3 
dpt, BrdU incorporation could no longer be assessed due to widespread deterioration of the t1EK2-expressing 
neurons.
t1EK2 induces p53-dependent apoptosis in differentiated neurons. Cell cycle related cell death 
was expected, as Cyclin E is consistently associated to apoptotic cell death during aberrant neuronal cell cycle 
re-entry14,28,30,32–34. To confirm whether t1EK2 was inducing apoptosis we performed active caspase-3 immunola-
beling40. The proportion of neurons expressing t1EK2 that were positive for active caspase-3 (34.7%) was already 
significantly higher than control neurons (6.0%) at 1.5 dpt (p < 0.001, Fisher’s exact test) (Fig. 2a). As expected, 
apoptotic neurons displayed pyknotic nuclei (Fig. 2b). We therefore concluded that t1EK2 induced neuronal 
S-phase entry and this was followed by apoptotic cell death.
Figure 1. t1EK2 induces DNA synthesis in differentiated neurons. (a) Percentage of BrdU positive neurons 
expressing LacZ (Control) or t1EK2 at 1 (Control: n = 129; t1EK2: n = 153), 1.5 (Control: n = 201; t1EK2: 
n = 129), and 2 (Control: n = 161; t1EK2: n = 94) dpt (16–17 DIV). Control neurons never incorporate BrdU. 
Three independent experiments for each dpt were carried out. As control neurons never incorporated BrdU, 
statistical analysis was performed by comparing percent BrdU incorporation in t1EK2-expressing neurons 
with zero (***p < 0.001; one-tailed t test for each dpt). BrdU incorporation could not be assessed at 3 dpt 
due to widespread neuronal death of t1EK2-expressing neurons. (b) Representative confocal images of BrdU 
incorporation in a LacZ control neuron (1 dpt) and t1EK2-expressing neurons at 1, 1.5 and 2 dpt. Graphs 
represent mean ± s.e.m. Scale bar: 25 µm.
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A key barrier to Cyclin E/Cdk2 deregulation is the p53 tumor suppressor protein41. It is therefore possible 
that p53 activity could underlie the apoptotic response of hippocampal neurons to t1EK2-induced cell cycle 
re-entry. In consequence, cell cycle-related cell death in t1EK2-expressing neurons should be blocked by sup-
pressing p53 signaling. To test this hypothesis, we prevented p53 function in t1EK2-expressing neurons by 
expressing a dominant negative mutant (p53DN)42. We assessed apoptosis using active caspase-3 immunostaing. 
p53 blockade prevented cell cycle re-entry-induced apoptosis in neurons (Fig. 2c–e). The proportion of active 
caspase-3-positive t1EK2/p53DN-expressing neurons (6.0%) was not statistically significantly different from 
control neurons expressing p53DN (1.3%) at 1.5 dpt (p = 0.061, Fisher’s exact test) (Fig. 2c). Moreover, rescued 
Figure 2. t1EK2 induces p53-dependent apoptosis in differentiated neurons. (a) Percentage of active caspase-3 
positive neurons expressing LacZ (n = 150) or t1EK2 (n = 150) at 1.5 dpt (17 DIV). Three independent 
experiments were carried out (***p < 0.001; two-sided Fisher’s exact test). (b) Representative confocal images 
of active caspase-3-specific immunostaining in a LacZ control neuron and a t1EK2-expressing neuron. Note 
that the active caspase-3-positive nuclei is pyknotic. Arrows identify RFP positive neurons. (c) Percentage 
of active caspase-3 positive neurons expressing LacZ/p53DN (n = 150) or t1EK2/p53DN (n = 150) at 1.5 
dpt (17 DIV). Three independent experiments were carried out (***p < 0.001; two-sided Fisher’s exact 
test). (d) Representative confocal images of active caspase-3-negative LacZ/p53DN (Control) and t1EK2/
p53DN expressing neurons. (e) Confocal image of an active caspase-3-negative neuron presenting chromatin 
condensation characteristic of prophase with 3D reconstruction of the nucleus. Blue, red and green arrows 
represent 3D orientation. Graphs represent mean ± s.e.m. Scale bar: 25 µm.
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neurons occasionally showed chromatin condensation (Fig. 2e), suggesting that t1EK2 overexpression plus p53 
blockade can enable neuronal cell cycle progression into M-phase.
p53 tumor suppressor blockade rescues t1EK2-induced BrdU incorporation. We quantified BrdU 
incorporation at 1, 2, and 3 dpt to confirm that preventing p53-dependent apoptosis rescued BrdU-positive neu-
rons. As we could not analyze BrdU incorporation at 3 dpt when expressing t1EK2 without p53DN (Fig. 1a), we 
included this time point to determine whether the effects of p53DN were sustained. Control neurons never incor-
porated BrdU (n = 1,043) (Fig. 3a,b). In contrast, a substantial proportion of t1EK2/p53DN-expressing neurons 
was positive for BrdU labelling at 1 (38.8%) (t375 = 15.429, p < 0.001), 2 (61.2%) (t293 = 21.509, p < 0.001), and 3 
dpt (61.8%) (t203 = 18.109, p < 0.001) (Fig. 3a,b). Co-expressing p53DN with t1EK2 rescued BrdU incorporation 
Figure 3. p53 tumor suppressor blockade rescues t1EK2-induced BrdU incorporation. (a) Percentage of BrdU 
positive neurons expressing LacZ/p53DN (Control) or t1EK2/p53DN at 1 (Control: n = 325; t1EK2/p53DN: 
n = 376), 2 (Control: n = 406; t1EK2/p53DN: n = 294), and 3 (Control: n = 312; t1EK2/p53DN: n = 204) dpt 
(16–18 DIV). Control neurons never incorporate BrdU. Three independent experiments for each dpt were 
carried out. As control neurons never incorporated BrdU, statistical analysis was performed by comparing 
percent BrdU incorporation in t1EK2/p53DN-expressing neurons with zero (***p < 0.001; one-tailed t test for 
each dpt). (b) Representative confocal images of BrdU incorporation of a LacZ/p53DN control neuron (3 dpt) 
and t1EK2/p53DN-expressing neurons at 1, 2, and 3 dpt. (c) Confocal images showing BrdU incorporation 
in t1EK2/p53DN-expressing neurons at 5 dpt. Arrows identify RFP positive neurons and arrowheads MAP2-
negative (non-neuronal) cells. Graphs represent mean ± s.e.m. Scale bar: 25 µm.
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at 3 dpt and, although we did not quantify it, neurons with BrdU incorporation could still be found at 5 dpt 
(Fig. 3c). In summary, p53 tumor suppressor loss of function prevented t1EK2-induced apoptosis and rescued 
S-phase viability.
Wee1 inhibition enables G2/M transition in differentiated neurons. Next, we wanted to deter-
mine whether neurons could continue cell cycle progression beyond S-phase. To assess this possibility, we per-
formed Phospho-Ser10 Histone H3 (pH3) immunostaining to identify t1EK2-expressing neurons in late G2 and 
M-phase43. Cdk1 activity is required for the phosphorylation of Histone H344 and, although detected at low levels 
during G245, the onset of pH3 staining starts at late G2, prior to M-phase, in the form of nuclear pH3 foci43. This 
transitions to pan-nuclear pH3 staining just prior to the formation of prophase chromosomes and remains from 
prophase to metaphase43. However, the loss of pH3 staining begins while cells are still in M-phase, at anaphase 
onset43. Thus, we blocked anaphase onset with the proteasome inhibitor MG13246 to identify all neurons that 
entered M-phase (see Supplementary Fig. S1a,b for protocol details). Consistent with the absence of spontaneous 
DNA replication, control MAP2-positive neurons were never positive for pH3 (n = 150) (Fig. 4a). In contrast, 
45.3% (t149 = 11.116, p < 0.001) of t1EK2/p53DN-expressing neurons reached late G2 (evidenced by pH3-specific 
foci). In addition, 2.7% (t149 = 2.020, p < 0.05) of t1EK2/p53DN-expressing neurons showed pan-nuclear pH3 
labelling (Fig. 4a), an observation consistent with the capacity of active caspase-3-negative neurons expressing 
t1EK2/p53DN to occasionally enter M-phase (Fig. 2e). Therefore, although most neurons could not undergo 
G2/M transition, some neurons did enter M-phase upon t1EK2 expression and p53 inhibition.
In mitotic cells, G2/M transition can be blocked by G2 checkpoint activation19, which is triggered by DNA 
damage acquired during a genotoxic S-phase. Deregulated Cyclin E can induce DNA damage resulting from the 
aberrant activation of the DNA replication machinery47–50. Thus, we assessed whether DNA damage in t1EK2/
p53DN neurons was present and could account for the overall block in G2/M transition. DNA damage was 
assessed by Phospho-Ser139 Histone H2AX (γ-H2AX) immunostaining51. We quantified the amount of neurons 
that were negative for γ-H2AX, had 1–5, 6–10, or more than 10 γ-H2AX foci, or showed γ-H2AX pan-nuclear 
staining. At 1.5 dpt, t1EK2/p53DN-expressing neurons generally presented more than 5 γ-H2AX foci and 
control neurons 5 or less foci (Supplementary Fig. S1c). Thus, we analyzed whether the proportion of t1EK2/
p53DN-expressing neurons with more than 5 γ-H2AX foci was significantly higher than that of control neurons. 
This analysis indicated that the proportion of neurons presenting more than 5 γ-H2AX foci was significantly 
higher in the t1EK2/p53DN-expressing group (78%) than in the p53DN-expressing controls (24%) (p < 0.001, 
Fisher’s exact test) (Fig. 4b). Neurons with pan-nuclear γ-H2AX staining generally displayed interphase nuclei 
(Fig. 4c left neuron; for 360° view of DAPI-stained nuclei see Supplementary Video S1). Neurons presenting 
reduced γ-H2AX foci formation could be occasionally found with prophasic-like mitotic chromatin condensation 
(Fig. 4c right; Supplementary Video S1). These results support the possibility that DNA damage in neurons could 
be blocking M-phase entry by activating the canonical G2 checkpoint.
M-phase block exerted by G2 checkpoint signaling is reversible19. This checkpoint largely relies on the phos-
phorylation of Cdk1 in Tyr15 by Wee1 kinase, and the subsequent inhibition of Cyclin B1/Cdk1 activity52. We 
found that Cyclin B1 and Cdk1 are expressed by t1EK2/p53DN-transfected neurons. Cyclin B1 is present in both 
non-transfected and transfected t1EK2/p53DN expressing neurons (Supplementary Fig. S1e,f). This is not unex-
pected, as several cell cycle regulators are present in neurons53,54, where they perform non-cell cycle functions 
related to neuronal maturation and synaptic activity55. The expression pattern shown in Supplementary Fig. S1e,f 
is consistent with t1EK2 inducing an increase in expression of Cyclin B1, both in interphase (Supplementary 
Fig. S1e) and in neurons presenting chromatin condensation (Supplementary Fig. S1f). In contrast, neurons 
presenting apoptotic chromatin condensation (Supplementary Fig. S1g) do not show Cyclin B1 expression. As a 
proof of specificity, non-neuronal cells lack cyclin B1 expression (yellow arrows in Supplementary Fig. S1e), as 
previously described54. To verify that Cdk1 is present in t1EK2/p53DN-transfected neurons, becoming active in 
those that spontaneously enter M-phase, we resorted to double labeling of Cdk1 and phosphoTyr15 phosphoryl-
ation of Cdk1 (pTyr15-Cdk1) (Supplementary Fig. S1h,i). t1EK2/p53DN-transfected neurons showing uncon-
densed DNA were positive for Cdk1 and pTyr15-Cdk1 (Supplementary Fig. S1h). This is consistent with neurons 
in G2. As expected, transfected neurons presenting chromatin condensation consistent with M-phase entry were 
positive for Cdk1 and negative for pTyr15-Cdk1 (Supplementary Fig. S1i), reflecting Cdk1 activation.
In mitotic cells, G2/M transition can be induced by inhibiting Wee1 kinase with MK177556. To test whether 
Wee1 kinase was preventing neurons from entering M-phase, we abrogated G2 checkpoint signaling by inhibiting 
Wee1 with MK1775 and assessed pH3 immunostaining. Again, we blocked anaphase onset with MG13246 to cap-
ture all neurons that entered M-phase (see Supplementary Fig. S1a,d for protocol details). Control MAP2-positive 
neurons were not found in late G2 or M-phase (n = 150) (Fig. 4d). In contrast, Wee1 inhibition with MK1775 
resulted in a substantial increase of t1EK2/p53DN-expressing neurons in M-phase with pan-nuclear pH3 labeling 
(31.3%) (t149 = 8.246, p < 0.001) and chromatin condensation (Fig. 4d,f,g, Supplementary Fig. S1k–p; for 360° 
view of RFP/pH3 labeling illustrated in Fig. 4f, see Supplementary Video S2). Chromatin condensation in these 
neurons was not apoptotic since it was negative for active caspase-3 (Supplementary Fig. S1q,r). In addition, 
37.3% (t149 = 9.422, p < 0.001) of t1EK2/p53DN-expressing neurons were still found in late G2 as reflected by pH3 
foci (Fig. 4d,e, Supplementary Fig. S1j). The total percentage of neurons in late G2 and M-phase after Wee1 inhi-
bition (68.6%) was consistent with the percent of BrdU positive neurons at 2 (61.2%) or 3 dpt (61.8%) (Fig. 3a).
We confirmed that MK1775-dependent G2/M transition in t1EK2/p53DN-transfected neurons relies 
on canonical Cdk1 activity since the Cdk1-specific inhibitor RO-3306 prevented both pH3 labeling and 
mitotic-like chromatin condensation in these neurons (n = 115) (Supplementary Fig. S1s). As an internal control, 
MAP2-negative cells in the cultures also lacked pH3 immunostaining and lacked mitotic chromatin condensation 
(see low magnification in Supplementary Fig. S1t).
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Figure 4. Wee1 inhibition enables G2/M transition in differentiated neurons. (a) Percentage of LacZ/p53DN- 
(Control) or t1EK2/p53DN-expressing neurons with pH3 foci (Control: n = 150; t1EK2/p53DN: n = 150) or 
pan-nuclear pH3 staining (Control: n = 150; t1EK2/p53DN: n = 150) at 1.5 dpt. Anaphase onset was blocked 
with MG132. Control neurons were never positive for pH3. Three independent experiments were carried out. 
As control neurons never were never positive for pH3, statistical analysis was performed by comparing pH3-
positive t1EK2 neurons with zero (***p < 0.001, *p < 0.05; one-tailed t test). (b) Percentage of LacZ/p53DN- 
(Control) or t1EK2/p53DN-expressing neurons with more than 5 γ-H2AX foci (Control: n = 150; t1EK2/
p53DN: n = 150) at 1.5 dpt (see Supplementary Fig. S1c for additional γ-H2AX results). Three independent 
experiments were carried out (***p < 0.001; Fisher’s exact test). (c) Confocal image of pan-nuclear γ-H2AX 
staining of an interphase nucleus (left neuron) and γ-H2AX foci of a prophase-like nucleus (right neuron) (see 
Supplementary Video S1). (d) Percentage of LacZ/p53DN- (Control) or t1EK2/p53DN-expressing neurons 
(Control: n = 150; t1EK2/p53DN: n = 150) at 1.5 dpt with pH3 foci or pan-nuclear pH3 staining after G2 
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Neuronal M-phase progression was confirmed by the loss of lamin B1, the major component of the nuclear 
lamina57, which becomes disassembled during mitosis58, thus providing evidence of nuclear envelope breakdown. 
As expected, t1EK2/p53DN-transfected neurons without chromatin condensation conserve Lamin B1 immuno-
labeling (Supplementary Fig. S1u), while t1EK2/p53DN-transfected neurons with chromatin condensation do 
not (Supplementary Fig. S1v).
Neuronal M-phase progression was further confirmed by anillin immunolabeling, which localizes to the 
nucleus during interphase, the cortex following nuclear envelope breakdown, and the cleavage furrow dur-
ing cytokinesis59,60. In neurons with nuclei displaying characteristics of prometaphase/metaphase, anillin 
immunostaining was released from the cell nucleus (Fig. 4h). In contrast, anillin was located in the nucleus in 
t1EK2-transfected neurons in interphase (Supplementary Fig. S1w).
We also performed α-tubulin immunostaining of the mitotic spindle of neurons in M-phase to confirm 
mitosis progression in t1EK2/p53DN-transfected neurons. Although α-tubulin staining resulted in extensive 
background signal due to its presence in the cytoskeleton61,62, putative mitotic spindles with intense α-tubulin 
labeling could be identified in neurons with chromatin condensation, consistent with prometaphase/metaphase 
(Fig. 4i). This α-tubulin labeling is clearly different from that observed in non-transfected neurons (arrows in 
Supplementary Fig. S1x) and transfected neurons undergoing apoptosis (Supplementary Fig. S1y), which in these 
cases is absent from the nuclear compartment.
Finally, we performed time-lapse experiments to follow live neurons into M-phase. We expressed Histone H2B 
tagged with EGFP (H2B-GFP) to follow DNA dynamics and RFP reporter protein to study morphology. H2B-EGFP 
signal was consistent with mitotic chromatin condensation (Supplementary Video S3, right). Chromatin condensa-
tion was usually accompanied by a loss of RFP signal from dendrites. This may reflect a thinning and or retraction of 
the dendrites that is coordinated with M-phase entry. In contrast, t1EK2/p53DN expressing neurons in interphase 
remained with unaltered gross morphology (Supplementary Video S3, left). Occasionally, neurons underwent cell 
death either during interphase (Supplementary Video S4) or after attempting M-phase progression (Supplementary 
Video S5). In summary, primary neurons can progress through S and G2-phases and enter M-phase. M-phase entry 
in neurons is gated by G2 cell cycle checkpoint signaling as in mitotic cells.
Differentiated neurons can undergo cytokinesis. We again performed time-lapse experiments to see 
whether neurons can undergo cytokinesis. To improve the chances of cytokinesis, we used caffeine to inhibit G2 
checkpoint signaling63 upstream of Wee119 and co-expressed Topoisomerase-2α (TOP2α) to aid in the decate-
nation of intertwined sister chromatids64 (see Supplementary Fig. S2a for protocol details). Although sparse and 
highly asynchronous, attempts at anaphase/cytokinesis could be detected in 12.9% (n = 93) of recorded neurons. 
Neurons largely underwent anaphase/cytokinesis failure (n = 8) (Supplementary Videos S6, S7). Despite this, 
some neurons were able to complete cell division (n = 4). One of the daughter neurons could die whilst the other 
remained viable (Fig. 5a,b; Supplementary Video S8; see Supplementary Fig. S2a,b for protocol details), evidenc-
ing that neuronal cell division was complete. Alternatively, both neurons could remain viable for hours after 
abscission (Fig. 5c,d; Supplementary Video S9; see Supplementary Fig. S2a,c for protocol details).
We also assessed the assembly of the cytokinesis machinery by anillin immunocytochemistry. Anillin localizes 
to the cleavage furrow at cytokinesis onset and remains in the intercellular bridge after cleavage furrow ingres-
sion59. The detection of cytokinesis by immunocytochemistry only captures neurons undergoing cytokinesis at a 
single time-point. However, cytokinesis onset in different neurons could be hours apart (Fig. 5a,c; Supplementary 
Videos S8 and S9). To achieve some degree of synchronization, we forced anaphase/cytokinesis onset by abro-
gating the Spindle Assembly Checkpoint (SAC) with the Mps1 inhibitor AZ314665 (see Supplementary Fig. S2d,e 
for protocol details). Confirming our time-lapse experiments, neurons assembled the cytokinesis machin-
ery (Fig. 5e,f; Supplementary Fig. S2f–h). We found that, in most cases, cleavage furrow ingression began 
(Supplementary Fig. S2f) and proceeded asymmetrically (Supplementary Fig. S2g,h) up to the formation of the 
intercellular bridge/midbody (Fig. 5e,f; for 360° view of Fig. 5f see Supplementary Video S10). We were also able 
to detect putative daughter neurons after abscission completion (Fig. 5g,h). We also performed pH3 immunola-
belling to characterize chromatin decondensation during anaphase/telophase. The loss of pH3 staining begins at 
anaphase and is completed prior to detectable chromosome decondensation in telophase43. In agreement, neu-
rons locked in cytokinesis by chromatin bridges displayed both patterns of staining (Fig. 5i; for 360° view of 
Fig. 5i, see Supplementary Video S11). This suggests that the pH3-positive chromatin trapped in the intercellular 
bridge was still condensed while the portion of the chromatin outside the intercellular bridge lacking pH3 stain-
ing was already decondensed in a telophase-like state.
checkpoint abrogation with MK1775. Anaphase onset was blocked with MG132. Control neurons are never 
positive for pH3. Three independent experiments were carried out. As control neurons never were never 
positive for pH3, statistical analysis was performed by comparing pH3-positive t1EK2/p53DN neurons with 
zero (***p < 0.001, *p < 0.05; one-tailed t test). (e–g) Confocal images and 3D reconstructions of a pH3 
foci-positive neuron consistent with late G2 (e) and neurons with pan-nuclear pH3 staining consistent with 
prometaphase/metaphase (f, see also Supplementary Video S2, g). See also Supplementary Fig. S1j–p. Blue, 
red and green arrows represent 3D orientation. (h) Confocal images and 3D reconstruction showing diffuse 
anillin staining in a t1EK2/p53DN-expressing neuron treated with MK1775 in prometaphase. Blue, red and 
green arrows represent 3D orientation. (i) Confocal images of a neuron with α-tubulin staining of putative 
mitotic spindle. Bottom panels: three-dimensional reconstruction of DAPI (left) and of slices 1 to 23 out of 50 
from cytoskeleton α-tubulin staining to eliminate background (right). Graphs represent mean ± s.e.m. Arrows 
identify RFP positive neurons. Scale bars: 25 µm (c,e–i), 10 µm (i, bottom panels).
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Figure 5. Differentiated neurons can undergo cytokinesis. (a) Time-lapse video frames of a neuron undergoing 
cytokinesis (Supplementary Video S9). There is a delay between the formation of the intercellular bridge and 
final abscission, suggestive of the presence of a chromatin bridge. (b) Confocal images of daughter neurons 
(evidenced by MAP2 immunostaining) in a, confirming that abscission was complete. One daughter neuron 
survived (right) while the other (left) displayed pyknotic nucleus (white arrow). (c) Time-lapse video frames 
of a neuron undergoing cytokinesis (Supplementary Video S10). (d) Confocal images of daughter neurons 
(evidenced by MAP2 immunostaining) in c, confirming that abscission was complete. The daughter neuron on 
the left is multinucleated, indicative of aneuploidy. (e–h) Confocal images of anillin immunolabelling. Anillin 
stains the cleavage furrow/midbody during neuronal cytokinesis (e,f; for 360° view of f see Supplementary 
Video S10). White arrows indicate intercellular bridge/midbody. See also Supplementary Fig. S2f–h. Anillin is 
recycled from the midbody in putative daughter neurons after completing abscission (g,h). (i) Confocal images 
of a pH3 positive neuron undergoing cytokinesis (for 360° view see Supplementary Video S11). The intercellular 
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In sum, we conclude that cell cycle regulation in S, G2, and M phases in neurons is shared with mitotic cells.
Neurons recover AIS integrity after M-phase exit without cell division. Neuronal cell cycle 
re-entry in neuron disease is associated to cell death instead of cell division15,16. To determine whether cell cycle 
re-entry without cell division is necessarily fatal, we assessed the viability of t1EK2/p53DN/TOP2α-expressing 
multinucleated neurons, which were frequently detected in our cultures. Multinucleation requires M-phase entry 
and, therefore, enabled the identification of neurons that had entered and exited the cell cycle without cell divi-
sion. As a control, we did not detect any evidence of multinucleation in controls transfected neurons in BrdU 
(n = 491, Fig. 1a; n = 1,043, Fig. 3a) or pH3 (n = 150, Fig. 4a; n = 150, Fig. 4d) experiments. As neurons expressed 
the p53DN mutant, we assessed AIS integrity rather than active caspase-3 to study viability. The AIS sustains 
neuronal polarity and integrates synaptic input to generate action potentials66,67, and previous studies demon-
strate that AIS integrity is required to maintain neuronal viability67,68. Within the AIS, AnkyrinG (AnkG) is the 
main structural constituent, necessary to maintain AIS functions and neuronal integrity66. We analyzed AnkG 
dynamics in t1EK2/p53DN/TOP2α-expressing neurons in interphase, prophase, and prometaphase/telophase 
3 h after G2 checkpoint abrogation. In multinucleated neurons we assessed AnkG 6 and 9 h after abrogating the 
G2 checkpoint. In control LacZ/p53DN/TOP2α-expressing neurons AnkG was assessed 9 h after G2 checkpoint 
abrogation.
AnkG signal varied significantly across cell cycle stages [Welch’s F test (5; 20,479) = 11.617, p < 0.001] 
(Fig. 6a,b), evidencing that AIS integrity fluctuated during the cell cycle. Multiple comparisons using the 
Games-Howell post-hoc test indicated that the AnkG signal of neurons in prophase was not significantly different 
from that of neurons in interphase (p = 0.448) or control transfected neurons (p = 0.703) (Fig. 6a,b). However, the 
AnkG signal did decrease significantly in prometaphase to telophase when compared to interphase (p = 0.003), 
prophase (p = 0.023) or control neurons (p = 0.009). These results evidence a loss of AIS integrity in M-phase, in 
between prometaphase and telophase. 6 h after inducing G2/M transition, multinucleated neurons had still not 
recovered the AnkG signal when compared to interphase (p = 0.033), prophase (p = 0.033), or control neurons 
(p = 0.041). However, 9 h after inducing G2/M transition, multinucleated neurons significantly increased their 
AnkG signal with respect to neurons in between prometaphase and telophase (p = 0.005), achieving an AnkG sig-
nal that was non-significantly different from control (p = 0.957), interphase (p = 0.999), or prophase (p = 0.349) 
neurons. The recovery of AnkG signal in multinucleated neurons was gradual, as multinucleated neurons 9 h 
after inducing G2/M transition displayed a non-significant trend to increase the AnkG signal when compared 
to 6 h (p = 0.065). Therefore, the AIS is coordinated with the neuronal cell cycle. After cell cycle exit without cell 
division, neurons can progressively yet fully recover the AIS.
Discussion
It was originally believed that the postmitotic status of neurons prohibited any form of cell cycle activity. This 
view is now outdated. There is ample evidence of neuronal cell cycle re-entry in human pathologies such as AD, 
PD, AML or brain injury, as well as in animal models and in primary neuronal cultures15,16. Notwithstanding, 
neuronal cell cycle re-entry in differentiated mature neurons does not result in cell division but it is instead 
associated to increased susceptibility to cell death16. Congruently, the activation of the cell cycle machinery itself 
has been deemed pathological17. We provide evidence that the lack of cell division and the susceptibility to cell 
death in neurons that reactivate the cell cycle likely relies on canonical cell cycle regulatory mechanisms. Primary 
neurons undergo apoptosis upon cell cycle re-entry. As with cycling cells, apoptosis in S-phase can be prevented 
by suppressing p53 signaling. Rescued neurons progress through S-phase into G2, where they are arrested at the 
G2/M transition. Inhibition of G2 checkpoint kinase Wee1 reveals neurons readily enter M-phase and a subset 
of neurons can undergo cytokinesis. Therefore, although our results have to be confirmed in vivo, we have shown 
that a large part of the regulation of the cell cycle in S, G2 and M-phase in primary neurons at post-synaptogenesis 
stages of development is shared with mitotic cells. Hence, cell cycle-induced cell death, lack of M-phase entry, 
or lack of cell division in neurons can be accounted for by standard cell cycle regulation present in mitotic cells.
Multinucleated neurons have been previously reported in Alzheimer’s disease (AD)69. Cellular multinuclea-
tion can result from premature exit from the cell cycle in M-phase, after aberrant anaphase and/or failed cytoki-
nesis21. Cells that prematurely exit the cell cycle and attain viability are largely in a senescent state, which entails 
a permanent withdrawal from the cell cycle70. Most senescent cells develop the senescence associated secretory 
phenotype (SASP), which can be pro-inflammatory, pro-oxidative and pro-mitogenic70. There is already evidence 
to support that the selective killing of senescent cells in the brain can be therapeutic71. Whether it is the selective 
killing of senescent neurons, non-neuronal cells or both is unclear because we are still lacking conclusive proof 
that neurons can undergo bona fide senescence71. Our results show that cytokinesis failure results in multinu-
cleated neurons that recover the AIS, a structural determinant of neuronal viability67,68. Hence, as with cells that 
undergo senescence, neurons prematurely exit the cell cycle into a viable state. The extent to which neurons that 
exit the cell cycle are viable, and whether they are indeed senescent will have to be determined by future studies. 
The recovery of the AIS in multinucleated neurons indicates that our protocol to induce cell cycle progression 
does not result in neuronal dedifferentiation.
Viable cell cycle exit is consistent with reports showing that neurons that re-enter the cell cycle in AD can 
remain viable for months to years16,72. Furthermore, the existence of multinucleated neurons in AD suggest that 
bridge is traversed by pH3 positive chromatin, evidencing the presence of a chromatin bridge. White arrows 
identify daughter neurons (g–i). Blue, red and green arrows represent 3D orientation (e–i). H2B: Histone H2B 
tagged with EGFP. Scale bars: 25 µm (a,c, RFP and H2B-EGFP stills), 5 µm (a,b, bottom panels), 25 µm (e–i).
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Figure 6. Neurons recover AIS integrity after M-phase exit without cell division. (a) AnkG signal per µm in 
t1EK2/p53DN/TOP2α-expressing neurons in different stages of the cell cycle (green) and in control neurons 
expressing LacZ/p53DN/TOP2α (blue) at the indicated time points after suppressing the G2 checkpoint with 
MK1775, normalized to neighboring RFP-negative/MAP2-positive neurons. All groups were treated with 
AZ3146 to abrogate the SAC 2.5 h after MK1775 treatment. A single experiment was carried out (**p < 0.01, 
*p < 0.05; Welch’s F test and two-sided Games-Howell post-hoc tests; Interphase: n = 9, Prophase: n = 7, 
Prometaphase to telophase: n = 9, Multinucleation 6 h: n = 8, Multinucleation 9 h: n = 10, Control: n = 10). (b) 
Confocal images of AnkG-immunolabelled neurons in interphase, prophase, and prometaphase to telophase, 
multinucleated neurons 6 and 9 h post transfection, and control neurons. High magnification of AIS (boxes) is 
shown for each case. Arrowheads identify RFP positive neurons and arrows their respective AIS when present. 
Graphs represent mean ± s.e.m. Scale bar: 25 µm.
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at least some neurons that re-enter the cell cycle can reach M-phase69. However, in current models, cell cycle 
re-entry invariantly results in cell death. This prevents understanding how neurons can survive cell cycle re-entry 
in neurodegenerative diseases and underscores the need for models of viable neuronal cell cycle entry16. In this 
study, we provide a model in which cell cycle-related cell death is prevented, and that allows the study of dividing 
or multinucleated neurons. We propose that canonical cell cycle regulation in neurons will afford a new frame-
work to study cell cycle deregulation in neurodegeneration and basic research.
We have shown that neurons possess functional cell cycle machinery and, although in rare occasions, can 
undergo cell division. Therefore, the manipulation of the neuronal cell cycle could theoretically be employed 
to modulate neuronal maturation and synaptic activity, as these processes are known to rely on mitotic mecha-
nisms55. Further, the loss of the AIS during M-phase entry and its recovery after premature cell cycle exit suggest 
the possibility that the neuronal cell cycle is a coordinated program. Rather than cell cycle activity in itself being 
deleterious for neurons, it is possible aberrant drivers of cell cycle re-entry such as t1EK2 and those reported in 
the literature15 deregulate the neuronal cell cycle machinery, trigger cell cycle checkpoints, and prevent cell cycle 
completion. Hence, the aberrant re-activation of an otherwise functional neuronal cell cycle program may explain 
why neuronal cell division is limited after unscheduled re-entry. Future work that improves on our methods will 
have to determine whether the neuronal cell cycle can be activated in ways that can bestow neuronal proliferation. 
This will require the development of an improved procedure aimed at organizing bipolar spindles and successful 
segregation of chromosomes in all neurons undergoing mitosis. For now, we have established that cell division in 
differentiated primary neurons can no longer be considered impossible.
Methods
ethics statement. All of the procedures for handling and sacrificing animals were approved by the CSIC 
Ethics Committee in accordance with the EU guidelines for the care and use of laboratory animals.
plasmids. Construction of a vector encoding a truncated form of Cyclin E (Trunk 1), which lacks the first 39 
amino acids of Cyclin E23, fused to Cdk2 isoform 1 (NCBI accession number NP_001789) (t1EK2) was based on 
the EK2 fusion protein described previously24. Briefly, a synthetic DNA construct encoding for t1EK2 was firstly 
cloned into the pUC vector, then subcloned into the HindIII and XbaI sites of pcDNA3 vector (ThermoFisher 
Scientific) and finally sequence verified. The pcDNA6/V5-His/lacZ vector expressing LacZ was purchased 
from Invitrogen. The pRFPRNAiC vector expressing red fluorescent protein (RFP), provided by Stuart Wilson 
(University of Sheffield, UK), has been previously described73. The T7-p53DD-pcDNA3 vector expressing a 
dominant negative form of p5342 was a gift from William Kaelin (Addgene plasmid # 25989). The H2B-GFP 
vector expressing a Histone-GFP fusion protein74 was a gift from Geoff Wahl (Addgene plasmid #11680). The 
TOP2α-WT pcDNA3.1(+) vector expressing topoisomerase IIα75 was a kind gift from Corrado Santocanale 
(National University of Ireland).
Antibodies and inhibitory compounds. Primary antibodies: The anti-BrdU rat monoclonal antibody 
(mAb) [BU1/75 (ICR1)] (AbDSerotec) was used at 1:200 dilution. The anti-RFP rabbit polyclonal antibody 
ab62341 (Abcam) was used at 1:100 dilution. The anti-MAP2 chicken antibody ab5392 (Abcam) was diluted 
1:5000-1:12000. The cleaved Caspase-3 rabbit antibody (Cell Signaling Technology) was used at 1:400 dilution. 
The anti-phospho Histone H3 (ser10) rabbit polyclonal antibody 06–570 (Millipore) was used at 1:500 dilution. 
The anti-anillin rabbit polyclonal antibody ab154337 (Abcam) was used at 1:100 dilution. The anti-α-tubulin 
mouse monoclonal antibody [DM1A] ab2791 (Abcam) was used at 1:10000 dilution. The anti-phosphoH2AX 
(ser139) mouse monoclonal antibody [9F3] ab26350 (Abcam) was used at 1:500 dilution. The anti-Ankyrin-G 
mouse antibody [N106/36] (NeuroMab) was diluted at 1:150. The anti-CDK1 mouse monoclonal antibody [A17] 
(Abcam) was used at 1/100 dilution. The anti-CDK1/2/3/5 (phospho Y15) rabbit monoclonal antibody [EPR7875] 
(Abcam) was diluted 1/100. The anti-Cyclin B1 rabbit monoclonal antibody [EPR17060] (Abcam) was used at 
1/500 dilution. The anti-Lamin B1 rabbit monoclonal antibody (Abcam) was diluted 1/100. Secondary antibodies: 
Alexa Fluor 488 Goat Anti-Rat IgG (H + L) (Life Technologies), Alexa Fluor 488 Goat Anti-Mouse IgG (H + L) 
(Life Technologies), Alexa Fluor 488 Goat anti-Mouse IgG2a A-21131 (Invitrogen), Alexa Fluor 488 Affinipure 
Goat Anti-Rabbit IgG (H + L) (Jackson Immunoresearch), Alexa Fluor 594 Goat Anti-Rabbit IgG (H + L) (Life 
Technologies), and Alexa Flour 647 Goat Anti-Chicken IgY (H + L) A-21449 (Invitrogen) were used at 1:1000 
dilution. Inhibitors: Cdk1 inhibitor RO-3306 (ref. 1530) was used at 9 µM, Wee1 inhibitor MK1775 (ref. 1494), 
used at 900 nM, and Mps1 inhibitor AZ3146 (ref. 1642), used at 10 µM, were purchased from Axon Medchem. 
The Eg5 inhibitor monastrol (ab14087), used at 100 µM, and the proteasome inhibitor MG132 (ab141003), used 
at 10 µM, were purchased from Abcam. Caffeine (Sigma), used at 3 mM, was diluted in Neurobasal without 
L-Glutamine (ThermoFisher Scientific) and filter sterilized with 0.2 μm syringe filters (Acrodisc).
Hippocampal Cultures. 10-mm diameter coverslips (Menzel Glässer) were placed in 65% nitric acid 
(Merck) overnight. Coverslips were then washed 4 times in Milli-Q water (Millipore), once in pure ethanol 
(Merck) and air-dried. Coverslips were sterilized overnight in oven at 185 °C, placed in CELLSTAR cell cul-
ture dishes with 4 inner rings (Greiner bio-one) and UV sterilized for 1 h. Coverslips were coated with 0.5 mg/
ml polyornithine (PLO) (Sigma-Aldrich) (prepared in 150 mM borate buffer, pH8.4) for at least 24 h. PLO was 
washed twice in sterilized Milli-Q water. CELLSTAR culture dishes were left in a humidified atmosphere con-
taining 5% CO2 at 37 °C with 2 ml of neuronal plating medium consistent of Dulbecco’s modified Eagle medium 
(DMEM) with D-Glucose, L-Glutamine and Pyruvate (ThermoFisher Scientific) containing 10% fetal bovine 
serum (FBS) (Life technologies) and penicillin-streptomycin (25 U/ml) (Gibco). Primary hippocampal neurons 
derived from CD-1 mice (Charles River) were harvested from embryonic day 17, staged as previously described76. 
Pups were decapitated and brains were placed in cold Hanks’ balanced salt solution (HBSS) without calcium 
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chloride, magnesium chloride, nor magnesium sulphate (Gibco). Hippocampi were then dissected and incubated 
for 15 min at 37 °C in 5 ml HBSS containing 2.5 mg/ml trypsin (Gibco) in a 15 ml conical centrifuge tube. 1 mg/
ml DNAse (Roche) was added for the last 30 s. Hippocampi were then washed 5 times in 5 ml of HBSS at 37 °C 
each time. Mechanical dissociation followed in 1 ml of HBSS at 37 °C by passing hippocampi through a Pasteur 
pipette 10–15 times. Non-dissociated tissue was allowed to collect at the bottom by gravity and clean supernatant 
with dissociated cells transferred to a new 15 ml centrifuge tube. 1 ml of HBSS at 37 °C was added to the remaining 
tissue and dissociated again with a flame polished Pasteur pipette to reduce the diameter of the tip 10–15 times. 
Non-dissociated tissue was allowed to collect at the bottom by gravity. Clean supernatant with dissociated cells 
was transferred to the same centrifuge tube in which cells from the first dissociation were collected. Neurons were 
transferred at a density of 24.000 cells/cm2 to CELLSTAR cell culture dishes (Greiner bio-one) with neuronal 
plating medium. Neurons were allowed to attach to coverslips for 3 to 4 h in a humidified atmosphere contain-
ing 5% CO2 at 37 °C. Once neurons were settled onto the coverslips, neuronal plating medium was washed with 
maintenance medium consistent of Neurobasal without L-Glutamine (ThermoFisher Scientific) medium supple-
mented with B27 (ThermoFisher Scientific), penicillin-streptomycin (25 U/ml) (Gibco) and GlutaMAX (Gibco) 
and differentiated with the same medium up to 3–4 DIV. Half of the culture medium was exchanged by fresh 
maintenance medium without penicillin-streptomycin every 3–4 days.
Lipofection. All lipofections were carried out in hippocampal neurons differentiated for 15 DIV. Two 
or three days prior to lipofection, half of the culture medium was changed for fresh growth medium without 
penicillin-streptomycin. In order to increase viability, recovery medium was prepared from conditioned medium 
of neuronal cultures and used after lipofection. Thus, 30–60 min prior to lipofection, half of the conditioned 
medium of each neuronal culture (1 ml) was removed and collected into a clean culture dish containing 1 ml 
of fresh growth medium. BrdU (5 µg/ml) and or inhibitors were added to the recovery medium as needed. The 
recovery medium was then incubated in a humidified atmosphere containing 5% CO2 at 37 °C for the duration of 
the lipofection. Neurobasal medium without supplements pre-warmed to 37 °C was added to each of the neuronal 
cultures. Cultures were returned to the incubator for a minimum of 30 min to stabilize CO2 levels. To maximize 
viability, neurons were lipofected in their own culture dish and remaining conditioned medium, which was free of 
penicillin-streptomycin by 15 DIV. Neurons were transfected with Lipofectamine 2000 (Invitrogen). Lipoplexes 
were prepared at a ratio of 1 μl of Lipofectamine per 1 μg of DNA. For immunocytochemistry experiments, RFP 
DNA was always transfected at a 1:20 ratio. Total transfected DNA per culture dish for t1EK2/RFP and LacZ/
RFP experiments was 6.4 μg and total transfected DNA per culture dish for t1EK2/p53DN/RFP, LacZ/p53DN/
RFP, t1EK2/p53DN/TOP2α/RFP, LacZ/p53DN/TOP2α-RFP experiments was 12.85 μg. For time-lapse experi-
ments, RFP DNA was also transfected at 1:20. Total transfected DNA for t1EK2/p53DN/H2B-EGFP was 10.27 μg 
and for t1EK2/p53DN/TOP2α/H2B-EGFP it was 12.44 μg. Lipofectamine was mixed with Neurobasal to a final 
volume of 250 μl per culture dishand left for 3–5 min. Next, plasmid DNA diluted in 250 μl of Neurobasal per 
culture dish was added and left for 20 min at room temperature. Thereafter, 0.5 ml of the mix was added to each 
culture dish and left for 90 min. Lipofectamine was then washed out 3 times with 2 ml of growth medium medium 
pre-warmed to 37 °C. After washout, the recovery medium was added to its corresponding neuronal culture. For 
cytokinesis experiments, cultures were supplemented with 1xEmbryoMax Nucleosides (Merck)49.
Immunocytochemistry. Hippocampal cultures were fixed for 15 min with 4% paraformaldehyde (PFA) 
at RT, and permeabilized for 30 min with phosphate buffered saline (PBS) containing 0.05% Triton X-100 
(Sigma-Aldrich) (0.1% for AnkG staining) (PBTx). To detect Lamin B1, a quick wash with methanol (−20 °C) 
was given after 10 min fixation with 4% PFA, followed by 3 PBS washes and permeabilization with 0.05% PBTx 
as described above. For BrdU inmunolabeling, DNA was denatured for 30 min at RT with 2 N HCl/0.33× PBS, 
and then neutralized with three 15-min washes with 0.1 M sodium borate, pH 8.9, and a wash of 5 min with 
PBTx. Cultures were then incubated for 30 min at RT with PBTx containing 10% FBS to block antibody unspe-
cific binding, followed by a 1-h incubation at RT with PBTx/1% FBS and the appropriate primary antibodies. 
After 4 washes in PBTx, cultures were incubated for 1 h at RT in PBTx containing 1% FBS and the appropriate 
secondary antibodies. After 4 additional washes as above, DNA labelling was performed using PBS containg 
100 ng/ml 4′,6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich) and the preparations were mounted in glyc-
erol (Panreac)/PBS (1:1).
Image analysis and cell counting studies. For BrdU incorporation time-course experiments, the pro-
portion of BrdU positive neurons out of all MAP2 positive transfected neurons of 10-mm diameter coverslips 
(Menzel Glässer) was calculated in 3 independent experiments. To assess apoptosis, the proportion of active 
Caspase-340 positive neurons of all MAP2 positive transfected neurons was calculated in each of 3 independent 
experiments. DNA damage was assessed with Phospho-Ser139 Histone H2AX (γ-H2AX)51. The proportion of 
neurons with more than 5 γ-H2AX foci or γ-H2AX pan-nuclear staining out of all MAP2 positive transfected 
neurons was calculated in each of 3 independent experiments. Phospho-Ser10 Histone H3 (pH3) immunos-
taining was used to assess late G2 and M-phase entry46, wherein the proportion of neurons positive for foci (late 
G2) or pan-nuclear (M-phase) staining out of all MAP2 positive transfected neurons was calculated in each 
of 3 independent experiments in each treatment condition. Cell counting in BrdU, active Caspase-3, pH3 and 
γ-H2AX experiments was done with 20x (Zoom, 1.5) or 40x objectives with AF 6500–7000 fluorescence micro-
scope (Leica) and a DU8285 VP-4324 camera (Andor). Confocal microscope images were acquired with 40x 
or 63x objectives using upright or inverted TCS SP5 confocal microscopes (Leica). For three-dimensional (3D) 
image reconstructions, images were taken with a 63x objective with 1.7- to 3.6-times zoom, in 50 to 69 z-stacks of 
0.13 to 0.25 µm step-sizes. 3D reconstructions and rotating 3D videos were generated using Icy bioimage infor-
matics platform77.
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Live imaging of neuronal cell cycle. Neurons were cultured as described above in µ-Dish 35 mm, high 
Grid-500 cell culture dishes with ibidi polymer coverslip bottom (Ibidi) coated with 0.5 mg/ml polyornithine 
(Sigma-Aldrich). Live neuronal imaging was performed in a sealed chamber at 37 °C and 5% CO2 with 20x objec-
tive of an AF 6500–7000 fluorescence microscope and recorded with DU8285 VP-4324 camera. Pictures and 
videos were generated using Leica Application Suite X (Leica). Time intervals between pictures and experiments 
duration are described in each video. For cell counting studies of anaphase and cytokinesis, neurons were identi-
fied by morphological criteria based on RFP signal. When in doubt, cells were either not included in the quantifi-
cation or neuronal identity confirmed by MAP2 immunostaining and included in the quantification. Binucleated 
neurons were not quantified. Neurons that presented obvious signs of cell death during the first hour of recording 
were not included in the quantification. Chromosome segregation during anaphase was identified by H2B-GFP74 
and cleavage furrow ingression by RFP.
Measurement of the AIs. AnkyrinG (AnkG) was used to evaluate changes in the AIS of neurons at dif-
ferent stages of the cell cycle. All groups were treated with Wee1 inhibitor MK177556 (900 nM) to abrogate the 
G2 checkpoint and with the Mps1 inhibitor AZ314665 (10 µM) 2.5 h later to abrogate the SAC. Neurons in the 
interphase, prophase and prometaphase to telophase groups were fixed 3 h after G2 checkpoint abrogation. Stages 
in between prometaphase and telophase could not be reliably distinguished by nuclear morphology and were 
thus grouped together. Multinucleated neurons were used to assess premature M-phase exit and were fixed 6 
and 9 h after G2 checkpoint abrogation. Multinucleated neurons still presenting mitotic chromatin condensation 
or evidence of pyknosis were not included in the quantification. Neurons in all of the aforementioned groups 
co-expressed t1EK2/p53DN/TOP2α/RFP. Control neurons expressing LacZ/p53DN/TOP2α/RFP were fixed 9 h 
after G2 checkpoint abrogation. Images were acquired on an upright Leica SP5 confocal microscope with a 63× 
objective, 1024 × 1024 pixels in z stacks with 0.5-μm steps and a Z-projection was obtained. Measurements of 
AnkG fluorescence intensity were performed by Fiji-ImageJ software. We drew a line starting at the limit of 
neuronal soma identified by MAP2 staining, and extended it along the AnkG staining or the RFP signal of the 
axon. Data were obtained after background subtraction. Then, data were smoothed every 1 μm using Sigma Plot 
12.5 software. AIS start and end positions were obtained following the criteria described previously78. Then total 
fluorescence intensity for each AIS was obtained. Total fluorescent intensity was then divided by the length of the 
AIS to obtain the mean AnkG fluorescence per 1 µm (AnkG/µm). To avoid variability between cell cultures and 
treatment exposure times, we normalized the mean AnkG/µm of transfected neurons to the nearest neighboring 
non-transfected neurons in the same image.
statistical Analysis. Statistical analysis was performed using SPSS (version 24.0). Statistical analysis of BrdU 
time-course experiments of pH3 experiments were done with one-sample t test against 0 because control neurons 
never incorporated BrdU or were positive for pH3 (α = 0.05, one-tailed). For BrdU time-course experiments, 
the mean percent BrdU incorporation of the treatment group was compared to 0 in each time-point. Analysis of 
active-caspase-3 and γ-H2AX experiments were done with Fisher’s exact test (α = 0.05, two-tailed). For AnkG/
µm in AIS experiments, outliers were identified by boxplots. Normality was assessed with Shapiro-Wilk test of 
normality and Normal Q-Q Plots. Homogeneity of variances with Levene’s test for equality of variances. Omnibus 
testing was performed with Welch’s F test and post-hoc multiple comparisons with the Games-Howell method 
(α = 0.05, two-tailed). Quantitative data are expressed as mean ± standard error of the mean (s.e.m.). Significance 
was p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***).
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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